Isofuranone compound as well as pharmaceutical composition and application thereof
By developing isofurone HPK1 PROTAC degrader, the problem of low selectivity of HPK1 inhibitors was solved, and the efficient degradation of HPK1 protein and the improvement of T cell anti-tumor activity were achieved, providing stronger anti-tumor treatment effects.
Patent Information
- Application Number
- CN202310597137.9
- Authority / Receiving Office
- CN · China
- Patent Type
- Applications(China)
- Current Assignee / Owner
- Filing Date
- 2023-05-25
- Publication Date
- 2024-11-26
- Estimated Expiration
- 2043-05-25
AI Technical Summary
The existing HPK1 inhibitors have low selectivity and are difficult to effectively target HPK1 protein, resulting in poor efficacy and strong drug resistance in tumor immunotherapy. PROTAC has few applications in this field, lacking high selectivity and high efficiency. HPK1 PROTAC molecule.
A class of isofuranone HPK1 PROTAC degrading agents were developed. Through the design of specific compound structures, they can efficiently and selectively degrade HPK1 proteins, but have no degradation activity on other proteins of the same family, enhancing the anti-tumor immune response of T cells. .
It achieves efficient degradation of HPK1 protein, improves the anti-tumor activity of T cells, releases effector cytokines, has stronger anti-tumor effect, and has lower toxicity.
Smart Images

Figure CN119019379A_ABST
Abstract
Description
Technical Field
[0001] The invention belongs to the field of medical technology, and specifically relates to an isofuranoside compound and a drug combination and use thereof. Background Art
[0002] Immunotherapy has completely changed the way cancer is treated and brought new hope to patients. In particular, immune checkpoint inhibitors targeting the PD-1 and CTLA-4 pathways have shown significant clinical effects, but they are only effective in specific patient groups and specific types of tumors, with low tumor response rates (~30%), and most patients do not show lasting symptom relief and develop drug resistance after a period of medication. Therefore, it is urgent to discover new tumor immunotherapy targets and improve the clinical effects of immune checkpoints, which is of great significance to the application and promotion of tumor immunotherapy.
[0003] Hematopoietic progenitor kinase 1 (HPK1, MAP4K1) is a member of the MAP4K family and is a Ste20 serine / threonine protein kinase. In addition to HPK1, there are five other members in the MAP4K family, including MAP4K2, MAP4K3, MAP4K4, MAP4K5, and MAP4K6. HPK1 is mainly expressed in hematopoietic cells, such as T cells, B cells, neutrophils, dendritic cells (DC), natural killer (NK) cells, and macrophages. A large number of studies have shown that HPK1 is a negative regulator of T cell receptors and B cell receptors. After TCR activation, HPK1 in the cytoplasm is recruited to the plasma membrane, and its amino acid residues Y381, S171, and T165 are phosphorylated to obtain a fully kinase-activated HPK1 kinase. Activated HPK1 phosphorylates the amino acid residue S376 of its adaptor protein SLP76, providing a binding site for the negative regulatory factor 14-3-3, promoting the proteasomal degradation of SLP76, and ultimately destroying the stability of the TCR signaling complex, thereby hindering the downstream kinase signaling pathway that promotes T cell activation and proliferation. In addition to TCR signals, HPK1 also negatively regulates T cell signals through the prostaglandin E2 (PGE2) receptor. In addition, under the stimulation of growth factors, stress, inflammatory factors, and differentiation factors, HPK1 can also transmit immunosuppressive signals in B cells, NK cells, and dendritic cells. In addition, a recent study has shown that the kinase activity of HPK1 inhibits the immune function of multiple cells, including CD4 + T cells, CD8 +T cells, NK cells and dendritic cells, and showed that inhibition of HPK1 kinase activity is sufficient to induce anti-tumor immune responses. In addition, inhibition of HPK1 kinase activity can further promote T cell effector function and significantly increase the therapeutic effect of PD-L1 monoclonal antibody. HPK1 gene deletion, HPK1 inhibitors or HPK1 protac degraders can enhance CAR-T cell-based immunotherapy and show better anti-tumor activity in various preclinical hematological and solid tumor mouse models. It is worth noting that neither HPK1 gene knockout nor inactivated kinase knock-in mice showed lethal inflammatory responses, which are significant in the absence of some other immune negative regulators, such as CTLA-4 and Cbl-b, indicating that HPK1 inhibitors have high safety. In summary, HPK1 is a potentially effective new target for tumor immunotherapy, and the research and development of HPK1 inhibitors is of great significance for improving the key issues currently facing tumor immunotherapy.
[0004] At present, a variety of HPK1 inhibitors with different structures have been reported, and four HPK1 inhibitors are in the early clinical research stage, including Treadwell Therapeutics' CFI-402411, BeiGene's BGB-15025, Zhuhai Yufan's PRJ1-3024, and Nimbus Therapeutics' NDI-101150. Although a variety of HPK1 inhibitors have been reported, no HPK1 inhibitor has been approved for marketing. The challenge faced in the development of HPK1 inhibitors is that the functions of HPK1 family members are different, but the structural homology is very high, and it is difficult to design highly selective inhibitors.
[0005] Compared with traditional drugs, PROTAC has significant advantages: wider range of action, higher activity, and can target "undruggable" targets; improve selectivity, activity and safety; overcome tumor drug resistance, etc. PROTAC can achieve selectivity that is difficult to achieve with small molecules on certain targets. Therefore, the development of HPK1 PROTAC molecules is expected to solve the problems of low selectivity of HPK1 inhibitors and non-dose-dependent efficacy. However, there are few reports on HPK1 PROTAC molecules. Therefore, the research and development of HPK1 PROTAC molecules is imminent and has important scientific significance and development value. Summary of the invention
[0006] Purpose of the invention: In view of the problem of low selectivity of HPK1 small molecule inhibitors, the present invention utilizes the advantage of PROTAC that can achieve selectivity that is difficult to achieve with small molecules, develops PROTAC molecules targeting HPK1, and provides a class of isofuranoside HPK1 PROTAC degraders. The HPK1 PROTACF molecules of the present invention can efficiently and selectively degrade HPK1 protein, while having no degradation activity on other proteins in the same family. Compared with HPK1 small molecule inhibitors, it can more efficiently stimulate T cell anti-tumor immune responses, release effector cytokines, and has stronger anti-tumor activity.
[0007] Technical solution: The present invention provides a compound as shown in formula I or its enantiomer, diastereomer, racemate, cis-trans isomer, deuterated product, metabolite, prodrug, solvate, hydrate, pharmaceutically acceptable salt or cocrystal, the general structural formula of which is shown below:
[0008] E——L——B (I)
[0009] In Formula I:
[0010] E is
[0011] R is -CH-, -C(CH3)- or N;
[0012] Y is deuterium, halogen, cyano, C 1-4 Alkyl, deuterated (C 1-4 Alkyl), halogenated (C 1-4 Alkyl), deuterated (C 1-4 Alkoxy) or halogen (C 1-4 Alkoxy);
[0013] M is deuterium, halogen, C 1-4 Alkyl, deuterated (C 1-4 Alkyl) or halo (C 1-4 alkyl);
[0014] a is 0, 1, 2, 3 or 4;
[0015] b is 0, 1, 2, or 3;
[0016] Q is a single bond, -NH-, -CH2- or -O-;
[0017] W is -CH2-, -C(CH3)2 or
[0018] L is L1 is connected to E, L4 is connected to B;
[0019] L1 is a single bond, -O-, or -NR a-, -C≡C-, 4-10 membered monocyclic heterocycloalkylene, 6-20 membered spirocyclic heterocycloalkylene, 6-18 membered cyclic heterocycloalkylene or 7-10 membered bridged heterocycloalkylene;
[0020] L2 is a single bond, -(CH2)r2-, -(CH2)r2NH-, (CH2)r3NH(C=O)-, -(CH2)r3(C=O)NH-, 4-10 membered monocyclic heterocycloalkylene, 6-20 membered spirocyclic heterocycloalkylene, 6-18 membered cycloheterocycloalkylene or 7-10 membered bridged heterocycloalkylene;
[0021] L3 is a single bond, -(CH2)r4NH-, a 4-10 membered monocyclic heterocycloalkylene, a 6-20 membered spirocyclic heterocycloalkylene, a 6-18 membered cycloheterocycloalkylene or a 7-10 membered bridged heterocycloalkylene;
[0022] L4 is a single bond or -(CH2)r5NR b -;
[0023] R a is hydrogen or C 1-4 alkyl;
[0024] R b is hydrogen or C 1-4 alkyl;
[0025] r2 is 0, 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11 or 12;
[0026] r3 is 1, 2, 3, 4, 5, 6, 7 or 8;
[0027] r4 is 0, 1, 2, 3, 4, 5, 6, 7, 8, 9 or 10;
[0028] r5 is 0, 1, 2, 3, 4, 5 or 6;
[0029] B is
[0030] X is or "a 5- to 6-membered heteroarylene group having a heteroatom selected from one or more of N, O and S, and having 1 to 3 heteroatoms";
[0031] Z is C 4-10 Alkylene, C 4-10 Alkenylene or C 4-10 Alkyne, the C 4-10 Alkylene, C 4-10 Alkenylene, C 4-10 One or two methylene groups -CH2- in the alkynylene group are optionally and independently replaced by O, -NH- or -N(C 1-4 alkyl).
[0032] In some embodiments, R is -CH- or N;
[0033] In some embodiments, Y is deuterium, fluorine, chlorine, cyano, methyl, trifluoromethyl, methoxy, or trifluoromethoxy.
[0034] In some embodiments, M is deuterium, fluorine, methyl, or trifluoromethyl.
[0035] In some embodiments, a is 0, 1, 2, or 3.
[0036] In some embodiments, b is 0 or 1.
[0037] In some embodiments, Q is a single bond or -NH-.
[0038] In some embodiments, W is -CH2- or
[0039] In some embodiments, X is pyrazolylene, 1,3,4-oxadiazolylene or 1,2,4-oxadiazolylene.
[0040] In some embodiments, Z is -OCH2CH2CH2CH2-, -OCH2CH2CH2CH2CH2-, -OCH2CH2OCH2CH2-, -OCH2CH2OCH2-, -OCH2CH2OCH2-, -OCH2CH2N(CH3)CH2-, or -CH2OCH2CH=CHCH2OCH2CH2-.
[0041] In some embodiments, X is The left side is connected to L and the right side is connected to connected.
[0042] In some embodiments, E is
[0043]
[0044] In some embodiments, L1 is a single bond, -O-, -NH-, -N(CH3)-, -C≡C-,
[0045] L2 is a single bond, -(CH2)r2-, -(CH2)r2NH-, -(CH2)r3NH(C=O)-, -(CH2)r3(C=O)NH-,
[0046] L3 is a single bond, -(CH2)r4NH-,
[0047] L4 is a single bond, -(CH2)r5NH- or -(CH2)r5NCH3-.
[0048] n1 is 1, 2, 3 or 4.
[0049] n2 is 1, 2, 3 or 4;
[0050] n3 is 1, 2 or 3.
[0051] n4 is 1, 2 or 3.
[0052] n5 is 1, 2 or 3.
[0053] n6 is 1, 2 or 3.
[0054] n7 is 0, 1, 2 or 3.
[0055] n8 is 0, 1, 2 or 3.
[0056] n9 is 0, 1, 2 or 3.
[0057] n10 is 0, 1, 2 or 3.
[0058] Q 1 It is CH or N.
[0059] Q 2 It is CH or N.
[0060] Q 3 It is CH or N.
[0061] R 1 is hydrogen, halogen, -(C=O) or C 1-3 alkyl.
[0062] c is 1, 2, 3 or 4.
[0063] r2 is 0, 1, 2, 3, 4, 5, 6, 7, 8, 9, 10 or 11.
[0064] r3 is 1, 2, 3, 4, 5 or 6.
[0065] r4 is 0, 1, 2, 3, 4, 5, 6, 7 or 8.
[0066] r5 is 0, 1, 2, 3 or 4.
[0067] In some embodiments, L1 is -O-, -NH-, -C≡C-, In some embodiments, L2 is a single bond, -(CH2)r2-, -(CH2)r2NH-, -(CH2)r3NH(C=O)-, -(CH2)r3(C=O)NH-,
[0068] In some embodiments, L3 is a single bond, -(CH2)r4NH-.
[0069] In some embodiments, L4 is a single bond or -(CH2)r5NH-.
[0070] In some embodiments, n1 is 1, 2 or 3.
[0071] In some embodiments, n2 is 1, 2 or 3.
[0072] In some embodiments, n3 is 1 or 2.
[0073] In some embodiments, n4 is 1 or 2.
[0074] In some embodiments, n5 is 1 or 2.
[0075] In some embodiments, n6 is 1 or 2.
[0076] In some embodiments, n7 is 1 or 2.
[0077] In some embodiments, n8 is 1 or 2.
[0078] In some embodiments, n9 is 0, 1, or 2.
[0079] In some embodiments, n10 is 0, 1 or 2.
[0080] In some embodiments, Q 2 For CH, Q 3 is N.
[0081] In some embodiments, Q 2 N, Q 3 For CH.
[0082] In some embodiments, R 1 For hydrogen.
[0083] In some embodiments, c is 0, 1 or 2.
[0084] In some embodiments, r2 is 0, 1, 2, 3, 4, 5, 6, 7, 8, 9, or 10.
[0085] In some embodiments, r3 is 1, 2, 3 or 4.
[0086] In some embodiments, r4 is 0, 1, 2, 3, 4, 5 or 6.
[0087] In some embodiments, r5 is 0, 1, 2 or 3.
[0088] In some embodiments, L is -O-(CH2)r2NH-single bond-single bond-, -O-(CH2)r3NH(C=O)-(CH2)r4NH-single bond-, -O-(CH2)r3(C=O)NH-(CH2)r4NH-single bond-, -NH-(CH2)r2NH-single bond-single bond-, -NH-(CH2)r3NH(C=O)-(CH2)r4NH-single bond-, -NH-(CH2)r3(C=O)NH-(CH2)r4NH-single bond-, -NH-(CH2)r2-single bond-single bond, -C≡C-(CH2)r2NH-single bond-single bond-, -C≡C-(CH2)r2-single bond-single bond-,
[0089]
[0090]
[0091] The left side is connected to E, and the right side is connected to B;
[0092] n1 is 1, 2 or 3;
[0093] n2 is 1, 2 or 3;
[0094] n3 is 1 or 2;
[0095] n4 is 1 or 2;
[0096] n5 is 1 or 2;
[0097] n6 is 1 or 2;
[0098] n7 is 1 or 2;
[0099] n8 is 1 or 2;
[0100] n9 is 0, 1 or 2;
[0101] n10 is 0, 1 or 2;
[0102] Q 1 is CH or N;
[0103] Q 2 is CH or N;
[0104] Q 3 is CH or N;
[0105] R 1 is hydrogen;
[0106] c is 0, 1, or 2;
[0107] r2 is 0, 1, 2, 3, 4, 5, 6, 7, 8, 9 or 10;
[0108] r3 is 1, 2, 3 or 4;
[0109] r4 is 0, 1, 2, 3, 4, 5 or 6;
[0110] r5 is 0, 1, 2 or 3.
[0111] In some embodiments,
[0112] L1 is -O-, -NH-, -C≡C-,
[0113]
[0114] The left side is connected to E, and the right side is connected to L2;
[0115] In some embodiments,
[0116] L2 is a single bond, -(CH2)r2-, -(CH2)r2NH-, -(CH2)r3NH(C=O)-, -(CH2)r3(C=O)NH-,
[0117]
[0118] r2 is 0, 1, 2, 3, 4, 5, 6, 7, 8 or 9;
[0119] r3 is 1, 2 or 3;
[0120] The left side is connected to L1 and the right side is connected to L3.
[0121] In some embodiments, L3 is a single bond, -(CH2)r4NH-,
[0122]
[0123] The left side is connected to L2, and the right side is connected to L4;
[0124] r4 is 0, 1, 2 or 3.
[0125] In some embodiments, L4 is a single bond or -(CH2)r5NH-,
[0126] r5 is 0, 1 or 2.
[0127] In some embodiments, L is
[0128]
[0129] The left side is connected to E, and the right side is connected to B;
[0130] r21 is 1, 2, 3, 4, 5, 6, 7 or 8;
[0131] r22 is 0, 1, 2 or 3;
[0132] r31 is 1, 2 or 3;
[0133] r41 is 1, 2 or 3;
[0134] r42 is 0, 1, 2, or 3;
[0135] r52 is 0 or 1.
[0136] In some embodiments, the compound represented by Formula I is selected from compounds of any of the following structures:
[0137]
[0138]
[0139]
[0140]
[0141]
[0142]
[0143] The present invention provides a use of a compound represented by formula I or its enantiomer, diastereomer, racemate, cis-trans isomer, deuterated product, metabolite, prodrug, solvate, hydrate, pharmaceutically acceptable salt or cocrystal in preparing a hematopoietic progenitor cell kinase 1 degrader.
[0144] The present invention provides a use of a compound represented by formula I or its enantiomer, diastereomer, racemate, cis-trans isomer, deuterated product, metabolite, prodrug, solvate, hydrate, pharmaceutically acceptable salt or cocrystal in the preparation of a drug for treating and / or preventing cancer.
[0145] In some embodiments, the cancer is a cancer associated with abnormal hematopoietic progenitor cell kinase 1 activity or expression.
[0146] In some embodiments, the cancer is one or more of bone cancer, lung cancer, gastric cancer, colorectal cancer, pancreatic cancer, breast cancer, prostate cancer, liver cancer, brain cancer, ovarian cancer, bladder cancer, gastrointestinal stromal tumor, cervical cancer, testicular cancer, kidney cancer, head and neck cancer, thyroid cancer, pancreatic cancer, esophageal cancer, lymphoma, leukemia, or skin cancer.
[0147] The present invention provides a pharmaceutical composition, which contains any one of the compounds as shown in Formula I or its enantiomers, diastereomers, racemates, cis-trans isomers, deuterated substances, metabolites, prodrugs, solvates, hydrates, pharmaceutically acceptable salts or cocrystals, and pharmaceutically acceptable carriers or excipients.
[0148] In some embodiments, in the pharmaceutical composition, the amount of the compound as shown in Formula I, or its pharmaceutically acceptable salt, isomer, metabolite, prodrug, solvate or hydrate is a therapeutically effective amount.
[0149] The present invention provides use of a pharmaceutical composition in preparing a drug for treating and / or preventing cancer.
[0150] In some embodiments, the cancer is one or more of bone cancer, lung cancer, gastric cancer, colorectal cancer, pancreatic cancer, breast cancer, prostate cancer, liver cancer, brain cancer, ovarian cancer, bladder cancer, gastrointestinal stromal tumor, cervical cancer, testicular cancer, kidney cancer, head and neck cancer, thyroid cancer, pancreatic cancer, esophageal cancer, lymphoma, leukemia, or skin cancer.
[0151] The pharmaceutical excipients can be those widely used in the field of drug production. Excipients are mainly used to provide a safe, stable and functional pharmaceutical composition, and can also provide methods to dissolve the active ingredient at a desired rate after the subject receives the administration, or promote the effective absorption of the active ingredient after the subject receives the composition. The pharmaceutical excipients can be inert fillers, or provide a certain function, such as stabilizing the overall pH value of the composition or preventing the degradation of the active ingredient of the composition. The pharmaceutical excipients can include one or more of the following excipients: adhesives, suspending agents, emulsifiers, diluents, fillers, granulating agents, adhesives, disintegrants, lubricants, anti-adhesive agents, glidants, wetting agents, gelling agents, absorption delay agents, dissolution inhibitors, enhancers, adsorbents, buffers, chelating agents, preservatives, colorants, flavoring agents and sweeteners.
[0152] The pharmaceutical composition of the present invention can be prepared according to the disclosed content using any method known to those skilled in the art, such as conventional mixing, dissolving, granulating, emulsifying, grinding, encapsulating, embedding or lyophilizing processes.
[0153] The pharmaceutical composition of the present invention can be administered in any form, including injection (intravenous), mucosal, oral (solid and liquid preparations), inhalation, ocular, rectal, topical or parenteral (infusion, injection, implantation, subcutaneous, intravenous, intraarterial, intramuscular) administration. The pharmaceutical composition of the present invention can also be a controlled release or delayed release dosage form (e.g., liposomes or microspheres). Examples of solid oral preparations include, but are not limited to, powders, capsules, caplets, soft capsules, and tablets. Examples of liquid preparations for oral or mucosal administration include, but are not limited to, suspensions, emulsions, elixirs, and solutions. Examples of topical preparations include, but are not limited to, emulsions, gels, ointments, creams, patches, pastes, foams, lotions, drops, or serum preparations. Examples of preparations for parenteral administration include, but are not limited to, solutions for injection, dry preparations that can be dissolved or suspended in a pharmaceutically acceptable carrier, suspensions for injection, and emulsions for injection. Examples of other suitable formulations of the pharmaceutical composition include, but are not limited to, eye drops and other ophthalmic preparations; aerosols such as nasal sprays or inhalers; liquid dosage forms suitable for parenteral administration; suppositories and lozenges.
[0154] The term "pharmaceutically acceptable salt" refers to salts of the compounds of the present invention, prepared from compounds having specific substituents discovered by the present invention with relatively nontoxic acids or bases. When the compounds of the present invention contain relatively acidic functional groups, base addition salts can be obtained by contacting the free form of such compounds with a sufficient amount of base in a pure solution or a suitable inert solvent. Pharmaceutically acceptable base addition salts include sodium, potassium, calcium, ammonium, organic amino or magnesium salts or similar salts. When the compounds of the present invention contain relatively basic functional groups, acid addition salts can be obtained by contacting the free form of such compounds with a sufficient amount of acid in a pure solution or a suitable inert solvent. Examples of pharmaceutically acceptable acid addition salts include inorganic acid salts such as hydrochloric acid, hydrobromic acid, nitric acid, carbonic acid (forming carbonate or bicarbonate), phosphoric acid (forming phosphate, monohydrogen phosphate, dihydrogen phosphate, sulfuric acid (forming sulfate or bisulfate), hydroiodic acid, phosphorous acid, and the like; and organic acid salts such as acetic acid, propionic acid, isobutyric acid, maleic acid, malonic acid, benzoic acid, succinic acid, suberic acid, fumaric acid, lactic acid, mandelic acid, phthalic acid, benzenesulfonic acid, p-toluenesulfonic acid, citric acid. Acids such as tartaric acid and methanesulfonic acid; organic acid salts also include salts of amino acids (such as arginine, etc.), and salts of organic acids such as glucuronic acid. Certain specific compounds of the present invention contain basic and acidic functional groups, and can be converted into any base or acid addition salt. Preferably, the salt is contacted with a base or acid in a conventional manner, and the parent compound is separated, thereby regenerating the free form of the compound. The free form of the compound differs from its various salt forms in certain physical properties, such as different solubility in polar solvents.
[0155] The "pharmaceutically acceptable salts" of the present invention can be synthesized from parent compounds containing acid radicals or bases by conventional chemical methods. In general, such salts are prepared by reacting these compounds in free acid or base form with a stoichiometric amount of an appropriate base or acid in water or an organic solvent or a mixture of the two. In general, non-aqueous media such as ether, ethyl acetate, ethanol, isopropanol or acetonitrile are preferred.
[0156] The term "enantiomer" refers to stereoisomers that are non-superimposable mirror images of each other. Examples of enantiomers include, but are not limited to and They are enantiomers.
[0157] The term "racemate" is a mixture of enantiomers. Examples of racemates include, but are not limited to
[0158] yes
[0159] The racemate of.
[0160] The term "diastereoisomers" refers to stereoisomers that have identical atomic composition but different arrangements in space and are not mirror images of each other.
[0161] The term "cis-trans isomers" refers to isomers caused by the inability of a double bond or a single bond of a ring-forming carbon atom to rotate freely.
[0162] The term "deuterated" means that any hydrogen atom in a molecule can be replaced by its isotope deuterium.
[0163] The term "metabolite" refers to a pharmaceutically active product produced by the in vivo metabolism of a compound of Formula I or a salt thereof. Such a product may be produced, for example, by oxidation, reduction, hydrolysis, amidation, deamidation, esterification, deesterification, glucuronidation, enzymatic cleavage, etc. of the administered compound. Therefore, the present invention includes metabolites of the compounds of the present invention, including compounds produced by a process of contacting a compound of the present invention with a mammal for a period of time sufficient to obtain a metabolite thereof.
[0164] Metabolites are typically identified by preparing radiolabeled isotopes of the compounds of the invention, administering them parenterally to animals, such as rats, mice, guinea pigs, monkeys, or humans, at detectable doses (e.g., greater than about 0.5 mg / kg), allowing sufficient time for metabolism to occur (typically about 30 seconds to 30 hours), and isolating the conversion products from urine, blood, or other biological samples. These products are easily isolated because they are labeled (others are isolated by using antibodies that can bind to antigenic epitopes present in the metabolites). The metabolite structure is determined in a conventional manner, for example, by MS, LC / MS or NMR analysis. Generally, the analysis of metabolites is performed in the same manner as conventional drug metabolism studies known to those skilled in the art. As long as the metabolite products are not otherwise not found in vivo, they can be used in assays for therapeutic dosing of the compounds of the invention. The compounds of the invention may contain non-natural proportions of atomic isotopes on one or more of the atoms that make up the compound. For example, compounds may be labeled with radioisotopes, such as tritium ( 3 H), iodine-125( 125 I) or C-14( 14 C) All isotopic variations of the compounds of the present invention, whether radioactive or not, are included within the scope of the present invention.
[0165] In addition to the form of salts, the compounds provided by the present invention also exist in the form of prodrugs. The prodrugs of the compounds described herein are easily chemically changed under physiological conditions to be converted into the compounds of the present invention. Any compound that can be converted in vivo to provide a bioactive substance (i.e., a compound shown in Formula I) is a prodrug within the scope and spirit of the present invention. For example, a carboxyl-containing compound can form a physiologically hydrolyzable ester, which acts as a prodrug by being hydrolyzed in vivo to obtain the compound shown in Formula I itself. The prodrug is preferably administered orally, because hydrolysis occurs mainly under the influence of digestive enzymes in many cases. When the ester itself is active or hydrolysis occurs in the blood, parenteral administration can be used.
[0166] Those skilled in the art will understand that according to the conventions used in the art, the “ It means that the corresponding group is connected to other fragments and groups in the compound shown in Formula I through this site.
[0167] The term "degrader" refers to a compound shown in Formula I or its enantiomer, diastereomer, cis-trans isomer, racemate, deuterated product, metabolite, prodrug, solvate, hydrate, pharmaceutically acceptable salt or cocrystal, which binds to E3 ubiquitin ligase and hematopoietic progenitor cell kinase 1 protein at the same time, and makes the hematopoietic progenitor cell kinase 1 protein and E3 ubiquitin ligase close to each other, thereby degrading the hematopoietic progenitor cell kinase 1 protein under the action of E3 ubiquitin ligase.
[0168] The term "halogen" refers to fluorine, chlorine, bromine or iodine.
[0169] The term "alkyl" refers to a straight or branched chain alkyl group having a specified number of carbon atoms. Examples of alkyl groups include methyl, ethyl, n-propyl, isopropyl, n-butyl, tert-butyl, isobutyl, sec-butyl, and the like.
[0170] The term "alkoxy" refers to the group -O-alkyl, wherein alkyl is as defined above.
[0171] The term "heterocycloalkyl" refers to a saturated or partially saturated monocyclic or polycyclic group with heteroatoms, which contains 3-20 ring atoms, one or more of which are independently selected from heteroatoms N, O or S, and the remaining ring atoms are carbon. Preferably 3 to 20 ring atoms, 1-3 of which are heteroatoms. More preferably 4-16 ring atoms, 1-2 of which are N, including 4-10-membered monocyclic heterocycloalkyl, 6-16-membered spirocyclic heterocycloalkyl, 6-15-membered ring heterocycloalkyl, 7-10-membered bridged heterocycloalkyl. The term "heterocycloalkylene" refers to a divalent group formed by removing another hydrogen atom on the basis of the above-mentioned "heterocycloalkyl", including 4-10-membered monocyclic heterocycloalkylene, 6-16-membered spirocyclic heterocycloalkylene, 6-15-membered ring heterocycloalkylene, 7-10-membered bridged heterocycloalkylene. Examples include but are not limited to
[0172]
[0173] The term "haloalkyl" refers to an alkyl group substituted with one or more halogens, as defined above. Examples of haloalkyl groups include, but are not limited to, trifluoromethyl.
[0174] The term "haloalkoxy" refers to an alkoxy group substituted with one or more halogens, as defined above. Examples of haloalkoxy include, but are not limited to, trifluoromethoxy.
[0175] The term "deuterated alkyl" refers to an alkyl group substituted with one or more deuterium groups, as defined above. Examples of deuterated alkyl groups include, but are not limited to, -CD3.
[0176] The term "deuterated alkoxy" refers to an alkoxy group substituted with one or more deuterium groups, as defined above. Examples of deuterated alkoxy groups include, but are not limited to -OCD3.
[0177] The hydrogen atoms described in the present invention can be replaced by their isotope deuterium, and any hydrogen atom in the example compounds of the present invention can also be replaced by a deuterium atom.
[0178] Without violating the common sense in the art, the above-mentioned preferred conditions can be arbitrarily combined to obtain the preferred embodiments of the present invention.
[0179] The reagents and raw materials used in the present invention are commercially available.
[0180] Beneficial effects: The positive and progressive effects of the present invention are: (1) The hematopoietic progenitor cell kinase 1 PROTAC molecule provided by the present invention can efficiently and selectively degrade various hematopoietic progenitor cell kinase 1 proteins, but has no degradation activity on other proteins in the same family, and has low toxicity. (2) The hematopoietic progenitor cell kinase 1 PROTAC molecule provided by the present invention has a good therapeutic effect on cancer. BRIEF DESCRIPTION OF THE DRAWINGS
[0181] Figure 1 The example compound S10 restored or enhanced the killing effect of PBMC cells on tumor cells;
[0182] Figure 2 The example compound S47 restores or enhances the killing effect of PBMC cells on tumor cells. DETAILED DESCRIPTION
[0183] The present invention is further described below by way of examples, but the present invention is not limited to the scope of the examples. The experimental methods in the following examples without specifying specific conditions are carried out according to conventional methods and conditions, or selected according to the product specifications.
[0184] Example 1 Synthesis of Intermediate 3
[0185]
[0186] a) Under argon protection, raw material 1 (8 g, 40.6 mmol), isopropenylboronic acid pinacol ester (8.2 g, 48.72 mmol), K2CO3 (14 g, 101.52 mmol) and Pd(dppf)Cl2 (292.68 mg, 0.4 mmol) were dissolved in 1,4-dioxane (200 mL) and water (40 mL), and stirred at 95°C for overnight reaction. After the reaction was complete, the reaction solution was cooled to room temperature, diluted with water, extracted with ethyl acetate (30 mL×3), and the combined organic layer was washed with saturated NaCl solution, dried over anhydrous Na2SO4, filtered and concentrated, and purified by column chromatography to obtain intermediate 2 (5.56 g, 87%). MS (ESI, m / z): 159 (M + +1).
[0187] b) Under oxygen atmosphere, intermediate 2 (5.5 g, 34.7 mmol) and Mn(Dpm)3 (2.1 g, 3.47 mmol) were dissolved in isopropanol (220 mL) and dichloromethane (10 mL). Phenylsilane (7.52 g, 69.53 mmol) was added to the reaction system at 0°C and stirred for 2 h. After the reaction was complete, 20% Na2S2O3 aqueous solution was added to quench the reaction, and ethyl acetate was used for extraction (30 mL×3). The organic phases were combined, washed with saturated NaCl solution, dried over anhydrous Na2SO4, filtered and concentrated to obtain crude 4-amino-2-(2-hydroxypropyl-2-yl)benzonitrile. MS (ESI, m / z): 177 (M + +1).
[0188] c) Dissolve the crude 4-amino-2-(2-hydroxypropan-2-yl)benzonitrile (34.7 mmol) in DMF (70 mL) and water (70 mL), and add solid NaHCO3 (11.67 g, 138.8 mmol) in batches. Stir the reaction at 80°C for 24 h. After the reaction is complete, cool the reaction solution to room temperature and filter it with diatomaceous earth, and wash it with ethyl acetate. Extract the mixture with ethyl acetate (30 mL×3), combine the organic layers, wash them with saturated NaCl solution, dry them over anhydrous Na2SO4, filter them and concentrate them. Purify by column chromatography to obtain intermediate 3 (4.73 g, 77%). MS (ESI, m / z): 178 (M + +1).
[0189] Example 2 Synthesis of Intermediate 7
[0190]
[0191] a) Dissolve the raw material 4 (6 g, 27.14 mmol) in acetonitrile (70 mL), add DIPEA (9 mL, 54.24 mmol) and (s)-2-amino-2-phenylethanol (4.08 g, 29.7 mmol) to the reaction system. Stir the reaction solution at room temperature for 3 h. After the reaction is complete, filter the reaction solution, and concentrate the filtrate under reduced pressure. Purify by column chromatography to obtain intermediate 5 (6.95 g, 79%). MS (ESI, m / z): 322 (M + +1).
[0192] b) Intermediate 3 (2.95 g, 16.64 mmol) and intermediate 5 (5.35 mg, 16.64 mmol) were dissolved in isopropanol (42 ml), hydrochloric acid (7 mL) was added dropwise to the reaction system, and the reaction was stirred at 80°C overnight. After the reaction was completed, the reaction solution was cooled to room temperature, triethylamine was added to quench the reaction, and the mixture was extracted with ethyl acetate (30 mL×3). The combined organic layers were washed with saturated NaCl solution, dried over anhydrous Na2SO4, filtered and concentrated to obtain intermediate 6 (6.5 g, 84%). MS (ESI, m / z): 463 (M + +1).
[0193] c) Intermediate 6 (6 g, 12.9 mmol) was dissolved in tetrahydrofuran (50 mL), 2M NaOH aqueous solution (15 mL) was added to the reaction system, and the reaction was stirred at 50°C overnight. After the reaction was complete, the reaction solution was cooled to room temperature, the pH was adjusted to 4 with 2M HCl, and filtered to obtain white solid intermediate 7 (4.1 g, 73%). MS (ESI, m / z): 435 (M + +1).
[0194] Example 3 Synthesis of Intermediate 12
[0195]
[0196] a) According to the synthetic step a of intermediate 7, intermediate 9 can be obtained by simply replacing the corresponding raw materials. MS (ESI, m / z): 327 (M + +1).
[0197] b) According to the synthetic step b of intermediate 7, intermediate 10 can be obtained by simply replacing the corresponding raw materials. MS (ESI, m / z): 469 (M + +1).
[0198] c) Add intermediate 10 (155 mg, 0.33 mmol), raw material 11a (135.2 mg, 0.52 mmol), Pd(PPh3)4 (42 mg, 0.036 mmol) and sodium bicarbonate (106 mg, 1.0 mmol) into a sealed tube and protect with argon. Add 1,4-dioxane (20 mL) and water (4 mL) at room temperature, stir and react at 100°C for 12 h under argon. After the reaction is complete, cool the reaction solution to room temperature, extract with ethyl acetate (10 mL×3), combine the organic layers, wash with saturated NaCl solution, dry with anhydrous Na2SO4, filter and concentrate, purify by column chromatography to obtain intermediate 12a (57 mg, 33%). Intermediate 12b can be obtained by simply replacing the corresponding raw materials and following the same preparation method. MS (ESI, m / z): 523 (M + +1).
[0199] Example 4 Synthesis of Intermediate 13
[0200]
[0201] Intermediate 12b (74 mg, 0.12 mmol) was dissolved in dichloromethane (0.5 mL), trifluoroacetic acid (0.5 mL) was added, and the mixture was stirred at room temperature for 2 h. The reaction solution was then dried to obtain intermediate 13 (72 mg, 98%). MS (ESI, m / z): 611 (M + +1).
[0202] Example 5 Synthesis of Intermediate 16
[0203]
[0204] a) 4-cyano-1-butyne (1 g, 10.74 mmol) was dissolved in isopropanol (20 mL), solid NaHCO3 (1.98 g, 23.63 mg) was added to the reaction system, and hydroxylamine hydrochloride (1.12 g, 16.11 mmol) was added after stirring at room temperature for 15 min, and the mixture was stirred at 80°C for 3 h. After the reaction was complete, the reaction solution was cooled to room temperature, filtered, and the filtrate was concentrated under reduced pressure to obtain intermediate 14a (1.35 g, 99%). MS (ESI, m / z): 113 (M + +1). Intermediate 14b can be prepared by the same method by simply replacing the corresponding raw materials.
[0205] b) Intermediate 14b (600 mg, 4.76 mmol), compound 7 (1.88 g, 4.32 mmol) and HATU (2.71 g, 7.14 mmol) were dissolved in dichloromethane (40 mL), and DIPEA (1.25 mL, 7.14 mmol) was added to the reaction system, and the reaction was stirred at room temperature overnight. After the reaction was completed, the reaction solution was extracted with dichloromethane (30 mL×3), and the combined organic layers were washed with saturated NaCl solution, dried over anhydrous Na2SO4, filtered and concentrated, and purified by column chromatography to obtain intermediate 15a (790 mg, 31%). MS (ESI, m / z): 529 (M + +1). Intermediate 15b can be obtained by simply replacing the corresponding raw materials and following the same preparation method.
[0206] c) Intermediate 15a (790 mg, 1.46 mmol) was dissolved in pyridine (8 mL) and stirred at 100°C overnight. After the reaction was complete, the reaction solution was concentrated under reduced pressure and purified by column chromatography to obtain intermediate 16a (230 mg, 30%). MS (ESI, m / z): 511 (M + +1). Intermediate 16b can be obtained by simply replacing the corresponding raw materials and following the same preparation method.
[0207] Example 6 Synthesis of Intermediate 13
[0208]
[0209] a) Compound 7 (400 mg, 0.46 mmol) was dissolved in anhydrous dichloromethane (3 mL), EDCI (210 mg, 0.55 mmol) was added to the reaction system, and the mixture was stirred at room temperature for 30 min. Then tert-butyl carbazate (213 mg, 0.8 mmol) was added, and the mixture was stirred at room temperature for 10 h. After the reaction was completed, the reaction solution was washed with 5% HCl (10 mL), the organic layer was washed with NaHCO3 (10 mL) and extracted with dichloromethane (30 mL×3), the combined organic layers were washed with saturated NaCl solution, dried over anhydrous Na2So4, filtered and concentrated, and purified by column chromatography to obtain intermediate 17 (280 mg, 55%). MS (ESI, m / z): 549 (M + +1).
[0210] b) Intermediate 17 (200 mg, 0.36 mmol) was dissolved in dichloromethane (2 mL), and a solution of hydrochloric acid in 1,4-dioxane (4 M, 0.3 mmol) was added dropwise to the reaction system. The mixture was stirred at room temperature for 1 h. After the reaction was complete, the reaction solution was filtered and the filter cake was washed with dichloromethane. The filter cake was dried to obtain intermediate 18 (155 mg, 89%). MS (ESI, m / z): 485 (M + +1).
[0211] Example 7 Synthesis of Intermediates 20, 23, and 26
[0212]
[0213] a) Intermediate 18 (145 mg, 0.32 mmol) was dissolved in anhydrous DMF (2 mL), and DIPEA (0.21 mL, 1.29 mmol) was added to the reaction system at 0°C and stirred at room temperature for 30 min. At the same time, 5-hexynoic acid (32 mg, 0.32 mmol) was added to the reaction system at room temperature. EDCI (80 mg, 0.42 mmol) and HOBt (57 mg, 0.42 mmol) were added to the reaction system at room temperature and stirred at room temperature for 30 min. The two reaction systems were then mixed and stirred at room temperature for 10 h. After the reaction was complete, the mixture was extracted with ethyl acetate (10 mL×3), and the combined organic layers were washed with saturated NaCl solution, dried over anhydrous Na2SO4, filtered and concentrated. Intermediate 19 (110 mg, 65%) was obtained by column chromatography. MS (ESI, m / z): 543 (M + +1). Intermediates 21 and 24 can be prepared by the same method by simply replacing the corresponding raw materials.
[0214] b) Intermediate 19 (90 mg, 0.17 mmol) was dissolved in anhydrous acetonitrile (3 mL), p-toluene yellow acid chloride (97.4 mL, 0.51 mmol) and DIPEA (56 μL, 0.34 mmol) were added to the reaction system, and the reaction was stirred at room temperature overnight. After the reaction was complete, the mixture was extracted with ethyl acetate (10 mL×3), and the combined organic layers were washed with saturated NaCl solution, dried over anhydrous Na2SO4, filtered and concentrated. Intermediate 20 (110 mg, 65%) was obtained by column chromatography purification. MS (ESI, m / z): 525 (M + +1). Intermediates 22 and 25 can be prepared by the same method by simply replacing the corresponding raw materials.
[0215] c) Referring to the synthesis method of intermediate 13, intermediates 23 and 26 can be prepared by simply replacing the corresponding raw materials.
[0216] Example 8 Synthesis of Intermediate 30
[0217]
[0218] a) The raw material 27 (1.8 g, 6.5 mmol), the raw material 28 (2.5 g, 6.9 mmol), and triphenylphosphine (3.9 g, 14.8 mmol) were dissolved in toluene (50 mL), and then diisopropyl azodicarboxylate (DIAD, 2.8 g, 13.9 mmol) was added dropwise, and the mixture was stirred at 70°C for 1 h. After the reaction was complete, the mixture was concentrated and purified by column chromatography to obtain compound 29 (2.3 g, 50.2%) as a light yellow solid. MS (ESI, m / z): 640 (M + +1).
[0219] b) Compound 29 was dissolved in ethyl acetate (2 mL), and then a 1,4-dioxane solution of hydrochloric acid (4 M, 2 mL) was added to the reaction system and stirred at room temperature for 12 h to obtain a white suspension. The reaction solution was filtered and washed with ethyl acetate, and the filter cake was collected and dried to obtain a white solid intermediate 30 (1.1 g, 83%). MS (ESI, m / z): 326 (M + +1).
[0220] Example 9 Synthesis of Intermediate 33
[0221]
[0222] a) Intermediate 30 (1.25 g, 3.4 mmol) was dissolved in acetonitrile (5 mL), and DIPEA (1.2 g, 8.8 mmol) and raw material 8 (778.8 mg, 3.4 mmol) were added at 0°C and stirred at room temperature for 5 h. After the reaction was completed, the reaction solution was concentrated and purified by column chromatography to obtain intermediate 31 (1.0 g, 55%). MS (ESI, m / z): 516 (M + +1).
[0223] b) Intermediate 31 (1.0 g, 1.9 mmol) was dissolved in acetonitrile (5 mL), and the solution was added dropwise to a solution of acetonitrile / water / HCl (4 M) (100:10:0.5 (mL)) under reflux. The reaction solution was stirred at reflux for 5 h. After the reaction was completed, the reaction solution was concentrated and washed with methanol to obtain intermediate 32 (710.5 mg, 68%). MS (ESI, m / z): 480 (M + +1).
[0224] c) Intermediates 33a and 33b were prepared by referring to the synthetic step c of Intermediate 12.
[0225] Example 10 Synthesis of Intermediate 37
[0226]
[0227] a) According to the synthetic step a of intermediate 30, intermediates 35a-35b can be obtained.
[0228] b) Intermediate 35a (1.9 g, 3.34 mmol) was dissolved in methanol (60 mL), and then 10% Pd / C (381 mg, 55% water content) was added and stirred at room temperature for 12 h under hydrogen. The reaction solution was filtered and washed with methanol (30 mL). The crude intermediate 36a was obtained by concentration and filtration. MS (ESI, m / z): 328 (M + +1). Intermediate 36b can be obtained by simply replacing the corresponding raw materials and following the same preparation method.
[0229] c) Referring to the synthesis step b of intermediate 30, intermediates 37a-37b can be prepared by simply replacing the corresponding raw materials.
[0230] Example 11 Synthesis of Intermediate 40
[0231]
[0232] a) Referring to the synthetic step a of intermediate 33, intermediates 38a-38b can be prepared by simply replacing the corresponding raw materials.
[0233] b) Referring to the synthetic step b of intermediate 33, intermediates 39a-39b can be prepared by simply replacing the corresponding raw materials.
[0234] c) Referring to step c of the synthesis of intermediate 33, intermediates 40a-40c can be prepared by simply replacing the corresponding raw materials.
[0235] Example 12 Synthesis of Intermediates 44 and 47
[0236]
[0237] a) The raw material 28 (41 mg, 0.1 mmol) and the raw material 41 (144 mg, 1.192 mmol) were dissolved in anhydrous THF (2 mL), and a solution of NaH (8 mg, 0.8 mmol) in anhydrous THF was added dropwise and refluxed for 6 h. After the reaction was complete, the reaction solution was cooled to room temperature and quenched with water (2 mL). The reaction solution was extracted with dichloromethane (10 mL×3), the combined organic layers were washed with saturated NaCl solution, dried over anhydrous Na2SO4, filtered and concentrated, and purified by column chromatography to obtain intermediate 45 (20 mg, 50%). MS (ESI, m / z): 408 (M + +1). Intermediate 43 can be obtained by simply replacing the corresponding raw materials and following the same preparation method.
[0238] b) Referring to the synthesis method of intermediate 13, intermediates 44 and 46 can be prepared by simply replacing the corresponding raw materials.
[0239] c) Referring to the synthetic step a of intermediate 33, intermediate 47 can be prepared by simply replacing the corresponding raw materials.
[0240] Example 13 Synthesis of Intermediate 50
[0241]
[0242] a) According to the synthetic step a of intermediate 33, intermediate 48 can be obtained.
[0243] b) Dissolve intermediate 48 (29.4 mg, 0.052 mmol) in dichloromethane (5 mL), add 4 M HCl to adjust the pH to 2.0-2.2, add HOVEYDA-GRUBBS catalyst (7 mg, 0.005 mmol) under nitrogen protection, add two portions every 1 h. Heat and stir at 45 °C for 4 h. Cool the reaction mixture. Extract the reaction solution with dichloromethane (10 mL×3), wash the combined organic layers with saturated NaCl solution, dry over anhydrous Na2SO4, filter and concentrate, and purify by column chromatography to obtain intermediate 49 (22.3 mg, 80%). MS (ESI, m / z): 536 (M + +1).
[0244] c) Referring to the synthesis step c of intermediate 12, intermediate 50 can be prepared by simply replacing the corresponding raw materials.
[0245] Example 14 Synthesis of Intermediates 53, 55, and 57
[0246]
[0247] a) The raw material 51 (4.05 g, 14.66 mmol) was dissolved in 1,4-dioxane (50 mL), and N-Boc-ethylenediamine (3.06 g, 17.59 mmol) and DIPEA (3.16 mL, 19.06 mmol) were added to the reaction system, and the reaction was stirred at 90°C overnight. After the reaction was completed, the reaction solution was cooled to room temperature, concentrated under reduced pressure, diluted with water, extracted with ethyl acetate (30 mL×3), and the combined organic layers were washed with saturated NaCl solution, dried over anhydrous Na2SO4, filtered and concentrated, and purified by column chromatography to obtain intermediate 52a (1.59 g, 25%). MS (ESI, m / z): 417 (M + +1). Intermediates 53b-53d, 54, 56a-56b can be obtained by simply replacing the corresponding raw materials and following the same preparation method.
[0248] b) Referring to the synthesis method of intermediate 13, intermediates 53a-53d, 55, 57a-57b can be prepared by simply replacing the corresponding raw materials.
[0249] Example 15 Synthesis of Intermediate 59
[0250]
[0251] a) The raw material 55 (3.31 g, 10 mmol) was dissolved in DMF (50 mL), and N-tert-butyloxycarbonyl-1,3-propanediamine (2.1 g, 12 mmol), DIPEA (5.2 mL, 30 mmol) and HATU (5.7 g, 15 mmol) were added to the reaction system. The reaction was stirred at room temperature for 6 h. After the reaction was complete, it was extracted with ethyl acetate (30 mL×3). The combined organic phases were washed with saturated NaCl solution, dried over anhydrous Na2SO4, filtered and concentrated under reduced pressure, and purified by column chromatography to obtain intermediate 58 (3.17 g, 65%). MS (ESI, m / z): 488 (M + +1).
[0252] b) Intermediate 59 was prepared by referring to the synthetic method of Intermediate 13.
[0253] Example 16 Synthesis of Intermediates 62, 64, 66, 68, 70, 72
[0254]
[0255] a) Referring to step a of the synthesis of intermediate 53, intermediates 61, 63, 65a-65c, 67a-67b, 69, and 71 can be prepared by simply replacing the corresponding raw materials.
[0256] b) Referring to the synthesis method of intermediate 13, intermediates 62, 64, 66a-66c, 68a-68b, 70, and 72 can be prepared by simply replacing the corresponding raw materials.
[0257] Example 17 Synthesis of Intermediate 74
[0258]
[0259] a) Referring to the synthetic step a of intermediate 59, intermediate 73 can be prepared by simply replacing the corresponding raw materials.
[0260] b) Referring to the synthetic step b of intermediate 59, intermediate 74 can be prepared by simply replacing the corresponding raw materials.
[0261] Example 18 Synthesis of Intermediates 76, 78, 80, 82, 84, 86, 88
[0262]
[0263] a) Referring to the synthetic step a of intermediate 53, intermediates 75, 77, 79, 81, 83, 85, and 87 can be prepared by simply replacing the corresponding raw materials.
[0264] b) Referring to the synthesis method of intermediate 13, intermediates 76, 78, 80, 82, 84, 86, and 88 can be prepared by simply replacing the corresponding raw materials.
[0265] Example 19 Synthesis of Intermediates 90, 92, 94, 96, 98, and 100
[0266]
[0267] a) Referring to step a of the synthesis of intermediate 53, intermediates 89, 91a-91b, 93, 95, 97, 99a-99b can be prepared by simply replacing the corresponding raw materials.
[0268] b) Referring to the synthesis method of intermediate 13, intermediates 90, 92a-92b, 94, 96, 98, 100a-100b can be prepared by simply replacing the corresponding raw materials.
[0269] Example 20 Synthesis of Intermediates 102, 104, 106, 108, 110, 112
[0270]
[0271] a) Referring to the synthetic step a of intermediate 53, intermediates 101, 103, 105, 107, 109 and 111 can be prepared by simply replacing the corresponding raw materials.
[0272] b) Referring to the synthesis method of intermediate 13, intermediates 102, 104, 106, 108, 110, and 112 can be prepared by simply replacing the corresponding raw materials.
[0273] Example 21 Synthesis of Intermediates 114, 116, 118, 120, 122, 124, 126, 128
[0274]
[0275] a) Referring to the synthetic step a of intermediate 53, intermediates 113, 115, 117, 119, 121, 123, 125, and 127 can be prepared by simply replacing the corresponding raw materials.
[0276] b) Referring to the synthesis method of intermediate 13, intermediates 114, 116, 118, 120, 122, 124, 126, and 128 can be prepared by simply replacing the corresponding raw materials.
[0277] Example 22 Synthesis of Intermediate 133
[0278]
[0279] a) Referring to the synthetic step a of intermediate 53, intermediate 130 can be prepared by simply replacing the corresponding raw materials.
[0280] b) Referring to the synthetic step a of intermediate 20, intermediate 132 can be prepared by simply replacing the corresponding raw materials.
[0281] c) Intermediate 133 was prepared by referring to the synthetic method of intermediate 13.
[0282] Example 23 Synthesis of Intermediate 133
[0283]
[0284] a) Under argon protection, the raw material 134 (1.38 g, 4.3 mmol), N-Boc-aminopropyne (1 g, 6.4 mmol), Pd(pph3)2Cl2 (301 mg, 0.43 mmol), and cuprous iodide (164 mg, 0.86 mmol) were dissolved in DMF (15 mL), and triethylamine (13 mL, 0.1 mmol) was added to the reaction system. The reaction was stirred at 80°C overnight. After the reaction was completed, the reaction solution was cooled to room temperature, filtered through diatomaceous earth, and the filtrate was extracted with ethyl acetate (30 mL×3). The combined organic layers were washed with saturated NaCl solution, dried over anhydrous Na2SO4, filtered and concentrated, and purified by column chromatography to obtain intermediate 135a (619 mg, 35%). MS (ESI, m / z): 398 (M + +1). Intermediates 135b-135d, 137, and 139 can be obtained by simply replacing the corresponding raw materials and following the same preparation method.
[0285] b) Intermediates 136a-136d, 138, and 140 were prepared by referring to the synthetic method of intermediate 13.
[0286] Example 24 Synthesis of Intermediate 143
[0287]
[0288] a) Referring to the synthesis method of intermediate 133, intermediate 142 can be obtained by simply replacing the corresponding raw materials.
[0289] b) Referring to the synthesis method of intermediate 13, intermediate 143 can be obtained by simply replacing the corresponding raw materials.
[0290] Example 25 Synthesis of Intermediate 146
[0291]
[0292] a) Referring to the synthesis method of intermediate 133, intermediate 145 can be obtained by simply replacing the corresponding raw materials.
[0293] b) Referring to the synthesis method of intermediate 13, intermediate 146 can be obtained by simply replacing the corresponding raw materials.
[0294] Example 25 Synthesis of Intermediate 149
[0295]
[0296] a) Referring to the synthesis method of intermediate 133, intermediate 148 can be obtained by simply replacing the corresponding raw materials.
[0297] b) Referring to the synthesis method of intermediate 13, intermediate 149 can be obtained by simply replacing the corresponding raw materials.
[0298] Example 26 Synthesis of Intermediates 153 and 158
[0299]
[0300] a) The raw material 150 (1.57 g, 5.71 mmol) was dissolved in DMF (57 mL), K2CO3 (1.19 g, 8.58 mmol) and raw material 151 (2.2 g, 5.71 mmol) were added, and the mixture was stirred at room temperature for 2 h. After the reaction was complete, water was added to quench the mixture, and the mixture was extracted with dichloromethane (30 mL×3). The organic phases were combined, washed with saturated NaCl solution, dried with anhydrous Na2SO4, filtered to remove salt, concentrated under reduced pressure, and purified by column chromatography to obtain intermediate 152 (3.07 g, 93%). MS (ESI, m / z): 418 (M + +1). Intermediate 155 can be obtained by simply replacing the corresponding raw materials and following the same preparation method.
[0301] b) Referring to the synthesis method of intermediate 13, intermediates 153 and 156 can be obtained by simply replacing the corresponding raw materials.
[0302] c) Referring to the synthetic step a of intermediate 59, intermediate 157 can be obtained by simply replacing the corresponding raw materials.
[0303] d) Referring to the synthesis method of intermediate 13, intermediate 158 can be obtained by simply replacing the corresponding raw materials.
[0304] Example 27 Synthesis of Compounds 162 and 164
[0305]
[0306] a) The raw material 159 (105.3 mg, 0.34 mmol), K2CO3 (140 mg, 1 mmol) and the raw material 160a (95 mg, 0.30 mmol) were dissolved in DMF (1 mL) and stirred at 60°C overnight. After the reaction was completed, the reaction mixture was cooled, diluted with H2O, extracted with ethyl acetate (10 mL×3), the organic phases were combined, washed with saturated NaCl solution, dried over anhydrous Na2SO4, filtered to remove salt, concentrated under reduced pressure, and purified by column chromatography to obtain intermediate 161a (12 mg, 8%). MS (ESI, m / z): 230 (M + +1). Intermediates 161b and 163 can be obtained by simply replacing the corresponding raw materials and following the same preparation method.
[0307] b) Referring to the synthesis method of intermediate 13, intermediates 162a-162b and 164 can be obtained by simply replacing the corresponding raw materials.
[0308] Example 28 Synthesis of Compounds 168, 170, 172, 174, 176, 178, 180, 182, 184, 186, 188, 190, 192, 194
[0309]
[0310] a) Referring to the synthetic step a of intermediate 162, intermediates 167, 169, 171, 173, 175, 177, 179, 181, 183, 185, 187, 189, 191, and 193 can be obtained by simply replacing the corresponding raw materials.
[0311] b) Referring to the synthesis method of intermediate 13, intermediates 168, 170, 172, 174, 176, 178, 180, 182, 184, 186, 188, 190, 192, and 194 can be obtained by simply replacing the corresponding raw materials.
[0312] Example 29 Synthesis of Compound 197
[0313]
[0314] a) Referring to the synthetic step a of intermediate 53, intermediate 196 can be obtained by simply replacing the corresponding starting materials.
[0315] b) Referring to the synthesis method of intermediate 13, intermediate 197 can be obtained by simply replacing the corresponding raw materials.
[0316] Example 30 Synthesis of Compound 200
[0317]
[0318] a) According to the synthetic step a of intermediate 53, intermediate 199 can be obtained by simply replacing the corresponding starting materials.
[0319] b) According to the synthesis method of intermediate 13, intermediate 200 can be obtained by simply replacing the corresponding raw materials.
[0320] Example 31 Synthesis of Compounds 203, 206, and 209
[0321]
[0322] a) Referring to the synthesis step a of intermediate 16, intermediates 201a-201b, 204a-204b, 205a-205b can be obtained by simply replacing the corresponding raw materials.
[0323] b) Referring to the synthesis step b of intermediate 16, intermediates 202a-202b, 205a-205b, 207a-207b can be obtained by simply replacing the corresponding raw materials.
[0324] c) Referring to the synthesis method of intermediate 13, intermediates 203a-203b, 206a-206b, 209a-209b can be obtained by simply replacing the corresponding raw materials.
[0325] Example 32 Synthesis of Compound 210
[0326]
[0327] Referring to the synthesis method of intermediate 13, intermediate 210 can be obtained by simply replacing the corresponding raw materials.
[0328] Example 33 Synthesis of Compound S1
[0329]
[0330] Intermediate 14a (100 mg, 0.24 mmol), compound 7 (105.1 mg, 0.24 mmol), EDCI (69 mg, 0.36 mmol) and HOBt (48.6 mg, 0.36 mmol) were dissolved in DMF (2 mL), NMM (139 μL, 1.2 mmol) was added to the reaction system, and the mixture was stirred at 25°C for overnight reaction. After the reaction was complete, water (15 mL) was added to the reaction solution for dilution, and the filter cake was filtered to obtain compound S1 (88 mg, 50%). 1H NMR (500 MHz, DMSO-d6) δ 11.10 (s, 1H), 10.07 (s, 1H), 9.81 (s, 1H), 8.21 (s, 1H), 8.02 (d, J=7.6Hz, 1H), 7.96 (dd, J=7.4, 2.1Hz, 1H), 7.65 (dd, J=7 .4, 1.9Hz, 1H), 7.44 (dd, J=6.1, 2.0Hz, 2H), 7.38 (t, J=7.4Hz, 1H), 7.34-7.26 (m, 2H), 7.25-7.18 (m, 1H), 7.17-7.10 (m, 2 H), 6.95 (s, 1H), 6.75 (s, 1H), 5.13 (d, J = 2.8Hz, 2H), 4.56 (t, J = 5.5Hz, 1H), 4.27 (d, J = 5.4Hz, 2H), 3.75 (d, J = 12.5Hz, 1H) ), 3.64-3.57(m, 3H), 2.66(s, 1H), 2.54(s, 1H), 2.49(s, 1H), 1.99(s, 1H), 1.78(s, 3H), 1.73(s, 3H).MS (ESI, m / z): 733(M + +1).
[0331] Example 34 Synthesis of Compound S2
[0332]
[0333] The synthesis method refers to the synthesis of compound S1, and compound S2 can be prepared by simply replacing the corresponding raw materials. 1H NMR(500MHz, DMSO-d6)δ 11.10 (s, 1H), 10.07 (s, 1H), 9.81 (s, 1H), 8.07-7.99 (m, 2H), 7.90 (dd, J=7.3, 2.2Hz, 1H), 7.65 (dd, J=7.4, 1.9Hz, 1H), 7.47-7.41 (m , 2H), 7.39 (t, J=7.4Hz, 1H), 7.34-7.26 (m, 2H), 7.25-7.18 (m, 1H), 7.17-7.10 (m, 2H), 6.76 (s, 1H), 6.70 (s, 1H), 5.13 (d, J=2.8Hz, 2H ), 4.56 (t, J=5.5Hz, 1H), 4.28 (dd, J=12.4, 5.5Hz, 1H), 4.20 (dd, J=12.4, 5.5Hz, 1H), 3.39 (d, J=2.7Hz, 2H), 3.32 (d, J=12.4Hz, 1H), 3 .26 (d, J=12.5Hz, 1H), 2.66 (s, 1H), 2.54 (s, 1H), 2.49 (s, 1H), 1.97 (d, J=19.2Hz, 3H), 1.78 (s, 3H), 1.73 (s, 3H). MS (ESI, m / z): 747 (M + +1).
[0334] Example 35 Synthesis of Compound S3
[0335]
[0336] The synthesis method refers to the synthesis of compound S1, and compound S3 can be prepared by simply replacing the corresponding raw materials. 1H NMR(500MHz, DMSO-d6)δ 11.10 (s, 1H), 10.07 (s, 1H), 9.81 (s, 1H), 8.04-7.93 (m, 3H), 7.65 (dd, J=7.4, 1.9Hz, 1H), 7.47-7.35 (m, 3H), 7.34- 7.26 (m, 2H), 7.26-7.18 (m, 3H), 7.03 (s, 1H), 6.88 (s, 1H), 5.20-5.15 (m, 1H), 5.12 (s, 1H), 4.56 (t, J=5.5Hz, 1H), 4 .30 (dd, J=12.4, 5.4Hz, 1H), 4.20 (dd, J=12.4, 5.5Hz, 1H), 3.56 (s, 2H), 3.19 (s, 2H), 2.66 (s, 1H), 2.54 (s, 1H), 2.2 4 (d, J=0.9Hz, 2H), 1.78 (s, 3H), 1.73 (s, 3H), 1.65 (d, J=4.7Hz, 4H), 1.34 (s, 2H), 1.28 (s, 2H). MS (ESI, m / z): 789 (M + +1).
[0337] Example 36 Synthesis of Compound S4
[0338]
[0339] The synthesis method refers to the synthesis of compound S1, and compound S4 can be prepared by simply replacing the corresponding raw materials. 1H NMR(500MHz, DMSO-d6)δ 11.10 (s, 1H), 10.07 (s, 1H), 9.81 (s, 1H), 8.07-7.99 (m, 3H), 7.65 (dd, J=7.4, 1.9Hz, 1H), 7.49 (d, J=1.9Hz, 1H), 7.47-7.40 ( m, 2H), 7.34-7.26 (m, 2H), 7.25-7.18 (m, 1H), 7.17-7.10 (m, 2H), 6.70 (s, 1H), 6.55 (s, 1H), 5.13 (d, J=1.3Hz, 1H), 5.01 (s, 1H) ), 4.56 (t, J=5.5Hz, 1H), 4.28 (dd, J=12.4, 5.5Hz, 1H), 4.20 (dd, J=12.4, 5.5Hz, 1H), 3.46 (s, 2H), 3.32 (d, J=12.5Hz, 1H), 3. 24 (d, J=12.3Hz, 1H), 2.62 (d, J=11.5Hz, 2H), 2.24 (d, J=0.9Hz, 2H), 1.79 (d, J=10.1Hz, 5H), 1.73 (s, 3H). MS (ESI, m / z): 747 (M + +1).
[0340] Example 37 Synthesis of Compound S5
[0341]
[0342] The synthesis method refers to the synthesis of compound S1, and compound S5 can be prepared by simply replacing the corresponding raw materials. 1H NMR(500MHz, DMSO-d6)δ 11.10 (s, 1H), 10.07 (s, 1H), 9.81 (s, 1H), 8.18 (s, 1H), 8.02 (d, J=7.5Hz, 1H), 7.96 (dd, J=7.4, 2.1Hz, 1H), 7.65 (dd, J=7.4, 1.9Hz, 1H), 7.44 ( dd, J=6.1, 2.0Hz, 2H), 7.39 (t, J=7.5Hz, 1H), 7.34-7.26 (m, 2H), 7.25-7.18 (m, 1H), 7.17-7.10 (m, 2H), 6.88 (s, 1H), 6.70 (s, 1H), 5.15-5.10 ( m, 2H), 4.56 (t, J=5.5Hz, 1H), 4.28 (dd, J=12.4, 5.5Hz, 1H), 4.20 (dd, J=12.4, 5.5Hz, 1H), 3.49 (d, J=1.8Hz, 2H), 3.19 (d, J=1.2Hz, 2H), 2.66 ( s, 1H), 2.54 (s, 1H), 2.24 (d, J=0.9Hz, 2H), 1.78 (s, 3H), 1.73 (s, 3H), 1.66-1.54 (m, 4H), 1.34 (s, 2H), 1.32-1.24 (m, 6H). MS (ESI, m / z): 817 (M + +1).
[0343] Example 38 Synthesis of Compound S6
[0344]
[0345] The synthesis method refers to the synthesis of compound S1, and compound S6 can be prepared by simply replacing the corresponding raw materials. 1H NMR(500MHz, DMSO-d6)δ 11.10 (s, 1H), 9.10 (s, 1H), 8.34 (s, 1H), 8.02 (d, J=7.5Hz, 1H), 7.99-7.94 (m, 2H), 7.68-7.62 (m, 2H), 7.47-7.41 (m, 2H), 7. 34-7.27 (m, 3H), 7.26-7.18 (m, 3H), 7.03 (s, 1H), 6.12 (s, 1H), 5.20-5.15 (m, 1H), 5.12 (s, 1H), 4.56 (t, J=5.5Hz, 1H), 4.52- 4.43 (m, 2H), 4.30 (dd, J=12.4, 5.4Hz, 1H), 4.20 (dd, J=12.4, 5.5Hz, 1H), 3.36 (d, J=12.5Hz, 1H), 3.28 (d, J=12.5Hz, 1H), 3. 09-2.98 (m, 2H), 2.66 (s, 1H), 2.54 (s, 1H), 2.25 (d, J=11.2Hz, 2H), 1.78 (s, 3H), 1.72 (d, J=17.0Hz, 5H). MS (ESI, m / z): 804 (M + +1).
[0346] Example 39 Synthesis of Compound S7
[0347]
[0348] The synthesis method refers to the synthesis of compound S1, and compound S7 can be prepared by simply replacing the corresponding raw materials. 1 H NMR(500MHz, DMSO-d6)δ 11.10 (s, 1H), 10.2 (s, 1H), 9.10 (s, 1H), 8.22 (s, 1H), 8.02 (d, J = 7.5Hz, 1H), 7.91 (d, J = 7.3Hz, 1H), 7.72 (s, 1H), 7.65 (dd, J=7.4, 1.9Hz, 1H), 7.52-7.41 (m, 4H), 7.34-7.26 (m, 2H), 7.26-7.18 (m, 3H), 6.55 (s, 1 H), 5.19-5.15 (m, 1H), 5.01 (s, 1H), 4.56 (t, J=5.5Hz, 1H), 4.33-4.25 (m, 2H), 3.45-3.36 (m, 4H), 3.36-3 .25 (m, 2H), 2.62 (d, J=11.4Hz, 4H), 2.24 (d, J=0.9Hz, 2H), 1.78 (s, 3H), 1.73 (s, 3H).MS (ESI, m / z): 804 (M + +1).
[0349] Example 40 Synthesis of Compound S8
[0350]
[0351] The synthesis method refers to the synthesis of compound S1, and compound S8 can be prepared by simply replacing the corresponding raw materials. 1 H NMR(500MHz, DMSO-d6)δ 11.10 (s, 1H), 10.2 (s, 1H), 9.10 (s, 1H), 8.14 (s, 1H), 8.04-7.95 (m, 2H), 7.65 (dd, J=7.4, 1.9Hz, 1H), 7.48-7.41 (m, 2H), 7.34-7.26 (m, 2H), 7.26-7.18 (m, 4H), 7.07 (dd, J=7.5, 2.0Hz, 1H), 5.15-5 .10 (m, 2H), 4.56 (t, J = 5.5Hz, 1H), 4.42-4.31 (m, 2H), 4.22 (d, J = 2.0Hz, 2H), 3.68-3.58 (m, 2H), 2 .66 (s, 1H), 2.54 (s, 1H), 2.49 (s, 1H), 1.99 (s, 1H), 1.78 (s, 3H), 1.73 (s, 3H). MS (ESI, m / z): 734 (M + +1).
[0352] Example 41 Synthesis of Compound S9
[0353]
[0354] The synthesis method refers to the synthesis of compound S1, and compound S9 can be prepared by simply replacing the corresponding raw materials. 1H NMR(500MHz, DMSO-d6)δ 11.10 (s, 1H), 10.2 (s, 1H), 8.97 (s, 1H), 8.04-7.94 (m, 3H), 7.78 (s, 1H), 7.65 (dd, J=7.4, 1.9Hz, 1H), 7.45 (d, J=2 .0Hz, 1H), 7.34-7.26 (m, 2H), 7.26-7.16 (m, 4H), 7.12 (dd, J=7.5, 2.0Hz, 1H), 7.03 (s, 1H), 5.20-5.15 (m, 1H), 5.1 2 (s, 1H), 4.59-4.52 (m, 3H), 4.30 (dd, J=12.4, 5.4Hz, 1H), 4.20 (dd, J=12.4, 5.5Hz, 1H), 3.39-3.29 (m, 2H), 3.13 ( s, 2H), 2.66 (s, 1H), 2.54 (s, 1H), 2.25 (d, J=11.2Hz, 2H), 1.78 (s, 3H), 1.72 (d, J=17.0Hz, 5H). MS (ESI, m / z): 805 (M + +1).
[0355] Example 42 Synthesis of Compound S10
[0356]
[0357] The synthesis method refers to the synthesis of compound S1, and compound S10 can be prepared by simply replacing the corresponding raw materials. 1 H NMR(500MHz, DMSO-d6)δ 11.10 (s, 1H), 10.2 (s, 1H), 9.10 (s, 1H), 8.02 (d, J=7.5Hz, 1H), 7.96 (s, 1H), 7.82 (d, J=7.4Hz, 1H), 7.68-7 .62 (m, 2H), 7.47-7.41 (m, 2H), 7.34-7.26 (m, 2H), 7.26-7.18 (m, 4H), 5.18 (t, J=1.1Hz, 1H), 5.01 (s, 1H), 4 .56 (t, J=5.5Hz, 1H), 4.30 (dd, J=12.4, 5.4Hz, 1H), 4.20 (dd, J=12.4, 5.5Hz, 1H), 3.45-3.39 (m, 6H), 2.62 ( d, J=11.5Hz, 2H), 2.23 (d, J=3.8Hz, 2H), 1.80-1.71 (m, 7H), 1.63 (s, 2H), 1.59 (s, 2H). MS (ESI, m / z): 787 (M + +1).
[0358] Example 43 Synthesis of Compound S11
[0359]
[0360] The synthesis method refers to the synthesis of compound S1, and compound S11 can be prepared by simply replacing the corresponding raw materials. 1 H NMR(500MHz, DMSO-d6)δ 11.10 (s, 1H), 10.2 (s, 1H), 9.12 (s, 1H), 8.26 (s, 1H), 8.02 (d, J = 7.5Hz, 1H), 7.86 (d, J = 7.5Hz, 1H), 7.65 (dd, J = 7.1, 1.9Hz, 2H), 7.45 (d, J=2.1Hz, 1H), 7.38 (dd, J=7.5, 2.0Hz, 1H), 7.34-7.26 (m, 2H), 7.26-7.18 (m, 3H), 7.03 (s, 1H), 5.19-5.15 (m, 1H), 5.01 (s, 1H), 4.5 6 (t, J=5.5Hz, 1H), 4.30 (dd, J=12.4, 5.4Hz, 1H), 4.20 (dd, J=12.4, 5.5Hz, 1H), 3.35 (s, 2H), 3.31 (s, 2H), 3.19 (s, 2H), 2.62 (d, J=11.5 Hz, 2H), 2.23 (d, J=3.8Hz, 2H), 1.94 (s, 1H), 1.86 (d, J=12.5Hz, 1H), 1.78 (s, 3H), 1.75-1.65 (m, 6H), 1.62 (s, 2H). MS (ESI, m / z): 801 (M + +1).
[0361] Example 44 Synthesis of Compound S12
[0362]
[0363] The synthesis method refers to the synthesis of compound S1, and compound S12 can be prepared by simply replacing the corresponding raw materials. 1H NMR(500MHz, DMSO-d6)δ 11.10 (s, 1H), 10.2 (s, 1H), 9.12 (s, 1H), 8.07-7.99 (m, 2H), 7.86 (d, J=7.5Hz, 1H), 7.68-7.62 (m, 2H), 7.47-7.38 (m, 2H) , 7.34-7.26 (m, 2H), 7.26-7.18 (m, 3H), 7.03 (s, 1H), 5.19-5.15 (m, 1H), 5.01 (s, 1H), 4.56 (t, J=5.5Hz, 1H), 4.30 (dd, J= 12.4, 5.4Hz, 1H), 4.20 (dd, J=12.4, 5.5Hz, 1H), 3.34 (s, 2H), 3.22 (d, J=19.4Hz, 4H), 2.62 (d, J=11.5Hz, 2H), 2.23 (d, J= 3.8Hz, 2H), 2.06 (s, 1H), 1.78 (s, 3H), 1.72 (d, J=16.3Hz, 5H), 1.66 (d, J=12.3Hz, 4H), 1.42 (s, 2H). MS (ESI, m / z): 815 (M + +1).
[0364] Example 45 Synthesis of Compound S13
[0365]
[0366] The synthesis method refers to the synthesis of compound S1, and compound S13 can be prepared by simply replacing the corresponding raw materials. 1 H NMR(500MHz, DMSO-d6)δ 11.10 (s, 1H), 10.2 (s, 1H), 9.12 (s, 1H), 8.08 (s, 1H), 8.02 (d, J=7.5Hz, 1H), 7.71-7.61 (m, 3H), 7.4 5(d, J=2.0Hz, 1H), 7.34-7.26(m, 2H), 7.26-7.18(m, 4H), 5.19-5.15(m, 1H), 5.01(s, 1H), 4.56(t, J =5.5Hz, 1H), 4.30 (dd, J = 12.4, 5.4Hz, 1H), 4.20 (dd, J = 12.4, 5.5Hz, 1H), 3.42 (s, 2H), 3.36 (s, 2H), 3.22 (s, 2H), 2.61 (d, J=6.4Hz, 2H), 2.23 (d, J=3.8Hz, 2H), 1.80-1.66 (m, 11H). MS (ESI, m / z): 805 (M + +1).
[0367] Example 46 Synthesis of Compound S14
[0368]
[0369] The synthesis method refers to the synthesis of compound S1, and compound S14 can be prepared by simply replacing the corresponding raw materials. 1 H NMR(500MHz, DMSO-d6)δ 11.10 (s, 1H), 10.2 (s, 1H), 8.99 (s, 1H), 8.16 (s, 1H), 8.02 (d, J = 7.5Hz, 1H), 7.86 (d, J = 7.5Hz, 1H), 7.65 (dd, J = 7.1, 1.9 Hz, 2H), 7.45 (d, J=2.0Hz, 1H), 7.38 (dd, J=7.5, 2.0Hz, 1H), 7.34-7.26 (m, 2H), 7.26-7.18 (m, 4H), 5.18 (t, J=1.1Hz, 1H) , 5.01 (s, 1H), 4.56 (t, J=5.5Hz, 1H), 4.30 (dd, J=12.4, 5.4Hz, 1H), 4.20 (dd, J=12.4, 5.5Hz, 1H), 3.53-3.42 (m, 2H), 3.2 1 (d, J=6.6Hz, 4H), 2.65-2.57 (m, 4H), 2.54 (s, 4H), 2.23 (d, J=3.8Hz, 2H), 1.78 (s, 3H), 1.73 (s, 3H). MS (ESI, m / z): 805 (M + +1).
[0370] Example 47 Synthesis of Compound S15
[0371]
[0372] The synthesis method refers to the synthesis of compound S1, and compound S15 can be prepared by simply replacing the corresponding raw materials. 1H NMR(500MHz, DMSO-d6)δ 11.10 (s, 1H), 10.2 (s, 1H), 9.12 (s, 1H), 8.26 (s, 1H), 8.02 (d, J=7.5Hz, 1H), 7.93 (dd, J=7.5, 2.0Hz, 1H), 7.65 (dd, J=7.4, 1.9 Hz, 1H), 7.48-7.41 (m, 2H), 7.38 (dd, J=7.5, 2.0Hz, 1H), 7.34-7.26 (m, 2H), 7.26-7.18 (m, 3H), 7.03 (s, 1H), 5.18 (t, J=1.1Hz, 1 H), 5.11 (s, 1H), 4.56 (t, J=5.5Hz, 1H), 4.30 (dd, J=12.4, 5.4Hz, 1H), 4.20 (dd, J=12.5, 5.5Hz, 1H), 3.38-3.31 (m, 3H), 3.25 (d, J=15.5Hz, 3H), 2.66 (s, 1H), 2.54 (s, 1H), 2.49 (s, 1H), 1.99 (s, 1H), 1.84-1.71 (m, 8H), 1.66-1.58 (m, 5H). MS (ESI, m / z): 801 (M + +1).
[0373] Example 48 Synthesis of Compound S16
[0374]
[0375] The synthesis method refers to the synthesis of compound S1, and compound S16 can be prepared by simply replacing the corresponding raw materials. 1 H NMR(500MHz, DMSO-d6)δ 11.10 (s, 1H), 10.2 (s, 1H), 9.10 (s, 1H), 8.02 (d, J=7.5Hz, 1H), 7.83 (d, J=7.5Hz, 1H), 7.72-7.62 (m, 2H), 7 .60(d, J=2.0Hz, 1H), 7.47-7.41(m, 3H), 7.34-7.26(m, 2H), 7.26-7.18(m, 3H), 5.19-5.15(m, 1H), 5.01(s, 1 H), 4.56 (t, J=5.5Hz, 1H), 4.37 (d, J=12.3Hz, 1H), 4.30 (dd, J=12.4, 5.4Hz, 1H), 4.25-4.16 (m, 2H), 3.17 (s , 2H), 3.11 (s, 2H), 2.68-2.59 (m, 6H), 2.23 (d, J=3.8Hz, 2H), 1.78 (s, 3H), 1.73 (s, 3H). MS (ESI, m / z): 788 (M+ +1).
[0376] Example 49 Synthesis of Compound S17
[0377]
[0378] The synthesis method refers to the synthesis of compound S1, and compound S17 can be prepared by simply replacing the corresponding raw materials. 1 H NMR(500MHz, DMSO-d6)δ 11.10 (s, 1H), 10.2 (s, 1H), 8.99 (s, 1H), 8.16 (s, 1H), 8.02 (d, J = 7.5Hz, 1H), 7.86 (d, J = 7.5Hz, 1H), 7.65 (dd, J = 7.1, 1.9 Hz, 2H), 7.45 (d, J=2.0Hz, 1H), 7.38 (dd, J=7.5, 2.0Hz, 1H), 7.34-7.26 (m, 2H), 7.26-7.18 (m, 4H), 5.18 (t, J=1.1Hz, 1H) , 4.90 (s, 1H), 4.56 (t, J=5.5Hz, 1H), 4.30 (dd, J=12.4, 5.4Hz, 1H), 4.20 (dd, J=12.4, 5.5Hz, 1H), 3.53-3.42 (m, 2H), 3.2 1 (d, J=6.6Hz, 4H), 2.65-2.57 (m, 4H), 2.54 (s, 4H), 2.23 (d, J=3.8Hz, 2H), 1.78 (s, 3H), 1.73 (s, 3H). MS (ESI, m / z): 802 (M + +1).
[0379] Example 50 Synthesis of Compound S18
[0380]
[0381] The synthesis method refers to the synthesis of compound S1, and compound S18 can be prepared by simply replacing the corresponding raw materials. 1H NMR(500MHz, DMSO-d6)δ 11.10 (s, 1H), 10.2 (s, 1H), 8.99 (s, 1H), 8.16 (s, 1H), 8.02 (d, J = 7.5Hz, 1H), 7.86 (d, J = 7.5Hz, 1H), 7.65 (dd, J = 7.1, 1. 9Hz, 2H), 7.45 (d, J=2.0Hz, 1H), 7.38 (dd, J=7.5, 2.0Hz, 1H), 7.34-7.26 (m, 2H), 7.26-7.18 (m, 4H), 5.19-5.15 (m, 1H), 4 .90 (s, 1H), 4.56 (t, J=5.5Hz, 1H), 4.30 (dd, J=12.4, 5.4Hz, 1H), 4.20 (dd, J=12.4, 5.5Hz, 1H), 3.53-3.42 (m, 2H), 3.21 (d, J=6.6Hz, 4H), 2.65-2.57 (m, 4H), 2.54 (s, 4H), 2.23 (d, J=3.8Hz, 2H), 1.78 (s, 3H), 1.73 (s, 3H). MS (ESI, m / z): 802 (M + +1).
[0382] Example 51 Synthesis of Compound S19
[0383]
[0384] The synthesis method refers to the synthesis of compound S1, and compound S19 can be prepared by simply replacing the corresponding raw materials. 1H NMR(500MHz, DMSO-d6)δ 11.10 (s, 1H), 10.2 (s, 1H), 9.10 (s, 1H), 8.26 (s, 1H), 8.02 (d, J = 7.5Hz, 1H), 7.82 (d, J = 7.4Hz, 1H), 7.65 (dd, J = 7.4, 1.9Hz, 1H), 7.60 (d, J=2.0Hz, 1H), 7.47-7.41 (m, 2H), 7.34-7.26 (m, 2H), 7.26-7.18 (m, 3H), 7.03 (s, 1H), 5.19-5.15 (m, 1H), 5.01 (s , 1H), 4.56 (t, J=5.5Hz, 1H), 4.30 (dd, J=12.4, 5.4Hz, 1H), 4.20 (dd, J=12.4, 5.5Hz, 1H), 3.50 (d, J=18.3Hz, 4H), 3.39 (s, 2H) , 2.62 (d, J=11.5Hz, 2H), 2.23 (d, J=3.8Hz, 2H), 2.03 (s, 1H), 1.93 (d, J=12.5Hz, 1H), 1.80-1.71 (m, 7H). MS (ESI, m / z): 773 (M + +1).
[0385] Example 52 Synthesis of Compound S20
[0386]
[0387] The synthesis method refers to the synthesis of compound S1, and compound S20 can be prepared by simply replacing the corresponding raw materials. 1H NMR (500 MHz, DMSO-d6) δ 11.10 (s, 1H), 10.2 (s, 1H), 9.10 (s, 1H), 8.03 (dd, J=11.2, 7.5Hz, 2H), 7.96 (s, 1H), 7.65 (dd, J=7.1, 1.9Hz, 2H), 7.45 (d, J=2.1Hz, 1H), 7.36-7. 26(m, 3H), 7.26-7.18(m, 3H), 7.03(s, 1H), 5.19-5.15(m, 1H), 5.01(s, 1 H), 4.56 (t, J=5.5Hz, 1H), 4.30 (dd, J=12.4, 5.4Hz, 1H), 4.20 (dd, J=12. 4, 5.5Hz, 1H), 3.78 (d, J = 9.5Hz, 1H), 3.66 (d, J = 12.4Hz, 1H), 3.56 (d, J = 9.5Hz, 1H), 3.44 (d, J = 9.5Hz, 1H), 3.38 (d, J = 9.5Hz, 1H), 3.16 (d, J = 12. 4Hz, 1H), 2.62 (d, J=11.5Hz, 2H), 2.52 (s, 1H), 2.23 (d, J=3.8Hz, 2H), 1.78 (s, 3H), 1.73 (s, 3H), 1.68 (s, 1H), 1.63 (s, 1H). MS (ESI, rm / z): 773 (M + +1).
[0388] Example 53 Synthesis of Compound S21
[0389]
[0390] The synthesis method refers to the synthesis of compound S1, and compound S21 can be prepared by simply replacing the corresponding raw materials. 1H NMR(500MHz, DMSO-d6)δ 11.10 (s, 1H), 10.2 (s, 1H), 9.12 (s, 1H), 8.33 (s, 1H), 8.02 (d, J = 7.5Hz, 1H), 7.83 (d, J = 7.5Hz, 1H), 7.62 (dd, J = 7.5, 2.0Hz, 1H), 7.47 (dd, J=18.4, 2.0Hz, 2H), 7.39 (dd, J=7.5, 1.8Hz, 1H), 7.37-7.29 (m, 2H), 7.29-7.17 (m, 3H), 7.03 (s, 1H), 5.18 (d, J=1.3Hz, 1H), 5.01 (s, 1H), 4.56 (t, J=5.5Hz, 1H), 4.30 (dd, J=12.4, 5.4Hz, 1H), 4.20 (dd, J=12.5, 5.5Hz, 1H), 3.72 (s, 4H), 3.34 (s, 2H), 2.77 (s, 4H), 2.65-2.55 (m, 4H), 2.23 (d, J=3.8Hz, 2H), 1.78 (d, J=4.2Hz, 5H), 1.73 (s, 3H). MS (ESI, m / z): 828 (M + +1).
[0391] Example 54 Synthesis of Compound S22
[0392]
[0393] The synthesis method refers to the synthesis of compound S1, and compound S22 can be prepared by simply replacing the corresponding raw materials. 1 H NMR(500MHz, DMSO-d6)δ 11.10 (s, 1H), 10.2 (s, 1H), 9.12 (s, 1H), 8.02 (d, J=7.5Hz, 1H), 7.96 (s, 1H), 7.86 (d, J=7.5Hz, 1H), 7.65 (d d, J=7.1, 1.9Hz, 2H), 7.47-7.41 (m, 2H), 7.39 (dd, J=7.5, 2.0Hz, 1H), 7.34-7.26 (m, 2H), 7.26-7.18 (m, 3H) , 5.19-5.15 (m, 1H), 5.01 (s, 1H), 4.56 (t, J=5.5Hz, 1H), 4.36-4.26 (m, 2H), 4.25-4.16 (m, 2H), 3.71 (s, 4H) , 2.84 (s, 4H), 2.62 (d, J = 11.5Hz, 2H), 2.23 (d, J = 3.8Hz, 2H), 1.78 (s, 3H), 1.73 (s, 3H). MS (ESI, m / z): 800 (M ++1).
[0394] Example 55 Synthesis of Compound S23
[0395]
[0396] The synthesis method refers to the synthesis of compound S1, and compound S23 can be prepared by simply replacing the corresponding raw materials. 1 H NMR(500MHz, DMSO-d6)δ 11.10 (s, 1H), 10.2 (s, 1H), 9.12 (s, 1H), 8.18 (s, 1H), 8.02 (d, J=7.4Hz, 1H), 7.83 (d, J=7.5Hz, 1H), 7.62 (dd, J=7.5, 2.0Hz, 1H), 7.47 (dd, J=1 8.4, 2.0Hz, 2H), 7.42-7.31 (m, 3H), 7.26-7.18 (m, 3H), 6.70 (s, 1H), 5.13 (q, J=0.8Hz, 1H), 5.01 (s, 1H), 4.56 (t, J=5.5Hz, 1H), 4.28 (dd, J=12. 4, 5.5Hz, 1H), 4.20 (dd, J=12.4, 5.5Hz, 1H), 3.72 (d, J=0.7Hz, 2H), 3.52-3.42 (m, 2H), 3.39-3.28 (m, 2H), 2.72-2.66 (m, 2H), 2.66-2.59 (m, 4H) , 2.59-2.53 (m, 1H), 2.50 (d, J=12.3Hz, 1H), 2.23 (d, J=3.8Hz, 2H), 1.90 (d, J=2.9Hz, 3H), 1.83-1.76 (m, 6H), 1.73 (s, 3H). MS (ESI, m / z): 856 (M + +1).
[0397] Example 56 Synthesis of Compound S24
[0398]
[0399] The synthesis method refers to the synthesis of compound S1, and compound S24 can be prepared by simply replacing the corresponding raw materials. 1H NMR(500MHz, DMSO-d6)δ 11.10 (s, 1H), 10.2 (s, 1H), 9.12 (s, 1H), 8.25 (s, 1H), 8.15 (d, J = 7.5Hz, 1H), 7.83 (d, J = 7.5Hz, 1H), 7.65-7.58 (m, 2H), 7 .47-7.38(m, 2H), 7.37-7.29(m, 2H), 7.29-7.17(m, 3H), 7.03(s, 1H), 5.19-5.15(m, 1H), 5.01(s, 1H), 4.56(t, J=5.5Hz, 1 H), 4.30 (dd, J=12.4, 5.4Hz, 1H), 4.20 (dd, J=12.5, 5.5Hz, 1H), 3.56 (s, 2H), 3.47 (s, 2H), 3.37-3.27 (m, 2H), 2.65-2.56 (m, 7H), 2.52 (d, J=12.5Hz, 1H), 2.23 (d, J=3.8Hz, 2H), 2.05 (s, 4H), 1.97 (s, 4H), 1.80-1.71 (m, 8H). MS (ESI, m / z): 856 (M + +1).
[0400] Example 57 Synthesis of Compound S25
[0401]
[0402] The synthesis method refers to the synthesis of compound S1, and compound S25 can be prepared by simply replacing the corresponding raw materials. 1H NMR(500MHz, DMSO-d6)δ 11.10 (s, 1H), 10.2 (s, 1H), 9.12 (s, 1H), 8.12 (s, 1H), 8.02 (d, J = 7.5Hz, 1H), 7.86 (d, J = 7.5Hz, 1H), 7.65 (dd, J = 7.4, 1.9Hz, 1H), 7.60 (d, J=2.0Hz, 1H), 7.47-7.38 (m, 2H), 7.34-7.26 (m, 2H), 7.26-7.18 (m, 3H), 7.03 (s, 1H), 5.18 (t, J=1.1Hz, 1H), 5.01 (s, 1H), 4.56 (t, J=5.5Hz, 1H), 4.30 (dd, J=12.4, 5.4Hz, 1H), 4.20 (dd, J=12.4, 5.5Hz, 1H), 3.73 (s, 4H), 3.30 (s, 2H), 2.62 (d, J=11.5Hz, 2 H), 2.23 (d, J=3.8Hz, 2H), 1.97 (s, 1H), 1.88 (d, J=12.5Hz, 1H), 1.78 (s, 3H), 1.76-1.69 (m, 4H), 1.54 (s, 4H). MS (ESI, m / z): 813 (M + +1).
[0403] Example 58 Synthesis of Compound S26
[0404]
[0405] The synthesis method refers to the synthesis of compound S1, and compound S26 can be prepared by simply replacing the corresponding raw materials. 1H NMR(500MHz, DMSO-d6)δ 11.10 (s, 1H), 10.2 (s, 1H), 9.12 (s, 1H), 8.16 (s, 1H), 8.02 (d, J = 7.4Hz, 1H), 7.78 (d, J = 7.5Hz, 1H), 7.62 (dd, J = 7.5, 2.0Hz, 1H), 7.49 (d, J=2.0Hz, 1H), 7.46-7.38 (m, 2H), 7.38-7.31 (m, 2H), 7.26-7.18 (m, 3H), 6.95 (s, 1H), 5.14 (d, J=1.1Hz, 1H), 5.01 (s, 1H), 4.56 (t, J=5.5Hz, 1H), 4.28 (dd, J=12.4, 5.5Hz, 1H), 4.20 (dd, J=12.4, 5.5Hz, 1H), 3.88 (s, 2H), 3.80 (s, 2H), 3.43 (d, J=12.3Hz, 1 H), 3.37 (d, J=12.5Hz, 1H), 2.68-2.59 (m, 8H), 2.23 (d, J=3.8Hz, 2H), 1.90 (s, 4H), 1.78 (s, 3H), 1.73 (s, 3H). MS (ESI, m / z): 842 (M + +1).
[0406] Example 59 Synthesis of Compound S27
[0407]
[0408] The synthesis method refers to the synthesis of compound S1, and compound S27 can be prepared by simply replacing the corresponding raw materials. 1H NMR(500MHz, DMSO-d6)δ 11.10 (s, 1H), 10.2 (s, 1H), 9.12 (s, 1H), 8.18 (s, 1H), 8.02 (d, J = 7.4Hz, 1H), 7.78 (d, J = 7.5Hz, 1H), 7.65-7.57 (m, 2H ), 7.47-7.38(m, 2H), 7.37-7.29(m, 2H), 7.29-7.17(m, 3H), 7.03(s, 1H), 5.18(d, J=1.4Hz, 1H), 5.01(s, 1H), 4.56(t, J=5.5Hz, 1H), 4.30 (dd, J=12.4, 5.4Hz, 1H), 4.20 (dd, J=12.5, 5.5Hz, 1H), 3.56 (s, 2H), 3.46 (s, 2H), 3.33 (s, 2H), 3.0 2 (s, 2H), 2.96 (s, 2H), 2.65-2.55 (m, 4H), 2.23 (d, J=3.8Hz, 2H), 1.92 (s, 4H), 1.80-1.71 (m, 8H). MS (ESI, m / z): 856 (M + +1).
[0409] Example 60 Synthesis of Compound S28
[0410]
[0411] The synthesis method refers to the synthesis of compound S1, and compound S28 can be prepared by simply replacing the corresponding raw materials. 1 H NMR(500MHz, DMSO-d6)δ 11.10 (s, 1H), 10.2 (s, 1H), 9.12 (s, 1H), 8.02 (d, J=7.5Hz, 1H), 7.96 (s, 1H), 7.78 (d, J=7.5Hz, 1H), 7.65- 7.57(m, 2H), 7.47-7.38(m, 3H), 7.37-7.29(m, 2H), 7.29-7.17(m, 3H), 5.19-5.15(m, 1H), 5.01(s, 1H), 4. 59-4.49 (m, 2H), 4.30 (dd, J=12.4, 5.4Hz, 1H), 4.26-4.16 (m, 2H), 3.59 (s, 2H), 3.46 (s, 2H), 2.81 (s, 4H), 2.62 (d, J=11.5Hz, 2H), 2.23 (d, J=3.8Hz, 2H), 1.94 (s, 4H), 1.78 (s, 3H), 1.73 (s, 3H). MS (ESI, m / z): 828 (M + +1).
[0412] Example 61 Synthesis of Compound S29
[0413]
[0414] The synthesis method refers to the synthesis of compound S1, and compound S29 can be prepared by simply replacing the corresponding raw materials. 1 H NMR(500MHz, DMSO-d6)δ 11.10 (s, 1H), 10.2 (s, 1H), 9.12 (s, 1H), 8.12 (s, 1H), 8.02 (d, J = 7.5Hz, 1H), 7.83 (d, J = 7.5Hz, 1H), 7.62 (dd, J = 7.5, 2.0Hz, 1 H), 7.49 (d, J=2.0Hz, 1H), 7.46-7.39 (m, 2H), 7.37-7.29 (m, 2H), 7.29-7.17 (m, 4H), 5.19-5.15 (m, 1H), 5.01 (s, 1H), 4.56 (t, J=5.5Hz, 1H), 4.30 (dd, J=12.4, 5.4Hz, 1H), 4.20 (dd, J=12.4, 5.5Hz, 1H), 3.69-3.59 (m, 4H), 3.49 (s, 2H), 2.76 (d, J=9.5Hz, 2H), 2.71-2.64 (m, 3H), 2.64-2.58 (m, 3H), 2.23 (d, J=3.8Hz, 2H), 2.11 (s, 2H), 1.78 (s, 3H), 1.73 (s, 3H). MS (ESI, m / z): 828 (M + +1).
[0415] Example 62 Synthesis of Compound S30
[0416]
[0417] The synthesis method refers to the synthesis of compound S1, and compound S30 can be prepared by simply replacing the corresponding raw materials. 1H NMR(500MHz, DMSO-d6)δ 11.10(s, 1H), 10.2(s, 1H), 9.12(s, 1H), 8.20-8.12(m, 2H), 7.78(d, J=7.5Hz, 1H), 7.65-7.57(m, 2H), 7.47-7.38(m , 2H), 7.37-7.29 (m, 2H), 7.29-7.17 (m, 3H), 7.03 (s, 1H), 5.17 (t, J=1.0Hz, 1H), 5.01 (s, 1H), 4.56 (t, J=5.5Hz, 1H), 4.30 (dd, J=12.4, 5.4Hz, 1H), 4.20 (dd, J=12.5, 5.5Hz, 1H), 3.42 (s, 1H), 3.39-3.27 (m, 5H), 2.84 (s, 1H), 2.66-2.5 8 (m, 6H), 2.50 (d, J=12.5Hz, 1H), 2.23 (d, J=3.8Hz, 2H), 1.98-1.91 (m, 4H), 1.80-1.69 (m, 10H). MS (ESI, m / z): 870 (M + +1).
[0418] Example 63 Synthesis of Compound S31
[0419]
[0420] The synthesis method refers to the synthesis of compound S1, and compound S31 can be prepared by simply replacing the corresponding raw materials. 1 H NMR(500MHz, DMSO-d6)δ 11.10 (s, 1H), 10.2 (s, 1H), 9.08 (s, 1H), 8.25 (s, 1H), 8.02 (d, J = 7.4Hz, 1H), 7.83 (d, J = 7.5Hz, 1H), 7.65-7.58 ( m, 2H), 7.45 (d, J=2.0Hz, 1H), 7.41-7.29 (m, 3H), 7.29-7.17 (m, 4H), 5.19-5.15 (m, 1H), 5.01 (s, 1H), 4.56 (t, J=5 .5Hz, 1H), 4.30 (dd, J=12.4, 5.4Hz, 1H), 4.20 (dd, J=12.5, 5.5Hz, 1H), 3.68 (s, 2H), 3.50 (s, 2H), 3.38 (s, 2H), 3. 03 (s, 1H), 2.65-2.53 (m, 8H), 2.45 (s, 4H), 2.24 (d, J=0.9Hz, 2H), 1.78 (s, 3H), 1.73 (s, 3H). MS (ESI, m / z): 857 (M + +1).
[0421] Example 64 Synthesis of Compound S32
[0422]
[0423] The synthesis method refers to the synthesis of compound S1, and compound S32 can be prepared by simply replacing the corresponding raw materials. 1 H NMR(500MHz, DMSO-d6)δ 11.10 (s, 1H), 10.2 (s, 1H), 9.12 (s, 1H), 8.02 (d, J=7.4Hz, 1H), 7.96 (s, 1H), 7.83 (d, J=7.5Hz, 1H), 7.65- 7.58 (m, 2H), 7.47-7.41 (m, 2H), 7.41-7.29 (m, 3H), 7.29-7.17 (m, 3H), 5.18 (d, J=1.3Hz, 1H), 5.01 (s, 1H), 4.56 (t, J=5.5Hz, 1H), 4.30 (dd, J=12.4, 5.4Hz, 1H), 4.24-4.16 (m, 3H), 3.68 (s, 2H), 3.40 (s, 2H), 3.16 (s, 1H), 2.65-2.57 (m, 6H), 2.48 (s, 4H), 2.24 (d, J=0.9Hz, 2H), 1.78 (s, 3H), 1.73 (s, 3H). MS (ESI, m / z): 843 (M + +1).
[0424] Example 65 Synthesis of Compound S33
[0425]
[0426] The synthesis method refers to the synthesis of compound S1, and compound S33 can be prepared by simply replacing the corresponding raw materials. 1H NMR(500MHz, DMSO-d6)δ 11.10 (s, 1H), 10.2 (s, 1H), 9.12 (s, 1H), 8.40 (s, 1H), 8.02 (d, J = 7.4Hz, 1H), 7.86 (d, J = 7.5Hz, 1H), 7.65-7.57 (m, 2H), 7. 47-7.39 (m, 2H), 7.37-7.29 (m, 2H), 7.29-7.17 (m, 3H), 7.03 (s, 1H), 5.18 (d, J=1.4Hz, 1H), 5.01 (s, 1H), 4.56 (t, J=5.5Hz , 1H), 4.30 (dd, J=12.4, 5.4Hz, 1H), 4.20 (dd, J=12.4, 5.5Hz, 1H), 3.46 (d, J=4.0Hz, 4H), 3.40 (s, 2H), 2.95 (s, 1H), 2.66- 2.59 (m, 4H), 2.55 (s, 2H), 2.23 (d, J=3.8Hz, 2H), 2.07 (s, 1H), 1.90-1.83 (m, 3H), 1.80-1.71 (m, 9H). MS (ESI, m / z): 856 (M + +1).
[0427] Example 66 Synthesis of Compound S34
[0428]
[0429] The synthesis method refers to the synthesis of compound S1, and compound S34 can be prepared by simply replacing the corresponding raw materials. 1H NMR(500MHz, DMSO-d6)δ 11.10 (s, 1H), 10.2 (s, 1H), 9.08 (s, 1H), 8.18-8.12 (m, 2H), 7.77 (d, J=7.5Hz, 1H), 7.62 (dd, J=7.5, 2.0Hz, 1H), 7.55 (d, J=2. 0Hz, 1H), 7.47-7.38 (m, 2H), 7.37-7.29 (m, 2H), 7.29-7.17 (m, 4H), 5.19-5.15 (m, 1H), 5.01 (s, 1H), 4.56 (t, J=5.5Hz, 1H), 4.3 0 (dd, J=12.4, 5.4Hz, 1H), 4.20 (dd, J=12.5, 5.5Hz, 1H), 3.85 (s, 2H), 3.62 (s, 2H), 3.50 (s, 2H), 2.67 (s, 1H), 2.65-2.56 (m, 4 H), 2.48 (d, J=7.0Hz, 8H), 2.23 (d, J=3.8Hz, 2H), 1.89 (d, J=13.0Hz, 2H), 1.84-1.76 (m, 5H), 1.73 (s, 3H). MS (ESI, m / z): 897 (M + +1).
[0430] Example 67 Synthesis of Compound S35
[0431]
[0432] The synthesis method refers to the synthesis of compound S1, and compound S35 can be prepared by simply replacing the corresponding raw materials. 1H NMR(500MHz, DMSO-d6)δ 11.10 (s, 1H), 10.2 (s, 1H), 9.12 (s, 1H), 8.15 (d, J=7.5Hz, 1H), 7.96 (s, 1H), 7.77 (d, J=7.5Hz, 1H), 7.62 (dd, J=7.5, 2.0Hz , 1H), 7.55 (d, J=2.0Hz, 1H), 7.47-7.38 (m, 3H), 7.37-7.29 (m, 2H), 7.29-7.17 (m, 3H), 5.19-5.15 (m, 1H), 5.01 (s, 1H), 4.56 (t, J=5.5Hz, 1H), 4.30 (dd, J=12.4, 5.4Hz, 1H), 4.24-4.16 (m, 3H), 3.53 (d, J=9.3Hz, 2H), 3.47 (d, J=9.5Hz, 2H), 2.87 (s, 1H ), 2.65-2.52 (m, 8H), 2.45 (s, 2H), 2.23 (d, J=3.8Hz, 2H), 2.10 (s, 2H), 1.78 (s, 3H), 1.77-1.67 (m, 7H). MS (ESI, m / z): 897 (M + +1).
[0433] Example 68 Synthesis of Compound S36
[0434]
[0435] The synthesis method refers to the synthesis of compound S1, and compound S36 can be prepared by simply replacing the corresponding raw materials. 1H NMR(500MHz, DMSO-d6)δ 11.10 (s, 1H), 10.2 (s, 1H), 9.12 (s, 1H), 8.02 (d, J=7.4Hz, 1H), 7.81-7.74 (m, 2H), 7.65-7.57 (m, 2H), 7.47-7.38 ( m, 2H), 7.37-7.29 (m, 2H), 7.29-7.17 (m, 4H), 5.19-5.15 (m, 1H), 5.01 (s, 1H), 4.56 (t, J=5.5Hz, 1H), 4.30 (dd, J=12 .4, 5.4Hz, 1H), 4.24-4.16 (m, 2H), 3.35 (s, 2H), 3.31 (s, 2H), 3.19 (s, 2H), 2.85 (s, 2H), 2.62 (d, J=11.5Hz, 2H), 2.5 2 (s, 2H), 2.23 (d, J=3.8Hz, 2H), 1.99 (s, 1H), 1.87 (d, J=9.5Hz, 4H), 1.78 (s, 3H), 1.73 (s, 3H). MS (ESI, m / z): 842 (M + +1).
[0436] Example 69 Synthesis of Compound S37
[0437]
[0438] The synthesis method refers to the synthesis of compound S1, and compound S37 can be prepared by simply replacing the corresponding raw materials. 1H NMR(500MHz, DMSO-d6)δ 11.10 (s, 1H), 10.2 (s, 1H), 9.12 (s, 1H), 8.18-8.12 (m, 2H), 7.82 (d, J=7.4Hz, 1H), 7.66-7.59 (m, 2H), 7.47-7.38 (m, 2H), 7.37-7.29 (m, 2H), 7.29-7.17 (m, 3H), 7.03 (s, 1H), 5.19-5.15 (m, 1H), 5.01 (s, 1H), 4.56 (t, J=5.5Hz, 1H), 4.30 (dd, J=12. 4, 5.4Hz, 1H), 4.20 (dd, J=12.5, 5.5Hz, 1H), 3.39 (s, 2H), 3.27-3.18 (m, 6H), 3.15 (s, 2H), 2.62 (d, J=11.5Hz, 2H), 2.42 (s , 1H), 2.23 (d, J=3.8Hz, 2H), 2.08 (s, 2H), 1.95 (s, 1H), 1.80-1.65 (m, 12H), 1.58 (s, 2H), 1.45 (s, 2H). MS (ESI, m / z): 926 (M + +1).
[0439] Example 70 Synthesis of Compound S38
[0440]
[0441] The synthesis method refers to the synthesis of compound S1, and compound S38 can be prepared by simply replacing the corresponding raw materials. 1H NMR(500MHz, DMSO-d6)δ 11.10 (s, 1H), 10.2 (s, 1H), 9.12 (s, 1H), 8.02 (d, J=7.4Hz, 1H), 7.86 (d, J=7.5Hz, 1H), 7.62 (dd, J=7.5, 2.0Hz, 1H), 7.49 (d, J=2.0H z, 1H), 7.46-7.39 (m, 2H), 7.39-7.29 (m, 3H), 7.29-7.17 (m, 4H), 5.18 (d, J=1.4Hz, 1H), 5.01 (s, 1H), 4.56 (t, J=5.5Hz, 1H), 4.30 (d d, J=12.4, 5.4Hz, 1H), 4.20 (dd, J=12.4, 5.5Hz, 1H), 3.83 (s, 1H), 3.68 (d, J=9.5Hz, 1H), 3.62 (d, J=9.5Hz, 1H), 3.42-3.31 (m, 2H), 2.66-2.52 (m, 8H), 2.47 (d, J=12.5Hz, 1H), 2.23 (d, J=3.8Hz, 2H), 1.89 (s, 2H), 1.85-1.76 (m, 7H), 1.73 (s, 3H). MS (ESI, m / z): 856 (M + +1).
[0442] Example 71 Synthesis of Compound S39
[0443]
[0444] The synthesis method refers to the synthesis of compound S1, and compound S39 can be prepared by simply replacing the corresponding raw materials. 1H NMR(500MHz, DMSO-d6)δ 11.10 (s, 1H), 10.2 (s, 1H), 9.12 (s, 1H), 8.18-8.12 (m, 2H), 7.83 (d, J=7.4Hz, 1H), 7.62 (dd, J=7.5, 2.0Hz, 1H), 7.51-7.41 (m, 3H), 7.37-7.29(m, 2H), 7.29-7.17(m, 4H), 5.19-5.15(m, 1H), 5.01(s, 1H), 4.56(t, J=5.5Hz, 1H), 4.30(dd, J=12.4, 5.4Hz, 1H) , 4.20 (dd, J=12.4, 5.5Hz, 1H), 3.43 (d, J=12.3Hz, 1H), 3.37 (d, J=12.5Hz, 1H), 3.22 (s, 4H), 2.67 (d, J=0.9Hz, 5H), 2.65-2.56 (m, 8H), 2.23 (d, J=3.8Hz, 2H), 1.96 (d, J=13.0Hz, 2H), 1.85 (d, J=13.0Hz, 2H), 1.78 (s, 3H), 1.73 (s, 3H). MS (ESI, rm / z): 897 (M + +1).
[0445] Example 72 Synthesis of Compound S40
[0446]
[0447] The synthesis method refers to the synthesis of compound S1, and compound S40 can be prepared by simply replacing the corresponding raw materials. 1H NMR(500MHz, DMSO-d6)δ 11.10 (s, 1H), 10.2 (s, 1H), 9.12 (s, 1H), 8.18-8.12 (m, 2H), 7.83 (d, J=7.5Hz, 1H), 7.62 (dd, J=7.5, 2.0Hz, 1H), 7 .47 (dd, J=18.4, 2.0Hz, 2H), 7.41-7.29 (m, 3H), 7.29-7.17 (m, 4H), 5.18 (d, J=1.4Hz, 1H), 5.01 (s, 1H), 4.56 (t, J= 5.5Hz, 1H), 4.30 (dd, J=12.4, 5.4Hz, 1H), 4.20 (dd, J=12.4, 5.5Hz, 1H), 3.68 (s, 2H), 3.49 (s, 2H), 3.40 (s, 2H), 3. 11 (s, 1H), 2.76-2.55 (m, 12H), 2.24 (d, J=0.9Hz, 2H), 2.10 (s, 2H), 1.78 (s, 3H), 1.73 (s, 3H). MS (ESI, m / z): 883 (M + +1).
[0448] Example 73 Synthesis of Compound S41
[0449]
[0450] The synthesis method refers to the synthesis of compound S1, and compound S41 can be prepared by simply replacing the corresponding raw materials. 1 H NMR(500MHz, DMSO-d6)δ 11.10 (s, 1H), 10.2 (s, 1H), 9.12 (s, 1H), 8.15 (d, J=7.5Hz, 1H), 7.83 (d, J=7.4Hz, 1H), 7.72 (s, 1H), 7.62 (dd, J=7.5, 2. 0Hz, 1H), 7.51-7.41 (m, 3H), 7.37-7.29 (m, 2H), 7.29-7.17 (m, 4H), 5.19-5.15 (m, 1H), 5.01 (s, 1H), 4.56 (t, J=5.5Hz, 1H ), 4.30 (dd, J=12.4, 5.4Hz, 1H), 4.26-4.16 (m, 3H), 3.28 (s, 2H), 3.22 (s, 2H), 2.69 (d, J=7.3Hz, 4H), 2.65-2.59 (m, 4H) , 2.53 (s, 2H), 2.46 (s, 1H), 2.23 (d, J = 3.8Hz, 2H), 1.78 (s, 3H), 1.74 (d, J = 1.8Hz, 5H), 1.67 (s, 2H). MS (ESI, m / z): 871 (M+ +1).
[0451] Example 74 Synthesis of Compound S42
[0452]
[0453] The synthesis method refers to the synthesis of compound S1, and compound S42 can be prepared by simply replacing the corresponding raw materials. 1 H NMR(500MHz, DMSO-d6)δ 11.10 (s, 1H), 10.2 (s, 1H), 9.12 (s, 1H), 8.15 (d, J=7.5Hz, 1H), 7.86 (d, J=7.5Hz, 1H), 7.70 (s, 1H), 7.65-7 .57(m, 2H), 7.47-7.39(m, 3H), 7.37-7.29(m, 2H), 7.29-7.17(m, 3H), 5.19-5.15(m, 1H), 5.01(s, 1H), 4.56( t, J=5.5Hz, 1H), 4.30 (dd, J=12.4, 5.4Hz, 1H), 4.24-4.16 (m, 3H), 3.46 (d, J=4.0Hz, 4H), 2.80 (s, 1H), 2.65 -2.53 (m, 10H), 2.23 (d, J=3.8Hz, 2H), 1.87 (s, 2H), 1.78 (d, J=4.6Hz, 5H), 1.73 (s, 3H). MS (ESI, m / z): 871 (M + +1).
[0454] Example 75 Synthesis of Compound S43
[0455]
[0456] The synthesis method refers to the synthesis of compound S1, and compound S43 can be prepared by simply replacing the corresponding raw materials. 1H NMR(500MHz, DMSO-d6)δ 11.10 (s, 1H), 10.2 (s, 1H), 9.10 (s, 1H), 8.33 (s, 1H), 8.02 (d, J=7.5Hz, 1H), 7.65 (dd, J=7.4, 1.9Hz, 1H), 7.52-7.38(m, 3H), 7.34-7.26(m, 3H), 7.26-7.18(m, 4H), 5.20-5.15(m, 1H), 4.70(t, J=5.5Hz, 1H ), 4.54 (d, J = 1.1Hz, 1H), 4.48-4.40 (m, 3H), 4.30 (dd, J = 12.3, 5.5Hz, 1H), 4.20 (dd, J = 12.4, 5.5Hz, 1H) ), 4.01 (s, 1H), 2.60 (s, 2H), 2.13 (s, 1H), 2.02 (s, 1H), 1.78 (s, 3H), 1.73 (s, 3H). MS (ESI, m / z): 714 (M + +1).
[0457] Example 76 Synthesis of Compound S44
[0458]
[0459] The synthesis method refers to the synthesis of compound S1, and compound S44 can be prepared by simply replacing the corresponding raw materials. 1 H NMR(500MHz, DMSO-d6)δ 11.10 (s, 1H), 10.2 (s, 1H), 9.10 (s, 1H), 8.47 (s, 1H), 8.10 (d, J = 2.0Hz, 1H), 8.02 (d, J = 7.5Hz, 1H), 7.65 ( dd, J=7.4, 1.9Hz, 1H), 7.47-7.39 (m, 2H), 7.34-7.26 (m, 2H), 7.26-7.14 (m, 5H), 5.18 (t, J=1.1Hz, 1H), 4.7 3-4.61 (m, 3H), 4.57 (dd, J=5.0, 1.0Hz, 2H), 4.30 (dd, J=12.3, 5.5Hz, 1H), 4.20 (dd, J=12.4, 5.5Hz, 1H), 4. 01 (s, 1H), 2.60 (d, J=2.6Hz, 2H), 2.19 (s, 1H), 2.12 (s, 1H), 1.78 (s, 3H), 1.73 (s, 3H). MS (ESI, m / z): 714 (M + +1).
[0460] Example 77 Synthesis of Compound S45
[0461]
[0462] The synthesis method refers to the synthesis of compound S1, and compound S45 can be prepared by simply replacing the corresponding raw materials. 1 H NMR(500MHz, DMSO-d6)δ 11.10 (s, 1H), 10.2 (s, 1H), 9.10 (s, 1H), 8.55 (s, 1H), 8.02 (d, J = 7.5Hz, 1H), 7.91 (d, J = 7.5Hz, 1H), 7.68- 7.62 (m, 2H), 7.47-7.39 (m, 2H), 7.34-7.26 (m, 2H), 7.26-7.18 (m, 4H), 5.19-5.15 (m, 1H), 4.70 (t, J=5.5Hz , 1H), 4.58-4.51 (m, 2H), 4.49-4.40 (m, 2H), 4.30 (dd, J=12.3, 5.5Hz, 1H), 4.20 (dd, J=12.4, 5.5Hz, 1H), 4. 01 (s, 1H), 2.60 (d, J=2.6Hz, 2H), 2.19 (s, 1H), 2.12 (s, 1H), 1.78 (s, 3H), 1.73 (s, 3H). MS (ESI, m / z): 714 (M + +1).
[0463] Example 78 Synthesis of Compound S46
[0464]
[0465] The synthesis method refers to the synthesis of compound S1, and compound S46 can be prepared by simply replacing the corresponding raw materials. 1H NMR(500MHz, DMSO-d6)δ 11.10 (s, 1H), 10.2 (s, 1H), 9.10 (s, 1H), 8.38 (s, 1H), 8.02 (d, J=7.5Hz, 1H), 7.82 (dd, J=7.3, 2.0Hz, 1H), 7.65 (d d, J=7.4, 1.9Hz, 1H), 7.52 (t, J=7.5Hz, 1H), 7.47-7.39 (m, 2H), 7.34-7.26 (m, 2H), 7.26-7.18 (m, 4H), 5.18 (t, J= 1.1Hz, 1H), 4.70 (t, J=5.5Hz, 1H), 4.55 (d, J=12.3Hz, 1H), 4.49-4.42 (m, 2H), 4.34-4.26 (m, 2H), 4.20 (dd, J=12. 4, 5.5Hz, 1H), 4.01 (s, 1H), 2.60 (s, 2H), 2.13 (s, 1H), 2.02 (s, 1H), 1.78 (s, 3H), 1.73 (s, 3H). MS (ESI, m / z): 714 (M + +1).
[0466] Example 79 Synthesis of Compound S47
[0467]
[0468] The synthesis method refers to the synthesis of compound S1, and compound S47 can be prepared by simply replacing the corresponding raw materials. 1 H NMR(500MHz, DMSO-d6)δ 11.10 (s, 1H), 10.2 (s, 1H), 9.10 (s, 1H), 8.25 (s, 1H), 8.02 (d, J=7.5Hz, 1H), 7.82 (dd, J=7.2, 2.3 Hz, 1H), 7.65 (dd, J=7.4, 1.9Hz, 1H), 7.53-7.43 (m, 3H), 7.34-7.26 (m, 2H), 7.26-7.18 (m, 4H), 5. 18 (t, J=1.1Hz, 1H), 4.56 (t, J=5.5Hz, 1H), 4.39 (s, 1H), 4.33-4.24 (m, 3H), 4.01 (s, 1H), 3.65-3. 53 (m, 2H), 2.71 (s, 2H), 2.19 (s, 1H), 2.12 (s, 1H), 1.78 (s, 3H), 1.73 (s, 3H). MS (ESI, m / z): 728 (M + +1).
[0469] Example 80 Synthesis of Compound S48
[0470]
[0471] The synthesis method refers to the synthesis of compound S1, and compound S48 can be prepared by simply replacing the corresponding raw materials. 1 H NMR(500MHz, DMSO-d6)δ 11.10 (s, 1H), 10.2 (s, 1H), 9.10 (s, 1H), 8.14 (s, 1H), 8.02 (d, J = 7.5Hz, 1H), 7.82 (dd, J = 7.3, 2.0Hz, 1H), 7.65 (dd, J = 7.4, 1.9Hz, 1H), 7.53 (t, J=7.4Hz, 1H), 7.50-7.43 (m, 2H), 7.34-7.26 (m, 2H), 7.26-7.18 (m, 3H), 7.03 (s, 1H), 5.19-5.15 (m, 1H) , 4.56 (t, J=5.5Hz, 1H), 4.46 (d, J=11.5Hz, 2H), 4.30 (dd, J=12.4, 5.4Hz, 1H), 4.20 (dd, J=12.4, 5.5Hz, 1H), 4.01 (s, 1H), 3 .35 (d, J=2.9Hz, 2H), 2.79 (s, 2H), 2.59 (d, J=7.5Hz, 2H), 2.19 (s, 1H), 2.12 (s, 1H), 1.80-1.71 (m, 8H). MS (ESI, m / z): 742 (M + +1).
[0472] Example 81 Synthesis of Compound S49
[0473]
[0474] The synthesis method refers to the synthesis of compound S1, and compound S49 can be prepared by simply replacing the corresponding raw materials. 1H NMR(500MHz, DMSO-d6)δ 11.10 (s, 1H), 10.2 (s, 1H), 9.10 (s, 1H), 8.14 (s, 1H), 8.02 (d, J = 7.5Hz, 1H), 7.82 (dd, J = 7.1, 2.2Hz, 1H), 7.65 (dd, J = 7.4, 1.9Hz, 1H), 7.52-7.43(m, 3H), 7.34-7.26(m, 2H), 7.26-7.18(m, 3H), 7.03(s, 1H), 5.19-5.15(m, 1H), 4.56(t, J=5.5Hz, 1H ), 4.47 (s, 1H), 4.34-4.26 (m, 2H), 4.20 (dd, J=12.4, 5.5Hz, 1H), 4.01 (s, 1H), 3.18 (d, J=0.8Hz, 2H), 2.64-2.56 (m, 4H), 2. 19 (s, 1H), 2.12 (s, 1H), 1.78 (s, 3H), 1.73 (s, 3H), 1.69-1.59 (m, 2H), 1.48 (s, 2H), 1.39-1.29 (m, 2H). MS (ESI, m / z): 770 (M + +1).
[0475] Example 82 Synthesis of Compound S50
[0476]
[0477] The synthesis method refers to the synthesis of compound S1, and compound S50 can be prepared by simply replacing the corresponding raw materials. 1H NMR(500MHz, DMSO-d6)δ 11.10 (s, 1H), 10.2 (s, 1H), 9.12 (s, 1H), 8.18 (s, 1H), 8.02 (d, J=7.5Hz, 1H), 7.81 (dd, J=7.1, 2.4Hz, 1H), 7.62 (dd, J=7.5, 2.0Hz, 1 H), 7.55-7.43(m, 3H), 7.39-7.31(m, 2H), 7.26-7.18(m, 3H), 6.70(s, 1H), 5.13(q, J=0.8Hz, 1H), 4.56(t, J=5.5Hz, 1H), 4.46(d, J= 11.5Hz, 2H), 4-28 (dd, J=12.4, 5.5Hz, 1H), 4.20 (dd, J=12.4, 5.5Hz, 1H), 4.01 (s, 1H), 3.32 (s, 2H), 3.02 (s, 1H), 2.67 (s, 2H), 2.62 -2.53 (m, 5H), 2.50 (d, J=12.5Hz, 1H), 2.19 (s, 1H), 2.12 (s, 1H), 1.90 (s, 2H), 1.83 (s, 2H), 1.80-1.71 (m, 8H). MS (ESI, m / z): 825 (M + +1).
[0478] Example 83 Synthesis of Compound S51
[0479]
[0480] The synthesis method refers to the synthesis of compound S1, and compound S51 can be prepared by simply replacing the corresponding raw materials. 1H NMR(500MHz, DMSO-d6)δ 11.10 (s, 1H), 10.2 (s, 1H), 8.97 (s, 1H), 8.14 (s, 1H), 8.02 (d, J=7.5Hz, 1H), 7.82 (dd, J=7.0, 2.4Hz, 1H), 7.65 (dd , J=7.4, 1.9Hz, 1H), 7.54-7.43 (m, 3H), 7.34-7.26 (m, 2H), 7.26-7.18 (m, 4H), 5.18 (t, J=1.1Hz, 1H), 4.56 (t, J=5. 5Hz, 1H), 4.47 (s, 1H), 4.34-4.26 (m, 2H), 4.20 (dd, J=12.4, 5.5Hz, 1H), 4.01 (s, 1H), 3.50 (s, 2H), 3.08 (s, 1H), 2. 72 (d, J=10.8Hz, 2H), 2.69-2.56 (m, 6H), 2.19 (s, 1H), 2.12 (s, 1H), 1.78 (s, 3H), 1.73 (s, 3H). MS (ESI, m / z): 783 (M + +1).
[0481] Example 84 Synthesis of Compound S52
[0482]
[0483] Under argon protection, the raw material 16a (327 mg, 0.64 mmol), 3-(5-iodo-1-oxoisoindolin-2-yl)piperidine-2,6-dione (159 mg, 0.43 mmol), Pd(pph3)2Cl2 (30.1 mg, 0.043 mmol), and cuprous iodide (16.4 mg, 0.086 mmol) were dissolved in DMF (2 mL), and triethylamine (1.3 mL, 0.01 mmol) was added to the reaction system, and the reaction was stirred at 80°C overnight. After the reaction was complete, the reaction solution was cooled to room temperature, and the filtrate was extracted with ethyl acetate (10 mL×3). The combined organic layers were washed with saturated NaCl solution, dried over anhydrous Na2So4, filtered and concentrated, and purified by column chromatography to obtain compound S54 (168 mg, 35%). 1HNMR(500MHz, DMSO-d6)δ 11.10 (s, 1H), 10.2 (s, 1H), 9.03 (s, 1H), 8.02 (d, J=7.5Hz, 1H), 7.89 (d, J=7.5Hz, 1H), 7.68-7.62 (m, 2H), 7.58 (dd, J=7.5, 2.0Hz, 1H), 7.45 (d, J=2.0Hz, 1H), 7.34-7.26 (m, 2H), 7.25-7.17 (m, 1H), 7.17-7.10 (m, 2H), 6.70 (s, 1H), 5.16-5.12 (m, 1H) , 4.59-4.52 (m, 2H), 4.42 (d, J=1.1Hz, 1H), 4.28 (dd, J=12.4, 5.5Hz, 1H), 4.20 (dd, J=12.4, 5.5Hz, 1H), 4.01 (s, 1H), 2.96- 2.88 (m, 3H), 2.83 (d, J=12.5Hz, 1H), 2.60 (s, 2H), 2.19 (s, 1H), 2.12 (s, 1H), 1.78 (s, 3H), 1.73 (s, 3H). MS (ESI, m / z): 753 (M + +1).
[0484] Example 85 Synthesis of Compound S53
[0485]
[0486] The synthesis method refers to the synthesis of compound S52, and compound S53 can be prepared by simply replacing the corresponding raw materials. 1HNMR(500MHz, DMSO-d6)δ 11.10 (s, 1H), 10.2 (s, 1H), 9.03 (s, 1H), 8.02 (d, J = 7.5Hz, 1H), 7.82 (dd, J = 7.3, 2.0Hz, 1H), 7.65 (dd, J = 7.4, 1.9Hz, 1H) , 7.51 (t, J=7.4Hz, 1H), 7.46 (dd, J=7.8, 2.1Hz, 2H), 7.34-7.26 (m, 2H), 7.25-7.18 (m, 1H), 7.17-7.10 (m, 2H), 6.70 (s, 1 H), 5.13 (d, J=1.3Hz, 1H), 4.56 (t, J=5.5Hz, 1H), 4.39 (s, 1H), 4.32-4.24 (m, 2H), 4.20 (dd, J=12.4, 5.5Hz, 1H), 4.01 (s, 1H), 2.79 (s, 2H), 2.62-2.56 (m, 4H), 2.19 (s, 1H), 2.12 (s, 1H), 1.79 (d, J=8.1Hz, 5H), 1.73 (s, 3H). MS (ESI, m / z): 767 (M + +1).
[0487] Example 86 Synthesis of Compound S54
[0488]
[0489] The synthesis method refers to the synthesis of compound S52, and compound S54 can be prepared by simply replacing the corresponding raw materials. 1 HNMR(500MHz, DMSO-d6)δ 11.10 (s, 1H), 10.2 (s, 1H), 9.03 (s, 1H), 8.02 (d, J=7.5Hz, 1H), 7.89 (d, J=2.0Hz, 1H), 7.65 (dd, J=7 .4, 1.9Hz, 1H), 7.49-7.43(m, 2H), 7.34-7.26(m, 2H), 7-25-7.10(m, 4H), 6.70(s, 1H), 5.16-5.12(m , 1H), 4.60-4.52 (m, 3H), 4.28 (dd, J=12.4, 5.5Hz, 1H), 4.20 (dd, J=12.4, 5.5Hz, 1H), 4.01 (s, 1H), 2 .76 (s, 2H), 2.60 (d, J=5.2Hz, 4H), 2.19 (s, 1H), 2.12 (s, 1H), 1.80-1.68 (m, 8H). MS (ESI, m / z): 767 (M + +1).
[0490] Example 87 Synthesis of Compound S55
[0491]
[0492] The synthesis method refers to the synthesis of compound S52, and compound S55 can be prepared by simply replacing the corresponding raw materials. 1 HNMR(500MHz, DMSO-d6)δ 11.10 (s, 1H), 10.2 (s, 1H), 9.03 (s, 1H), 8.02 (d, J=7.5Hz, 1H), 7.66 (ddd, J=12.6, 7.5, 2.0Hz, 2H), 7.45 (d, J=2.0Hz, 1H), 7. 39-7.32 (m, 1H), 7.32-7.26 (m, 2H), 7.25-7.18 (m, 1H), 7.17-7.10 (m, 2H), 7.08 (ddt, J=7.5, 2.0, 0.9Hz, 1H), 6.70 (s, 1H), 5. 13 (d, J=1.3Hz, 1H), 4.59-4.52 (m, 2H), 4.42 (d, J=1.1Hz, 1H), 4.28 (dd, J=12.4, 5.5Hz, 1H), 4.20 (dd, J=12.4, 5.5Hz, 1H), 4. 01 (s, 1H), 2.79 (s, 2H), 2.62-2.56 (m, 4H), 2.19 (s, 1H), 2.12 (s, 1H), 1.79 (d, J=8.1Hz, 5H), 1.73 (s, 3H). MS (ESI, m / z): 767 (M + +1).
[0493] Example 88 Synthesis of Compound S56
[0494]
[0495] The raw material 203b (89.8 mg, 0.147 mmol) was dissolved in 1,4-dioxane (2 mL), and N-Boc-ethylenediamine (30.6 mg, 0.176 mmol) and DIPEA (31.6 μ L, 0.19 mmol) were added to the reaction system, and the reaction was stirred at 90° C. overnight. After the reaction was completed, the reaction solution was cooled to room temperature, concentrated under reduced pressure, diluted with water, extracted with ethyl acetate (10 mL×3), and the combined organic layers were washed with saturated NaCl solution, dried over anhydrous Na2SO4, filtered and concentrated, and purified by column chromatography to obtain compound S58 (28.34 mg, 25%). 1H NMR(500MHz, DMSO-d6)δ 11.10 (s, 1H), 10.2 (s, 1H), 9.03 (s, 1H), 8.02 (d, J=7.5Hz, 1H), 7.93 (dd, J=7.4, 2.1Hz, 1H), 7.65 (dd, J=7.4, 1.9Hz, 1H), 7.5 0 (t, J=7.5Hz, 1H), 7.44 (dd, J=7.3, 2.1Hz, 2H), 7.34-7.26 (m, 2H), 7.25-7.18 (m, 1H), 7.17-7.08 (m, 3H), 6.70 (s, 1H), 5.13 ( d, J=8.1Hz, 2H), 4.56 (t, J=5.5Hz, 1H), 4.28 (dd, J=12.4, 5.5Hz, 1H), 4-20 (dd, J=12.4, 5.5Hz, 1H), 3.54 (s, 2H), 2.96-2.83 ( m, 2H), 2.66 (s, 1H), 2.54 (s, 1H), 2-24 (d, J=0.9Hz, 2H), 2.04 (d, J=1.4Hz, 2H), 1.78 (s, 3H), 1.73 (s, 3H). MS (ESI, m / z): 772 (M + +1).
[0496] Example 89 Synthesis of Compound S57
[0497]
[0498] The synthesis method refers to the synthesis of compound S56, and compound S57 can be prepared by simply replacing the corresponding raw materials. 1HNMR(500MHz, DMSO-d6)δ 11.10 (s, 1H), 10.2 (s, 1H), 9.03 (s, 1H), 8.02 (d, J=7.5Hz, 1H), 7.86 (d, J=7.5Hz, 1H), 7.68-7.60 (m, 2H), 7.51-7.43 (m, 2H), 7.34-7.26(m, 2H), 7.25-7.17(m, 1H), 7.17-7.10(m, 2H), 6.70(s, 1H), 6.48(s, 1H), 5.13(d, J=1.3Hz, 1H), 5.01(s, 1 H), 4.56 (t, J=5.5Hz, 1H), 4.28 (dd, J=12.4, 5.5Hz, 1H), 4.20 (dd, J=12.4, 5.5Hz, 1H), 3.65 (d, J=12.5Hz, 1H), 3.57 (d, J= 12.5Hz, 1H), 3.12 (s, 2H), 2.62 (d, J=11.5Hz, 2H), 2.24 (d, J=0.9Hz, 2H), 1.78 (s, 3H), 1.73 (s, 3H). MS (ESI, rm / z): 758 (M + +1).
[0499] Example 90 Synthesis of Compound S58
[0500]
[0501] The synthesis method refers to the synthesis of compound S56, and compound S58 can be prepared by simply replacing the corresponding raw materials. 1HNMR(500MHz, DMSO-d6)δ 11.10 (s, 1H), 10.2 (s, 1H), 9.08 (s, 1H), 8.02 (d, J=7.4Hz, 1H), 7.83 (d, J=7.5Hz, 1H), 7.62 (dd, J=7.5, 2.0Hz, 1H), 7.49 (d, J=2. 0Hz, 1H), 7.46-7.38 (m, 2H), 7.38-7.31 (m, 2H), 7.26-7.18 (m, 3H), 6.70 (s, 1H), 5.14 (d, J=1.2Hz, 1H), 5.01 (s, 1H), 4.56 (t, J=5 .5Hz, 1H), 4.28 (dd, J=12.4, 5.5Hz, 1H), 4.20 (dd, J=12.4, 5.5Hz, 1H), 3.20 (s, 4H), 2.79 (d, J=12.5Hz, 1H), 2.70 (d, J=12.5Hz, 1 H), 2.65-2.59 (m, 6H), 2.51 (d, J=2.5Hz, 2H), 2.23 (d, J=3.8Hz, 2H), 1.93 (s, 2H), 1.78 (s, 3H), 1.73 (s, 3H). MS (ESI, rm / z): 841 (M + +1).
[0502] Example 91 Synthesis of Compound S59
[0503]
[0504] The synthesis method refers to the synthesis of compound S56, and compound S59 can be prepared by simply replacing the corresponding raw materials. 1HNMR(500MHz, DMSO-d6)δ 11.10 (s, 1H), 10.2 (s, 1H), 9.08 (s, 1H), 8.02 (d, J=7.5Hz, 1H), 7.91 (d, J=7.5Hz, 1H), 7.65 (dd, J=7.1, 1.9Hz, 2H), 7.45 (d, J=2.0H z, 1H), 7.38 (dd, J=7.5, 2.0Hz, 1H), 7.34-7.26 (m, 2H), 7.25-7.18 (m, 1H), 7.17-7.10 (m, 2H), 6.70 (s, 1H), 5.16-5.12 (m, 1H), 5.01 (s, 1H), 4.56 (t, J=5.5Hz, 1H), 4.28 (dd, J=12.4, 5.5Hz, 1H), 4.20 (dd, J=12.4, 5.5Hz, 1H), 336 (s, 2H), 3.30 (s, 2H), 3.07 (s, 2H), 2 .62 (d, J=11.5Hz, 2H), 2.23 (d, J=3.8Hz, 2H), 1.96 (s, 2H), 1.91 (s, 1H), 1.78 (s, 3H), 1.73 (s, 3H), 1.46 (s, 2H). MS (ESI, m / z): 812 (M + +1).
[0505] Example 92 Synthesis of Compound S60
[0506]
[0507] The synthesis method refers to the synthesis of compound S56, and compound S60 can be prepared by simply replacing the corresponding raw materials. 1HNMR(500MHz, DMSO-d6)δ 11.10 (s, 1H), 10.2 (s, 1H), 9.08 (s, 1H), 8.02 (d, J=7.5Hz, 1H), 7.83 (d, J=7.5Hz, 1H), 7.65-7.57 (m, 2H), 7.47-7. 41 (m, 2H), 7.39-7.31 (m, 2H), 7.26-7.18 (m, 3H), 6.70 (s, 1H), 5.14 (d, J=1.2Hz, 1H), 5.01 (s, 1H), 4.56 (t, J=5.5H z, 1H), 4.28 (dd, J=12.4, 5.5Hz, 1H), 4.20 (dd, J=12.4, 5.5Hz, 1H), 3.33 (d, J=13.0Hz, 4H), 2.91 (s, 2H), 2.62 (d, J =11.5Hz, 2H), 2.23 (d, J = 3.8Hz, 2H), 1.80 (d, J = 17.9Hz, 4H), 1.75-1.67 (m, 7H), 1.64 (s, 2H). MS (ESI, m / z): 826 (M + +1).
[0508] Example 93 Synthesis of Compound S61
[0509]
[0510] The synthesis method refers to the synthesis of compound S52, and compound S61 can be obtained by simply replacing the corresponding raw materials. 1 HNMR(500MHz, DMSO-d6)δ 11.10 (s, 1H), 10.2 (s, 1H), 9.03 (s, 1H), 8.02 (d, J=7.5Hz, 1H), 7.82 (dd, J=7.5, 2.0Hz, 1H), 7.65 (dd, J=7.4, 1.9H z, 1H), 7.56 (t, J=7.5Hz, 1H), 7.47-7.41 (m, 2H), 7.34-7.26 (m, 2H), 7.26-7.18 (m, 3H), 7.03 (s, 1H), 5.19-5.15 (m , 1H), 4.56 (t, J=5.5Hz, 1H), 4.39 (s, 1H), 4.33-4.24 (m, 2H), 4.20 (dd, J=12.4, 5.5Hz, 1H), 4.01 (s, 1H), 2.97 (s, 2 H), 2.62-2.56 (m, 4H), 2.19 (s, 1H), 2.12 (s, 1H), 1.78 (s, 3H), 1.73 (s, 3H), 1.71-1.60 (m, 2H). MS (ESI, m / z): 767 (M + +1).
[0511] Example 94 Synthesis of Compound S62
[0512]
[0513] The synthesis method refers to the synthesis of compound S56, and compound S62 can be obtained by simply replacing the corresponding raw materials. 1 HNMR(500MHz, DMSO-d6)δ 11.10 (s, 1H), 10.2 (s, 1H), 9.03 (s, 1H), 8.02 (d, J=7.5Hz, 1H), 7.93 (t, J=4.8Hz, 1H), 7.65 (dd, J=7.4, 1.9Hz, 1H), 7.48- 7.40 (m, 3H), 7.34-7.26 (m, 2H), 7.26-7.18 (m, 3H), 7.10 (s, 1H), 7.03 (s, 1H), 5.17 (t, J=0.9Hz, 1H), 5.12 (s, 1H), 4.56 (t, J=5.5Hz, 1H), 4.30 (dd, J=12.4, 5.4Hz, 1H), 4.20 (dd, J=12.4, 5.5Hz, 1H), 3.54 (s, 2H), 3.05 (s, 2H), 2.66 (s, 1H), 2.54 (s, 1H), 2.24 (d, J=0.9Hz, 2H), 2.18 (d, J=12.5Hz, 1H), 2.08 (d, J=12.5Hz, 1H), 1.78 (s, 3H), 1.73 (s, 3H). MS (ESI, m / z): 772 (M + +1).
[0514] Example 95 Synthesis of Compound S63
[0515]
[0516] The synthesis method refers to the synthesis of compound S52, and compound S63 can be prepared by simply replacing the corresponding raw materials. 1HNMR(500MHz, DMSO-d6)δ 11.10 (s, 1H), 9.26 (s, 1H), 8.37 (s, 1H), 8.10 (d, J=7.5Hz, 1H), 7.97 (s, 1H), 7.82 (dd, J=7.3, 2.0Hz, 1H), 7.62 (dd, J=7 .5, 2.0Hz, 1H), 7.52 (t, J=7.5Hz, 1H), 7.49-7.40 (m, 2H), 7.34-7.26 (m, 2H), 7.267.18 (m, 3H), 7.11 (s, 1H), 5.19 (q, J= 0.8Hz, 1H), 4.494.41 (m, 3H), 4.30 (dd, J=12.4, 5.5Hz, 1H), 4.20 (dd, J=12.4, 5.6Hz, 1H), 4.08 (s, 2H), 4.01 (s, 1H), 2. 78 (s, 2H), 2.59 (d, J=7.5Hz, 2H), 2.19 (s, 1H), 2.12 (s, 1H), 1.98 (s, 2H), 1.78 (s, 3H), 1.73 (s, 3H). MS (ESI, m / z): 765 (M + +1).
[0517] Example 96 Synthesis of Compound S64
[0518]
[0519] The synthesis method refers to the synthesis of compound S56, and compound S64 can be prepared by simply replacing the corresponding raw materials. 1 HNMR(500MHz, DMSO-d6)δ 11.10 (s, 1H), 9.26 (s, 1H), 8.37 (s, 1H), 8.10 (d, J=7.5Hz, 1H), 7.99-7.89 (m, 2H), 7.62 (dd, J=7.5, 2.0Hz, 1H), 7.4 5-7.38 (m, 3H), 7.34-7.26 (m, 2H), 7.26-7.18 (m, 3H), 7.11 (s, 1H), 6.88 (s, 1H), 5.19 (q, J=0.8Hz, 1H), 5.12 (s, 1H), 4.44 (t, J=5.5Hz, 1H), 4.30 (dd, J=12.5, 5.5Hz, 1H), 4.244.15 (m, 3H), 3.46 (s, 2H), 2.66 (s, 1H), 2.54 (s, 1H), 2.49 (s, 1H), 2.14 (d, J=12.5Hz, 1H), 2.09 (d, J=12.3Hz, 1H), 1.99 (s, 1H), 1.78 (s, 3H), 1.73 (s, 3H). MS (ESI, m / z): 770 (M+ +1).
[0520] Example 97 Synthesis of Compound S65
[0521]
[0522] The synthesis method refers to the synthesis of compound S52, and compound S65 can be prepared by simply replacing the corresponding raw materials. 1 HNMR(500MHz, DMSO-d6)δ 11.10 (s, 1H), 9.65 (s, 1H), 9.43 (s, 1H), 9.10 (s, 1H), 8.16 (s, 1H), 7.85-7.76 (m, 2H), 7.64 (d, J=7.5Hz, 1H), 7.59-7.49 (m, 2H), 7.46 ( dd, J=7.5, 2.0Hz, 1H), 7.29 (ddd, J=7.4, 2.0, 1.0Hz, 1H), 7.20-7.10 (m, 2H), 7.06-6.97 (m, 2H), 6.83 (dt, J=2.0, 0.9Hz, 1H), 5.11 (t, J= 0.7Hz, 1H), 4.55 (t, J=5.5Hz, 1H), 4.50-4.35 (m, 4H), 4.21 (d, J=1.1Hz, 2H), 4.08 (s, 2H), 4.01 (s, 1H), 2.96 (t, J=0.8Hz, 2H), 2.78 (s, 2 H), 2.59 (d, J=7.5Hz, 2H), 2.19 (s, 1H), 2.12 (s, 1H), 1.98 (s, 2H), 1.86 (d, J=0.9Hz, 2H), 1.81 (s, 1H), 1.76 (s, 1H). MS (ESI, m / z): 776 (M + +1).
[0523] Example 98 Synthesis of Compound S66
[0524]
[0525] The synthesis method refers to the synthesis of compound S56, and compound S66 can be prepared by simply replacing the corresponding raw materials. 1HNMR(500MHz, DMSO-d6)δ 11.10(s, 1H), 9.65(s, 1H), 9.43(s, 1H), 9.12(s, 1H), 8.37(s, 1H), 7.87(s, 1H), 7.81 (dd, J=7.5, 2.0Hz, 1H), 7.64 (d, J=7.5Hz, 1H), 7.57 (dd, J=7.5, 2.0Hz, 1H), 7.39 (t, J =7.5Hz, 1H), 7.29 (ddd, J=7.4, 2.0, 1.0Hz, 1H), 7.24-7.10 (m, 3H), 7.02 (td, J=7.5, 2 .0Hz, 1H), 6.93 (dd, J=7.4, 2.0Hz, 1H), 6.83 (dt, J=1.9, 0.9Hz, 1H), 6.61 (s, 1H), 5.11 (t, J=0.7Hz, 1H), 4.55 (t, J=5.5Hz, 1H), 4.50-4.35 (m, 4H), 4.21 (d, J=1.1Hz, 2H), 4. 01 (s, 1H), 3.91 (s, 2H), 3.47 (d, J = 1.0Hz, 2H), 2.96 (t, J = 0.8Hz, 2H), 2.58 (d, J = 15.0H z, 2H), 2.19 (s, 1H), 2.12 (s, 1H), 1.97 (d, J=12.4Hz, 1H), 1.88-1.79 (m, 4H), 1.76 (s, 1H), 1.67 (s, 2H), 1.51 (d, J=12.3Hz, 1H), 1.44 (d, J=12.4Hz, 1H). MS (ESI, m / z): 795 (M + +1).
[0526] Example 99 Synthesis of Compound S67
[0527]
[0528] The synthesis method refers to the synthesis of compound S52, and compound S67 can be prepared by simply replacing the corresponding raw materials. 1HNMR(500MHz, DMSO-d6)δ 11.10(s, 1H), 9.65(s, 1H), 9.43(s, 1H), 9.26(s, 1H), 8.16(s, 1H), 7.85-7.76(m, 2H), 7.59-7.43(m, 4H), 7.36(dd d, J=7.5, 2.0, 1.0Hz, 1H), 7.19 (td, J=7.5, 2.0Hz, 1H), 7.06-6.92 (m, 3H), 6.71 (dt, J=2.0, 1.0Hz, 1H), 5.08 (t, J= 0.8Hz, 1H), 4.58-4.42 (m, 6H), 4.39 (dd, J=11.5, 4.8Hz, 1H), 4.16 (d, J=1.3Hz, 2H), 4.08 (s, 2H), 4.01 (s, 1H), 3.8 1 (d, J=0.9Hz, 2H), 2.78 (s, 2H), 2.59 (d, J=7.5Hz, 2H), 2.19 (s, 1H), 2.12 (s, 1H), 1.98 (s, 2H). MS (ESI, m / z): 778 (M + +1).
[0529] Example 100 Synthesis of Compound S68
[0530]
[0531] The synthesis method refers to the synthesis of compound S56, and compound S68 can be prepared by simply replacing the corresponding raw materials. 1HNMR(500MHz, DMSO-d6)δ 11.10 (s, 1H), 9.65 (s, 1H), 9.43 (s, 1H), 9.26 (s, 1H), 8.16 (s, 1H), 7.84-7.76 (m, 2H), 7.62 (d, J=2.0Hz, 1H), 7.57 (dd, J=7.5, 2.0Hz, 1H ), 7.48 (d, J=7.5Hz, 1H), 7.41 (dd, J=7.4, 1.9Hz, 1H), 7.36 (ddd, J=7.5, 2.1, 1.0Hz, 1H), 7.19 (td, J=7.5, 2.0Hz, 1H), 7.04 (s, 1H), 7.03 -6.92 (m, 2H), 6.71 (dt, J=2.0, 1.0Hz, 1H), 6.48 (s, 1H), 5.08 (d, J=0.7Hz, 1H), 5.01 (s, 1H), 4.58-4.49 (m, 2H), 4.46-4.34 (m, 3H), 4.20 -4.09 (m, 4H), 3.81 (d, J = 1.0Hz, 2H), 3.45 (s, 2H), 2.62 (d, J = 11.5Hz, 2H), 2.24 (d, J = 1.0Hz, 2H), 2.17-2.05 (m, 2H). MS (ESI, m / z): 783 (M + +1).
[0532] Example 101 Synthesis of Compound S69
[0533]
[0534] The synthesis method refers to the synthesis of compound S52, and compound S69 can be prepared by simply replacing the corresponding raw materials. 1HNMR(500MHz, DMSO-d6)δ 11.10 (s, 1H), 9.65 (s, 1H), 9.52 (s, 1H), 9.43 (s, 1H), 8.16 (s, 1H), 7.85-7.76 (m, 2H), 7.61-7.49 (m, 3H), 7.46 (dd, J=7.5, 2.0Hz, 1H), 7. 36 (ddd, J=7.5, 2.0, 1.0Hz, 1H), 7.19 (td, J=7.5, 2.0Hz, 1H), 7.06-6.98 (m, 2H), 6.93 (dd, J=7.5, 2.0Hz, 1H), 6.82 (dd, J=1.8, 1.1Hz, 1H), 5.08 (d, J=0.7Hz, 1H), 4.55 (t, J=5.5Hz, 1H), 4.50-4.35 (m, 4H), 4.15 (d, J=10.2Hz, 2H), 4.08 (s, 2H), 4.01 (s, 1H), 3.66 (dd, J=2.0, 1.1Hz , 2H), 3.13 (d, J=0.9Hz, 2H), 2.78 (s, 2H), 2.59 (d, J=7.5Hz, 2H), 2.41 (s, 3H), 2.19 (s, 1H), 2.12 (s, 1H), 1.98 (s, 2H). MS (ESI, m / z): 783 (M + +1).
[0535] Example 102 Synthesis of Compound S70
[0536]
[0537] The synthesis method refers to the synthesis of compound S52, and compound S70 can be prepared by simply replacing the corresponding raw materials. 1HNMR(500MHz, DMSO-d6)δ 11.10 (s, 1H), 9.65 (s, 1H), 9.43-9.40 (m, 2H), 8.37 (s, 1H), 7.97 (s, 1H), 7.81 (dd, J=7.1, 2.4Hz, 1H), 7.65-7.55 (m, 2H), 7.55-7.45 (m , 2H), 7.40 (ddt, J=7.6, 2.1, 1.1Hz, 1H), 7.32-7.16 (m, 3H), 6.94 (dt, J=2.0, 1.1Hz, 1H), 6.88 (s, 1H), 5.81 (d, J=6.0Hz, 2H), 5.07-5.03 (m, 1H), 4.57-4.49 (m, 2H), 4.49-4.41 (m, 3H), 4.35 (d, J=1.1Hz, 1H), 4.18 (d, J=1.0Hz, 1H), 4.10 (s, 4H), 4.08-3.99 (m, 3H), 3.97 (s, 1 H), 3.93 (s, 1H), 2.88 (d, J=1.0Hz, 2H), 2.78 (s, 2H), 2.59 (d, J=7.5Hz, 2H), 2.19 (s, 1H), 2.12 (s, 1H), 1.99 (s, 2H). MS (ESI, m / z): 832 (M + +1).
[0538] Example 103 Synthesis of Compound S71
[0539]
[0540] The synthesis method refers to the synthesis of compound S1, and compound S71 can be prepared by simply replacing the corresponding raw materials. 1H NMR(500MHz, DMSO-d6)δ 11.10 (s, 1H), 9.43 (s, 1H), 8.97 (s, 1H), 8.14 (s, 1H), 8.02 (d, J=7.5Hz, 1H), 7.65 (dd, J=7.4, 1.9Hz, 1H), 7.45 (d, J =2.0Hz, 1H), 7.34-7.26(m, 2H), 7.25-7.20(m, 1H), 7.20-7.10(m, 4H), 7.05-6.98(m, 2H), 6.95(s, 1H), 5.16-5.12(m , 1H), 4.56 (t, J=5.5Hz, 1H), 4.28 (dd, J=12.4, 5.5Hz, 1H), 4.23-4.16 (m, 2H), 3.53-3.42 (m, 2H), 3.22 (d, J=4.4Hz, 4 H), 2.60-2.53 (m, 6H), 2.49 (d, J=5.5Hz, 2H), 2.01 (d, J=12.5Hz, 2H), 1.78 (s, 3H), 1.73 (s, 3H). MS (ESI, m / z): 733 (M + +1).
[0541] Example 104 Synthesis of Compound S72
[0542]
[0543] The synthesis method refers to the synthesis of compound S1, and compound S72 can be obtained by simply replacing the corresponding raw materials. 1H NMR(500MHz, DMSO-d6)δ 11.10 (s, 1H), 10.2 (s, 1H), 9.10 (s, 1H), 8.38 (s, 1H), 8.02 (d, J = 7.5Hz, 1H), 7.65 (dd, J = 7.4, 1.9Hz, 1H), 7.45 (d, J = 2.0Hz, 1H), 7.34-7.26 (m, 2H), 7.25-7.10 (m, 5H), 7.00-6.93 (m, 2H), 6.70 (s, 1H), 5.13 (d, J=1.3Hz, 1H), 4.56 (t, J=5.5Hz, 1H), 4.28 (dd, J= 12.4, 5.5Hz, 1H), 4.20 (dd, J=12.4, 5.5Hz, 1H), 3.85 (t, J=1.0Hz, 1H), 3.35 (d, J=6.2Hz, 4H), 3.26 (s, 2H), 2.49 (d, J=5.5Hz, 2H) , 2.01 (d, J=12.5Hz, 2H), 1.94 (s, 1H), 1.86 (d, J=12.5Hz, 1H), 1.78 (s, 3H), 1.75-1.62 (m, 6H), 1.60 (s, 2H). MS (ESI, m / z): 732 (M + +1).
[0544] Example 105 Synthesis of Compound S73
[0545]
[0546] The synthesis method refers to the synthesis of compound S1, and compound S73 can be prepared by simply replacing the corresponding raw materials. 1H NMR(500MHz, DMSO-d6)δ 11.10 (s, 1H), 10.2 (s, 1H), 9.10 (s, 1H), 8.12 (s, 1H), 8.02 (d, J = 7.5Hz, 1H), 7.65 (dd, J = 7.4, 1.9Hz, 1H), 7.45 (d, J =2.0Hz, 1H), 7.34-7.26(m, 2H), 7.25-7.20(m, 1H), 7.20-7.10(m, 4H), 7.05-6.98(m, 2H), 6.70(s, 1H), 5.13(d, J=1. 3Hz, 1H), 4.56 (t, J=5.5Hz, 1H), 4.28 (dd, J=12.4, 5.5Hz, 1H), 4.23-4.16 (m, 2H), 3.33 (q, J=12.4Hz, 2H), 3.20 (s, 4 H), 2.61 (s, 4H), 2.51-2.43 (m, 4H), 2.01 (d, J=12.5Hz, 2H), 1.78 (d, J=4.2Hz, 5H), 1.73 (s, 3H). MS (ESI, m / z): 747 (M + +1).
[0547] Example 106 Synthesis of Compound S74
[0548]
[0549] The synthesis method refers to the synthesis of compound S1, and compound S74 can be prepared by simply replacing the corresponding raw materials. 1 H NMR(500MHz, DMSO-d6)δ 11.10 (s, 1H), 10.2 (s, 1H), 8.97 (s, 1H), 8.16 (s, 1H), 8.02 (d, J=7.5Hz, 1H), 7.65 (dd, J=7.4, 1.9Hz, 1H), 7.45 (d, J=2. 0Hz, 1H), 7.34-7.26 (m, 2H), 7.25-7.18 (m, 1H), 7.16-7.10 (m, 4H), 6.95 (s, 1H), 5.13 (d, J=1.3Hz, 1H), 4.56 (t, J=5.5H z, 1H), 4.44 (s, 1H), 4.28 (dd, J=12.4, 5.5Hz, 1H), 4.20 (dd, J=12.4, 5.5Hz, 1H), 3.50 (d, J=1.8Hz, 2H), 3.31 (s, 2H), 3. 23 (s, 2H), 2.59 (d, J=2.4Hz, 6H), 2.50 (s, 2H), 2.12 (d, J=11.7Hz, 2H), 1.78 (s, 3H), 1.73 (s, 3H). MS (ESI, rm / z): 769 (M+ +1).
[0550] Example 107 Synthesis of Compound S75
[0551]
[0552] The synthesis method refers to the synthesis of compound S1, and compound S75 can be prepared by simply replacing the corresponding raw materials. 1 H NMR(500MHz, DMSO-d6)δ 11.10 (s, 1H), 10.2 (s, 1H), 8.97 (s, 1H), 8.16 (s, 1H), 8.02 (d, J=7.5Hz, 1H), 7.65 (dd, J=7.4, 1.9Hz, 1H), 7.45 (d, J=2.0H z, 1H), 7.34-7.26 (m, 2H), 7.25-7.18 (m, 2H), 7.17-7.10 (m, 2H), 6.97-6.92 (m, 2H), 5.13 (d, J=1.3Hz, 1H), 4.56 (t, J=5.5 Hz, 1H), 4.44 (s, 1H), 4.28 (dd, J=12.4, 5.5Hz, 1H), 4.20 (dd, J=12.4, 5.5Hz, 1H), 3.50 (d, J=1.8Hz, 2H), 3.25 (s, 2H), 3.2 1 (s, 2H), 2.61-2.53 (m, 6H), 2.50 (d, J=2.4Hz, 2H), 2.12 (d, J=11.7Hz, 2H), 1.78 (s, 3H), 1.73 (s, 3H). MS (ESI, m / z): 785 (M + +1).
[0553] Example 108 Synthesis of Compound S76
[0554]
[0555] The synthesis method refers to the synthesis of compound S1, and compound S76 can be prepared by simply replacing the corresponding raw materials. 1H NMR(500MHz, DMSO-d6)δ 11.10 (s, 1H), 10.2 (s, 1H), 8.97 (s, 1H), 8.25 (s, 1H), 8.02 (d, J = 7.5Hz, 1H), 7.65 (dd, J = 7.4, 1.9Hz, 1H), 7.53 (d, J = 1.0Hz, 1H), 7.4 5 (d, J=2.0Hz, 1H), 7.34-7.26 (m, 2H), 7.25-7.18 (m, 1H), 7.17-7.10 (m, 2H), 6.95 (d, J=1.8Hz, 2H), 5.13 (d, J=1.3Hz, 1H), 4.64 (d, J =1.1Hz, 1H), 4.56 (t, J = 5.5Hz, 1H), 4.28 (dd, J = 12.4, 5.5Hz, 1H), 4.20 (dd, J = 12.4, 5.5Hz, 1H), 3.53-3.42 (m, 2H), 3.14 (s, 2H), 3.1 0 (s, 2H), 2.60 (dd, J=18.4, 1.5Hz, 6H), 2.47 (d, J=8.8Hz, 2H), 2.06 (d, J=2.4Hz, 2H), 1.78 (s, 3H), 1.73 (s, 3H). MS (ESI, rm / z): 769 (M + +1).
[0556] Example 109 Synthesis of Compound S77
[0557]
[0558] The synthesis method refers to the synthesis of compound S1, and compound S77 can be obtained by simply replacing the corresponding raw materials. 1H NMR(500MHz, DMSO-d6)δ 11.10 (s, 1H), 10.2 (s, 1H), δ 8.97 (s, 1H), 8.25 (s, 1H), 8.02 (d, J = 7.5Hz, 1H), 7.65 (dd, J = 7.4, 1.9Hz, 1H), 7.45 (d, J = 2.0Hz, 1H), 7.37 (d d, J=7.5, 1.1Hz, 1H), 7.34-7.26 (m, 2H), 7.25-7.18 (m, 1H), 7.17-7.10 (m, 2H), 7.03 (d, J=7.5Hz, 1H), 6.95 (s, 1H), 5.13 (d, J=1.3Hz, 1H) , 4.64 (d, J = 1.1Hz, 1H), 4.56 (t, J = 5.5Hz, 1H), 4.28 (dd, J = 12.4, 5.5Hz, 1H), 4.20 (dd, J = 12.4, 5.5Hz, 1H), 3.53-3.42 (m, 2H), 3.14 (s, 2H) ), 3.10 (s, 2H), 2.60 (dd, J=18.4, 1.5Hz, 6H), 2.47 (d, J=8.8Hz, 2H), 2.06 (d, J=2.4Hz, 2H), 1.78 (s, 3H), 1.73 (s, 3H). MS (ESI, m / z): 769 (M + +1).
[0559] Example 110 Synthesis of Compound S78
[0560]
[0561] The synthesis method refers to the synthesis of compound S1, and compound S78 can be prepared by simply replacing the corresponding raw materials. 1H NMR(500MHz, DMSO-d6)δ 11.10 (s, 1H), 10.2 (s, 1H), δ 8.97 (s, 1H), 8.16 (s, 1H), 8.02 (d, J = 7.5Hz, 1H), 7.65 (dd, J = 7.4, 1.9Hz, 1H), 7.45 (d, J = 2.0Hz, 1H) ), 7.36 (d, J = 1.9Hz, 1H), 7.34-7.26 (m, 2H), 7.26-7.17 (m, 2H), 7.17-7.09 (m, 3H), 6.95 (s, 1H), 5.13 (d, J = 1.3Hz, 1H), 4.64 (d, J=1.1Hz, 1H), 4.56 (t, J=5.5Hz, 1H), 4.28 (dd, J=12.4, 5.5Hz, 1H), 4.20 (dd, J=12.4, 5.5Hz, 1H), 3.53-3.42 (m, 2H), 3.28 (s, 2H ), 3.23 (s, 2H), 2.60-2.53 (m, 6H), 2.47 (d, J = 8.8Hz, 2H), 2.04 (d, J = 7.5Hz, 2H), 1.78 (s, 3H), 1.73 (s, 3H). MS (ESI, m / z): 758 (M + +1).
[0562] Example 111 Synthesis of Compound S79
[0563]
[0564] The synthesis method refers to the synthesis of compound S56, and compound S79 can be prepared by simply replacing the corresponding raw materials. 1HNMR(500MHz, DMSO-d6)δ 11.10 (s, 1H), 10.2 (s, 1H), δ9.03 (s, 1H), 8.02 (d, J=7.5Hz, 1H), 7.65 (dd, J=7.4, 1.9Hz, 1H), 7.45 (d, J=2.0Hz, 1H), 7.34-7.24 (m, 3H), 7.24-7.19 (m, 1H), 7.17 (dd, J=2.0, 1.0Hz, 1H), 7.16-7.10 (m, 2H), 7.02 (d, J=7.5Hz, 1H), 6.70 (s, 1H), 5.16-5.12 (m, 1H), 4.59 -4.52 (m, 2H), 4.28 (dd, J=12.4, 5.5Hz, 1H), 4.20 (dd, J=12.4, 5.5Hz, 1H), 3.12 (d, J=6.8Hz, 4H), 2.98 (s, 2H), 2.88 (d, J=12.4Hz, 1H ), 2.81 (d, J = 12.5Hz, 1H), 2.62 (s, 4H), 2.49 (d, J = 5.5Hz, 2H), 2.01 (d, J = 4.6Hz, 2H), 1.78 (s, 3H), 1.73 (s, 3H). MS (ESI, m / z): 776 (M + +1).
[0565] Example 112 Synthesis of Compound S80
[0566]
[0567] The synthesis method refers to the synthesis of compound S56, and compound S80 can be prepared by simply replacing the corresponding raw materials. 1HNMR(500MHz, DMSO-d6)δ 11.10 (s, 1H), 9.43 (s, 1H), δ 9.03 (s, 1H), 8.02 (d, J = 7.5Hz, 1H), 7.65 (dd, J = 7.4, 1.9Hz, 1H), 7.45 (d, J = 2.0Hz, 1H), 7.34- 7.24 (m, 3H), 7.24-7.18 (m, 1H), 7.17 (dd, J=2.0, 1.0Hz, 1H), 7.16-7.10 (m, 2H), 7.00 (d, J=7.5Hz, 1H), 6.70 (s, 1H), 5.16-5 .12 (m, 1H), 4.59-4.52 (m, 2H), 4.28 (dd, J=12.4, 5.5Hz, 1H), 4.20 (dd, J=12.4, 5.5Hz, 1H), 3.11 (d, J=3.8Hz, 4H), 3.05 (s, 2H), 2.71 (s, 2H), 2.61 (s, 4H), 2.49 (d, J=5.5Hz, 2H), 2.01 (d, J=4.6Hz, 2H), 1.78 (s, 3H), 1.73 (s, 3H). MS (ESI, m / z): 776 (M + +1).
[0568] Example 113 Synthesis of Compound S81
[0569]
[0570] The synthesis method refers to the synthesis of compound S1, and compound S81 can be prepared by simply replacing the corresponding raw materials. 1H NMR(500MHz, DMSO-d6)δ 11.10 (s, 1H), 10.2 (s, 1H), δ 8.97 (s, 1H), 8.16 (s, 1H), 8.02 (d, J = 7.5Hz, 1H), 7.65 (dd, J = 7.4, 1.9Hz, 1H), 7.45 (d, J = 2. 0Hz, 1H), 7.34-7.18 (m, 5H), 7.17-7.10 (m, 2H), 6.97-6.89 (m, 3H), 5.18 (s, 1H), 5.13 (d, J=1.3Hz, 1H), 4.56 (t, J=5.5Hz , 1H), 4.34 (s, 1H), 4.28 (dd, J=12.4, 5.5Hz, 1H), 4.20 (dd, J=12.4, 5.5Hz, 1H), 3.53-3.42 (m, 2H), 3.28 (s, 2H), 3.22 (s, 2H), 2.58 (d, J=0.8Hz, 3H), 2.52 (d, J=15.0Hz, 5H), 2.29 (s, 1H), 1.79 (d, J=5.5Hz, 4H), 1.73 (s, 3H). MS (ESI, m / z): 748 (M + +1).
[0571] Example 114 Synthesis of Compound S82
[0572]
[0573] The synthesis method refers to the synthesis of compound S1, and compound S82 can be prepared by simply replacing the corresponding raw materials. 1H NMR(500MHz, DMSO-d6)δ 11.10 (s, 1H), 10.2 (s, 1H), δ8.97 (s, 1H), 8.25 (s, 1H), 8.02 (d, J=7.5Hz, 1H), 7.65 (dd, J=7.4, 1.9Hz, 1H), 7.53-7.43 ( m, 2H), 7.34-7.26 (m, 2H), 7.25-7.18 (m, 2H), 7.17-7.10 (m, 2H), 6.94 (d, J=7.9Hz, 2H), 5.20-5.12 (m, 2H), 4.56 (t, J=5 .5Hz, 1H), 4.34 (s, 1H), 4.28 (dd, J=12.4, 5.5Hz, 1H), 4.20 (dd, J=12.4, 5.5Hz, 1H), 3.53-3.42 (m, 2H), 3.09 (d, J=2.4H z, 4H), 2.61 (d, J=2.6Hz, 5H), 2.58-2.52 (m, 3H), 2.29 (s, 1H), 1.79 (d, J=5.5Hz, 4H), 1.73 (s, 3H). MS (ESI, m / z): 766 (M + +1).
[0574] Example 115 Synthesis of Compound S83
[0575]
[0576] The synthesis method refers to the synthesis of compound S56, and compound S83 can be prepared by simply replacing the corresponding raw materials. 1HNMR(500MHz, DMSO-d6)δ 11.10 (s, 1H) 9.43 (s, 1H), 8.02 (d, J = 7.5Hz, 1H), 7.65 (dd, J = 7.4, 1.9Hz, 1H), 7.53-7.43 (m, 2H), 7.34-7.26 (m, 2H), 7.25-7.18 ( m, 2H), 7.17-7.10 (m, 2H), 7.03 (d, J=7.5Hz, 1H), 6.70 (s, 1H), 5.18 (s, 1H), 5.13 (d, J=1.3Hz, 1H), 4.56 (t, J=5.5Hz, 1H), 4.34 (s , 1H), 4.28 (dd, J=12.4, 5.5Hz, 1H), 4.20 (dd, J=12.4, 5.5Hz, 1H), 3.06 (d, J=15.4Hz, 4H), 2.98 (s, 2H), 2.88 (d, J=12.5Hz, 1H), 2 .81 (d, J=12.5Hz, 1H), 2.61 (d, J=6.6Hz, 5H), 2.54 (s, 1H), 2.29 (s, 1H), 1.79 (d, J=5.5Hz, 4H), 1.73 (s, 3H). MS (ESI, m / z): 791 (M + +1).
[0577] Example 116 Synthesis of Compound S84
[0578]
[0579] The synthesis method refers to the synthesis of compound S1, and compound S84 can be prepared by simply replacing the corresponding raw materials. 1H NMR(500MHz, DMSO-d6)δ 11.10 (s, 1H), 10.2 (s, 1H), δ8.97 (s, 1H), 8.14 (s, 1H), 8.02 (d, J=7.5Hz, 1H), 7.65 (dd, J=7.4, 1.9Hz, 1H), 7.45 (d, J=2. 0Hz, 1H), 7.34-7.26 (m, 2H), 7.25-7.16 (m, 3H), 7.16-7.05 (m, 4H), 6.95 (s, 1H), 5.13 (d, J=1.3Hz, 1H), 4.56 (t, J=5.5Hz, 1H), 4.28 (dd, J=12.4, 5.5Hz, 1H), 4.20 (dd, J=12.4, 5.5Hz, 1H), 3.533.42 (m, 2H), 3.22 (d, J=4.4Hz, 4H), 2.59 (d, J=3.8 Hz, 6H), 2.52 (s, 1H), 2.46 (s, 1H), 2.34 (s, 1H), 2.02 (s, 1H), 1.78 (s, 3H), 1.73 (s, 3H), 1.53 (s, 3H). MS (ESI, m / z): 747 (M + +1).
[0580] Example 117 Synthesis of Compound S85
[0581]
[0582] The synthesis method refers to the synthesis of compound S1, and compound S85 can be prepared by simply replacing the corresponding raw materials. 1H NMR(500MHz, DMSO-d6)δ 11.10 (s, 1H), 10.2 (s, 1H), δ8.97 (s, 1H), 8.16 (s, 1H), 8.02 (d, J=7.5Hz, 1H), 7.65 (dd, J=7.4, 1.9Hz, 1H), 7.45 (d, J=2.0 Hz, 1H), 7.42-7.36 (m, 2H), 7.34-7.26 (m, 2H), 7.25-7.18 (m, 1H), 7.17-7.10 (m, 2H), 6.99-6.93 (m, 3H), 5.16-5.12 (m, 1H) ), 4.56 (t, J=5.5Hz, 1H), 4.28 (dd, J=12.4, 5.5Hz, 1H), 4.20 (dd, J=12.4, 5.5Hz, 1H), 4.07 (d, J=13.9Hz, 2H), 3.53-3.42 ( m, 2H), 3.31 (s, 2H), 3.26 (s, 2H), 2.88 (s, 2H), 2.58 (s, 2H), 2.51 (s, 4H), 1.78 (s, 3H), 1.73 (s, 3H). MS (ESI, rm / z): 734 (M + +1).
[0583] Example 118 Synthesis of Compound S86
[0584]
[0585] The synthesis method refers to the synthesis of compound S1, and compound S86 can be prepared by simply replacing the corresponding raw materials. 1H NMR(500MHz, DMSO-d6)δ 11.10 (s, 1H), 10.2 (s, 1H), δ8.97 (s, 1H), 8.288.23 (m, 2H), 8.02 (d, J=7.5Hz, 1H), 7.65 (dd, J=7.4, 1.9Hz, 1H), 7.45 (d, J=2.0 Hz, 1H), 7.38 (d, J=7.5Hz, 1H), 7.34-7.26 (m, 2H), 7.25-7.18 (m, 1H), 7.17-7.10 (m, 2H), 7.04 (dd, J=7.5, 2.0Hz, 1H), 6.95 (s, 1 H), 5.20-5.12 (m, 2H), 4.56 (t, J=5.5Hz, 1H), 4.34 (s, 1H), 4.28 (dd, J=12.4, 5.5Hz, 1H), 4.20 (dd, J=12.4, 5.5Hz, 1H), 3.50 (d, J=1.8Hz, 2H), 3.05 (d, J=13.0Hz, 3H), 2.61-2.52 (m, 7H), 2.29 (s, 1H), 1.79 (d, J=5.5Hz, 4H), 1.73 (s, 2H). MS (ESI, m / z): 816 (M + +1).
[0586] Example 119 Synthesis of Compound S87
[0587]
[0588] The synthesis method refers to the synthesis of compound S56, and compound S87 can be prepared by simply replacing the corresponding raw materials. 1HNMR(500MHz, DMSO-d6)δ 11.10 (s, 1H), 9.43 (s, 1H), δ9.08 (s, 1H), 8.02 (d, J=7.5Hz, 1H), 7.65 (dd, J=7.4, 1.9Hz, 1H), 7.45 (d, J=2.0Hz, 1H), 7.39-7.2 6 (m, 4H), 7.25-7.18 (m, 1H), 7.17-7.10 (m, 2H), 6.91 (d, J = 1.8Hz, 1H), 6.70 (s, 1H), 5.18 (s, 1H), 5.13 (d, J = 1.3Hz, 1H), 4.56 (t , J=5.5Hz, 1H), 4.34 (s, 1H), 4.28 (dd, J=12.4, 5.5Hz, 1H), 4.20 (dd, J=12.5, 5.5Hz, 1H), 3.92 (s, 3H), 3.12 (s, 2H), 2.98 (s, 2H ), 2.82 (d, J=10.8Hz, 4H), 2.622.56 (m, 5H), 2.54 (s, 1H), 2.29 (s, 1H), 1.79 (d, J=5.5Hz, 4H), 1.73 (s, 3H). MS (ESI, m / z): 803 (M + +1).
[0589] Example 120 Synthesis of Compound S88
[0590]
[0591] The synthesis method refers to the synthesis of compound S56, and compound S88 can be prepared by simply replacing the corresponding raw materials. 1HNMR(500MHz, DMSO-d6)δ 11.10 (s, 1H), 9.43 (s, 1H), δ9.03 (s, 1H), 8.02 (d, J=7.5Hz, 1H), 7.65 (dd, J=7.4, 1.9Hz, 1H), 7.53-7.43 (m, 2H), 7 .34-7.26 (m, 2H), 7.25-7.18 (m, 2H), 7.17-7.10 (m, 2H), 7.03 (d, J=7.5Hz, 1H), 6.70 (s, 1H), 5.205.12 (m, 2H), 4.5 6 (t, J=5.5Hz, 1H), 4.34 (s, 1H), 4.28 (dd, J=12.4, 5.5Hz, 1H), 4.20 (dd, J=12.4, 5.5Hz, 1H), 3.093.02 (m, 6H), 2.7 1 (s, 2H), 2.61 (d, J=3.5Hz, 5H), 2.54 (s, 1H), 2.29 (s, 1H), 1.79 (d, J=5.5Hz, 4H), 1.73 (s, 3H). MS (ESI, m / z): 791 (M + +1).
[0592] Example 121 Synthesis of Compound S89
[0593]
[0594] The synthesis method refers to the synthesis of compound S1, and compound S89 can be prepared by simply replacing the corresponding raw materials. 1 H NMR(500MHz, DMSO-d6)δ 11.10 (s, 1H), 10.2 (s, 1H), δ8.99 (s, 1H), 8.16 (s, 1H), 8.02 (d, J=7.5Hz, 1H), 7.707.62 (m, 2H), 7.45 (d, J=2.0Hz, 1H), 7.36-7.26 (m, 3H), 7.26-7.18 (m, 4H), 6.85 (d, J=2.0Hz, 1H), 5.205.15 (m, 1H), 4.56 (t, J=5 .5Hz, 1H), 4.30 (dd, J=12.4, 5.4Hz, 1H), 4.24-4.16 (m, 2H), 3.53-3.42 (m, 2H), 3.20 (d, J=7.5Hz, 4H), 2. 62-2.56 (m, 8H), 2.19 (d, J=8.4Hz, 2H), 1.78 (d, J=3.1Hz, 6H), 1.73 (d, J=3.1Hz, 6H). MS (ESI, m / z): 816 (M + +1).
[0595] Example 122 Synthesis of Compound S90
[0596]
[0597] The synthesis method refers to the synthesis of compound S1, and compound S90 can be prepared by simply replacing the corresponding raw materials. 1 H NMR(500MHz, DMSO-d6)δ 11.10(s, 1H), 10.2(s, 1H), δ8.99(s, 1H), 8.16(s, 1H), 8.02(d, J=7.5Hz, 1H), 7.70-7.62(m, 2H), 7.45( d, J=2.0Hz, 1H), 7.36-7.26 (m, 3H), 7.26-7.18 (m, 4H), 6.89 (d, J=2.0Hz, 1H), 5.19-5.15 (m, 1H), 4.56 (t , J=5.5Hz, 1H), 4.33-4.25 (m, 2H), 4.20 (dd, J=12.5, 5.5Hz, 1H), 3.533.42 (m, 2H), 3.22 (s, 4H), 2.622.5 5 (m, 10H), 2.52 (d, J=4.9Hz, 2H), 2.19 (d, J=8.4Hz, 2H), 1.78 (s, 3H), 1.73 (s, 3H). MS (ESI, rm / z): 814 (M + +1).
[0598] Example 123 Synthesis of Compound S91
[0599]
[0600] The synthesis method refers to the synthesis of compound S1, and compound S91 can be prepared by simply replacing the corresponding raw materials. 1H NMR(500MHz, DMSO-d6)δ 11.10 (s, 1H), 10.2 (s, 1H), δ9.10 (s, 1H), 8.33 (s, 1H), 8.01 (dd, J=7.3, 2.2Hz, 2H), 7.65 (dd, J=7.4, 1.9Hz, 1H), 7. 47-7.34 (m, 4H), 7.34-7.26 (m, 2H), 7.26-7.17 (m, 3H), 6.61 (s, 1H), 5.19-5.15 (m, 1H), 4.56 (t, J=5.5Hz, 1H), 4.35 (s, 1H), 4.33-4.25 (m, 2H), 3.75 (d, J = 12.5Hz, 1H), 3.65 (s, 2H), 3.60 (d, J = 12.3Hz, 1H), 2.58 (d, J = 15.0Hz, 2H), 2. 46 (d, J=4.9Hz, 2H), 2.30 (d, J=5.1Hz, 2H), 2.22 (s, 1H), 2.14 (s, 1H), 1.78 (s, 3H), 1.73 (s, 3H). MS (ESI, m / z): 745 (M + +1).
[0601] Example 124 Synthesis of Compound S92
[0602]
[0603] The synthesis method refers to the synthesis of compound S1, and compound S92 can be prepared by simply replacing the corresponding raw materials. 1 H NMR(500MHz, DMSO-d6)δ 11.10 (s, 1H), 10.2 (s, 1H), δ9.08 (s, 1H), 8.188.12 (m, 2H), 7.83 (d, J=7.5Hz, 1H), 7.65-7.58 (m, 2H), 7.45 (d, J=2 .0Hz, 1H), 7.41-7.29(m, 3H), 7.29-7.17(m, 4H), 5.18(d, J=1.4Hz, 1H), 5.01(s, 1H), 4.56(t, J=5.5Hz, 1H), 4.30(d d, J=12.4, 5.4Hz, 1H), 4.20 (dd, J=12.4, 5.5Hz, 1H), 3.77 (s, 2H), 3.68 (s, 2H), 3.50 (s, 2H), 3.43 (s, 1H), 3.14 (d, J =1.3Hz, 3H), 2.662.56 (m, 10H), 2.46 (s, 4H), 2.24 (d, J = 0.9Hz, 2H), 1.78 (s, 3H), 1.73 (s, 3H). MS (ESI, m / z): 912 (M ++1).
[0604] Example 125 Synthesis of Compound S93
[0605]
[0606] The synthesis method refers to the synthesis of compound S1, and compound S93 can be prepared by simply replacing the corresponding raw materials. 1 H NMR(500MHz, DMSO-d6)δ 11.10 (s, 1H), 10.2 (s, 1H), δ9.08 (s, 1H), 8.18-8.12 (m, 2H), 7.86 (d, J=7.5Hz, 1H), 7.65-7.57 (m, 2H), 7.47-7.39 (m, 2H), 7.37-7.29 (m, 2H), 7.29-7.17 (m, 4H), 5.18 (d, J=1.3Hz, 1H), 5.01 (s, 1H), 4.56 (t, J=5.5Hz, 1H), 4.30 (dd, J=12.4, 5.4Hz, 1 H), 4.20 (dd, J=12.5, 5.5Hz, 1H), 3.53-3.45 (m, 6H), 3.03 (s, 1H), 2.87 (s, 2H), 2.80 (s, 1H), 2.68 (s, 2H), 2.65-2.57 (m, 4H) ), 2.55 (s, 4H), 2.46 (s, 4H), 2.23 (d, J = 3.8Hz, 2H), 1.85 (d, J = 17.0Hz, 4H), 1.78 (s, 3H), 1.73 (s, 3H). MS (ESI, rm / z): 940 (M + +1).
[0607] Example 126 Synthesis of Compound S94
[0608]
[0609] The synthesis method refers to the synthesis of compound S1, and compound S94 can be prepared by simply replacing the corresponding raw materials. 1H NMR(500MHz, DMSO-d6)δ 11.10 (s, 1H), 10.2 (s, 1H), δ9.12 (s, 1H), 8.15 (d, J=7.5Hz, 1H), 8.10 (s, 1H), 7.83 (d, J=7.5Hz, 1H), 7.62 (dd, J=7.5, 2.0Hz, 1H), 7.47 (dd, J=18.4, 2.0Hz, 2H), 7.39 (dd, J=7.5, 1.8Hz, 1H), 7.37-7.29 (m, 2H), 7.29-7.17 (m, 4H), 5.18 (d, J=1.4Hz, 1H), 5.01 (s, 1H), 4.56 (t, J=5.5H z, 1H), 4.30 (dd, J=12.4, 5.4Hz, 1H), 4.20 (dd, J=12.4, 5.5Hz, 1H), 3.73 (s, 4H), 3.50 (s, 2H), 3.16 (d, J=15.9Hz, 3H), 3.02 (s, 1H), 2.81 (d, J=6.2Hz, 4H), 2.70-2.59 (m, 8H), 2.49 (s, 2H), 2.23 (d, J=3.8Hz, 2H), 1.78 (s, 3H), 1.73 (s, 3H), 1.67 (d, J=16.5Hz, 4H). MS (ESI, m / z): 952 (M + +1).
[0610] Example 127 Synthesis of Compound S95
[0611]
[0612] The synthesis method refers to the synthesis of compound S1, and compound S95 can be prepared by simply replacing the corresponding raw materials. 1H NMR(500MHz, DMSO-d6)δ 11.10 (s, 1H), 10.2 (s, 1H), δ9.12 (s, 1H), 8.15 (d, J=7.5Hz, 1H), 8.10 (s, 1H), 7.83 (d, J=7.5Hz, 1H), 7.62 (dd, J=7.5, 2.0Hz, 1H), 7.47 (dd, J=18.4, 2.0Hz, 2H), 7.41-7.29 (m, 3H), 7.29-7.17 (m, 4H), 5.18 (d, J=1.4Hz, 1H), 5.01 (s, 1H), 4.56 (t, J=5.5Hz, 1H), 4. 30 (dd, J=12.4, 5.4Hz, 1H), 4.20 (dd, J=12.4, 5.5Hz, 1H), 3.68 (s, 2H), 3.50 (s, 2H), 3.39 (d, J=10.6Hz, 3H), 3.00 (s, 1H), 2.91 (s, 4H), 2.74 (s, 2H), 2.692.59 (m, 10H), 2.24 (d, J=0.9Hz, 2H), 1.78 (s, 3H), 1.73 (s, 3H), 1.63 (d, J=13.7Hz, 4H). MS (ESI, m / z): 952 (M + +1).
[0613] Example 128 Synthesis of Compound S96
[0614]
[0615] The synthesis method refers to the synthesis of compound S1, and compound S96 can be prepared by simply replacing the corresponding raw materials. 1H NMR(500MHz, DMSO-d6)δ 11.10 (s, 1H), 10.2 (s, 1H), δ9.12 (s, 1H), 8.15 (d, J=7.5Hz, 1H), 8.10 (s, 1H), 7.83 (d, J=7.5Hz, 1H), 7.62 (dd, J=7.5, 2.0Hz, 1H), 7.47 (dd , J=18.4, 2.0Hz, 2H), 7.41-7.29 (m, 3H), 7.29-7.17 (m, 4H), 5.19-5.15 (m, 1H), 5.01 (s, 1H), 4.56 (t, J=5.5Hz, 1H), 4.30 (dd, J=12.4, 5.4H z, 1H), 4.20 (dd, J=12.4, 5.5Hz, 1H), 3.68 (s, 2H), 3.50 (s, 2H), 3.38 (s, 2H), 3.11 (s, 1H), 2.95 (s, 1H), 2.93-2.86 (m, 6H), 2.81 (d, J=9.5H z, 2H), 2.74 (d, J=9.5Hz, 2H), 2.68-2.59 (m, 6H), 2.26-2.20 (m, 4H), 1.78 (s, 3H), 1.73 (s, 3H), 1.66 (d, J=10.1Hz, 4H). MS (ESI, m / z): 966 (M + +1).
[0616] Example 129 Synthesis of Compound S97
[0617]
[0618] The synthesis method refers to the synthesis of compound S1, and compound S97 can be prepared by simply replacing the corresponding raw materials. 1H NMR(500MHz, DMSO-d6)δ 11.10 (s, 1H), 10.2 (s, 1H), δ9.12 (s, 1H), 8.15 (d, J=7.5Hz, 1H), 7.96 (s, 1H), 7.83 (d, J=7.5Hz, 1H), 7.65-7.58 (m , 2H), 7.45 (d, J=2.1Hz, 1H), 7.41-7.29 (m, 3H), 7.29-7.17 (m, 4H), 5.195.15 (m, 1H), 5.01 (s, 1H), 4.60-4.52 (m, 2 H), 4.30 (dd, J=12.4, 5.4Hz, 1H), 4.26-4.16 (m, 2H), 3.68 (s, 2H), 3.40 (s, 2H), 3.16-3.10 (m, 3H), 3.05 (s, 1H), 2. 66-2.53 (m, 8H), 2.47 (d, J=2.6Hz, 4H), 2.24 (d, J=0.9Hz, 2H), 2.03 (s, 2H), 1.801.67 (m, 10H). MS (ESI, m / z): 952 (M + +1).
[0619] Example 130 Synthesis of Compound S98
[0620]
[0621] The synthesis method refers to the synthesis of compound S1, and compound S98 can be prepared by simply replacing the corresponding raw materials. 1 H NMR(500MHz, DMSO-d6)δ 11.10 (s, 1H), 10.2 (s, 1H), δ9.12 (s, 1H), 8.188.12 (m, 2H), 7.83 (d, J=7.5Hz, 1H), 7.65-7.58 (m, 2H), 7.45 (d, J= 2.0Hz, 1H), 7.41-7.29 (m, 3H), 7.29-7.17 (m, 4H), 5.195.15 (m, 1H), 5.01 (s, 1H), 4.56 (t, J=5.5Hz, 1H), 4.30 (dd , J=12.4, 5.4Hz, 1H), 4.20 (dd, J=12.5, 5.5Hz, 1H), 3.77 (s, 2H), 3.49 (d, J=13.9Hz, 3H), 3.41 (d, J=12.9Hz, 2H), 2.93 (s, 4H), 2.682.59 (m, 8H), 2.24 (d, J=0.9Hz, 2H), 1.87 (s, 4H), 1.78 (s, 3H), 1.73 (s, 3H). MS (ESI, m / z): 897 (M + +1).
[0622] Example 131 Synthesis of Compound S99
[0623]
[0624] The synthesis method refers to the synthesis of compound S1, and compound S99 can be prepared by simply replacing the corresponding raw materials. 1 H NMR(500MHz, DMSO-d6)δ 11.10 (s, 1H), 10.2 (s, 1H), δ9.12 (s, 1H), 8.188.12 (m, 2H), 7.83 (d, J=7.5Hz, 1H), 7.62 (dd, J=7.5, 2.0Hz, 1H), 7.47 (dd, J=18.4, 2.0Hz, 2H), 7.39 (dd, J=7.5, 1.8Hz, 1H), 7.37-7.29 (m, 2H), 7.29-7.17 (m, 4H), 5.18 (d, J=1.4Hz, 1H), 5.01 (s, 1H), 4.56 (t, J=5.5Hz, 1H), 4.30 (dd, J=12.4 . 63 (s, 3H), 2.62-2.56 (m, 4H), 2.49 (s, 2H), 2.23 (d, J=3.8Hz, 2H), 2.05 (s, 2H), 1.86 (d, J=12.8Hz, 2H), 1.81-1.71 (m, 8H). MS (ESI, m / z): 923 (M + +1).
[0625] Example 132 Synthesis of Compound S100
[0626]
[0627] The synthesis method refers to the synthesis of compound S1, and compound S100 can be prepared by simply replacing the corresponding raw materials. 1HNMR(500MHz, DMSO-d6)δ 11.10 (s, 1H), 10.2 (s, 1H), δ9.10 (s, 1H), 8.02 (d, J=7.5Hz, 1H), 7.90 (dd, J=7.5, 2.0Hz, 1H), 7.68-7.62 (m, 2H) , 7.48-7.41 (m, 2H), 7.36-7.26 (m, 3H), 7.26-7.18 (m, 4H), 5.18 (t, J=1.1Hz, 1H), 5.11 (s, 1H), 4.56 (t, J=5.5Hz , 1H), 4.30 (dd, J=12.4, 5.4Hz, 1H), 4.20 (dd, J=12.4, 5.5Hz, 1H), 3.83 (s, 1H), 3.59 (d, J=6.2Hz, 4H), 2.66 (s, 1 H), 2.54 (s, 1H), 2.49 (s, 1H), 1.99 (s, 1H), 1.93 (s, 2H), 1.79 (d, J=2.9Hz, 5H), 1.73 (s, 3H). MS (ESI, m / z): 773 (M + +1).
[0628] Example 133 Synthesis of Compound S101
[0629]
[0630] The synthesis method refers to the synthesis of compound S1, and compound S101 can be prepared by simply replacing the corresponding raw materials. 1 HNMR(500MHz, DMSO-d6)δ 11.10 (s, 1H), 10.2 (s, 1H), δ9.12 (s, 1H), 8.02 (d, J=7.5Hz, 1H), 7.85-7.79 (m, 2H), 7.65 (dd, J=7.4, 1.9Hz, 1H), 7.60 (d, J=2.0Hz, 1H), 7.47-7.41 (m, 2H), 7.34-7.26 (m, 2H), 7.26-7.18 (m, 4H), 5.195.15 (m, 1H), 4.90 (s, 1H), 4. 56 (t, J=5.5Hz, 1H), 4.30 (dd, J=12.4, 5.4Hz, 1H), 4.20 (dd, J=12.4, 5.5Hz, 1H), 4.00 (s, 1H), 3.85 (s, 2H), 3.73 ( s, 2H), 2.62 (d, J=11.5Hz, 2H), 2.23 (d, J=3.8Hz, 2H), 1.90 (s, 4H), 1.78 (s, 3H), 1.73 (s, 3H). MS (ESI, m / z): 785 (M + +1).
[0631] Example 134 Synthesis of Compound S102
[0632]
[0633] Step 1: Synthesis of compound 211
[0634] Compound 7 (434 mg, 1 mmol) and glycine tert-butyl ester hydrochloride (167 mg, 1 mmol) were dissolved in anhydrous DMF (5 mL), HATU (570 mg, 1.5 mmol) and DIPEA (646 mg, 5 mmol) were added to the above solution, and the reaction was stirred at room temperature for 5 h until the reaction was complete. Water was added to quench the reaction, and ethyl acetate was extracted (10 mL×3), washed with saturated brine, dried over anhydrous sodium sulfate, filtered, concentrated, and separated and purified by column chromatography to obtain compound 211 (437 mg, 80%). MS (ESI, m / z): 548 (M + +1).
[0635] Step 2: Synthesis of compound 212
[0636] Compound 211 (430 mg, 0.79 mmol) was dissolved in DCM (3 mL), and trifluoroacetic acid (1.5 mL) was added to the above solution. After the reaction was completed, the solvent and excess trifluoroacetic acid were removed under reduced pressure, and the mixture was slurried with ether, filtered, and dried to obtain compound 212, which was directly used for the next step without purification.
[0637] Step 3: Synthesis of compound S102
[0638] Compounds 212 (100 mg, 0.2 mmol) and 213 (55 mg, 0.2 mmol) were dissolved in anhydrous DMF (2 mL), and HATU (114 mg, 0.3 mmol) and DIPEA (129 mg, 1 mmol) were added to the above solution. The reaction was stirred at room temperature for 5 h until the reaction was complete. Water was added to quench the reaction, and the mixture was extracted with ethyl acetate (5 mL×3). The mixture was washed with saturated brine, dried over anhydrous sodium sulfate, filtered, concentrated, and separated and purified by column chromatography to obtain compound S102 (112 mg, 75%). 1H NMR(500MHz, DMSO-d6)δ 11.10 (s, 1H), 8.92 (s, 1H), 8.13 (dd, J=8.4, 1.8Hz, 1H), 7.98 (t, J=5.8Hz, 1H), 7.83 (d, J=8.4Hz, 1H), 7.49 (s, 1H), 7.3 5 (d, J=1.8Hz, 1H), 7.34-7.22 (m, 6H), 7.26-7.19 (m, 2H), 6.91-6.85 (m, 2H), 4.66 (dtt, J=9.0, 5.7, 0.9Hz, 1H), 4.20-4. 09 (m, 2H), 4.00 (ddd, J=11.9, 7.0, 5.7Hz, 1H), 3.86 (dd, J=16.7, 5.9Hz, 1H), 3.76 (t, J=5.3Hz, 4H), 3.70 (t, J=5.9Hz, 2H ), 3.34-3.21 (m, 4H), 2.98 (t, J=7.1Hz, 1H), 2.71 (td, J=5.9, 3.7Hz, 2H), 1.71 (s, 3H), 1.66 (s, 3H). MS (ESI, m / z): 748 (M + +1).
[0639] Example 135 Synthesis of Compound S103
[0640]
[0641] The synthesis method refers to the synthesis of compound S102, and compound S103 can be prepared by simply replacing the corresponding raw materials. 1 HNMR (500MHz, DMSO-d6) δ 11.10 (s, 1H), 9.04 (s, 1H), 8.47 (t, J=4.4Hz, 1H), 8.13 (dd, J=8.5, 1.9Hz, 1H), 7.88 (d, J=8.4Hz, 1H), 7.35 (d, J=1.8Hz, 1H), 7.34-7.20 (m, 9H), 6.91-6.85 (m, 2H), 4.81-4.73(m, 1H), 4.44-4.27(m, 1H), 4.20-4.18(m, 1H), 3.82-3.75(m, 2H), 3.74-3.65(m, 4H) , 3.52-3.44 (m, 1H), 3.36-3.20 (m, 5H), 3.17 (t, J=7.1Hz, 1H), 2.71 (td, J=5.9, 3.7Hz, 2H), 2.66 (d t, J=14.8, 6.2Hz, 1H), 2.58 (dt, J=15.0, 6.2Hz, 1H), 1.67 (s, 3H), 1.63 (s, 3H). MS (ESI, m / z): 762 (M+ +1).
[0642] Example 136 Synthesis of Compound S104
[0643]
[0644] The synthesis method refers to the synthesis of compound S102, and compound S104 can be prepared by simply replacing the corresponding raw materials. 1 HNMR(500MHz, DMSO-d6)δ 11.10 (s, 1H), 8.71 (s, 1H), 8.15 (dd, J=8.5, 1.9Hz, 1H), 7.84 (d, J=8.4Hz, 1H), 7.55 (s, 1H ), 7.35(d, J=1.8Hz, 1H), 7.34-7.23(m, 5H), 7.26-7.19(m, 3H), 6.91-6.85(m, 2H), 4.69(d tt, J=9.2, 5.7, 0.9Hz, 1H), 4.24-4.16 (m, 2H), 3.76-3.66 (m, 3H), 3.61-3.53 (m, 4H), 3.18 -3.13(m, 4H), 2.72(td, J=5.9, 2.8Hz, 2H), 1.73(s, 3H), 1.68(s, 3H).MS(ESI, m / z): 691(M + +1).
[0645] Example 137 Synthesis of Compound S105
[0646]
[0647] The synthesis method refers to the synthesis of compound S86, and compound S105 can be prepared by simply replacing the corresponding raw materials. 1HNMR(500MHz, DMSO-d6)δ 11.10 (s, 1H), 9.01 (s, 1H), 8.13 (dd, J=8.4, 2.0Hz, 1H), 8.02 (t, J=4.4Hz, 1H), 7.90 (d, J= 8.4Hz, 1H), 7.44 (s, 1H), 7.35 (d, J=1.8Hz, 1H), 7.34-7.23 (m, 6H), 7.26-7.18 (m, 2H), 6.91 6.85 (m, 2H), 4.75 (dtt, J=9.1, 5.7, 0.9Hz, 1H), 4.294.15 (m, 2H), 3.70 (t, J=6 .0Hz, 2H), 3.50 (dtd, J=14.3, 6.3, 4.4Hz, 1H), 3.33-3.18 (m, 5H), 3.08 (t, J=7. 0Hz, 1H), 2.71 (td, J=5.9, 3.7Hz, 2H), 1.73-1.52 (m, 12H), 1.56-1.45 (m, 1H), 1 .43 (dt, J=12.9, 6.3Hz, 1H), 1.33 (dq, J=12.7, 6.5Hz, 1H). MS (ESI, m / z): 747 (M + +1).
[0648] Example 138 Synthesis of Compound S106
[0649]
[0650] The synthesis method refers to the synthesis of compound S86, and compound S106 can be prepared by simply replacing the corresponding raw materials. 1HNMR(500MHz, DMSO-d6)δ 11.10 (s, 1H), 8.97 (s, 1H), 8.31 (t, J=4.3Hz, 1H), 8.15 (dd, J=8.4, 2.0Hz, 1H), 7.82 (d, J=8.4Hz, 1H), 7.47 (s, 1H), 735 (d, J=1.8Hz, 1H), 7.34-7.22 (m, 6H), 7.25-7.18 (m, 2H), 6.91-6.85 (m, 2H), 4.63 (dtt, J=9.2, 5.7, 1.0Hz, 1H), 4.25-4. 16 (m, 2H), 3.70 (t, J=6.0Hz, 2H), 3.35-3.21 (m, 5H), 3.12 (dtd, J=14.3, 5.8, 4.3Hz, 1H), 3.05 (t, J=7.0Hz, 1H), 2.71 (t d, J=5.9, 3.7Hz, 2H), 1.81-1.64 (m, 9H), 1.67-1.56 (m, 1H), 1.59-1.50 (m, 2H), 1.54-1.46 (m, 1H). MS (ESI, m / z): 733 (M + +1).
[0651] Example 139 Test of the activity of the compounds of the present invention on HPK1 kinase
[0652] The HPK1 kinase domain (1-307aa) was dissolved in kinase buffer (20mM HEPES pH7.5, 10mM MgCl2, 1mM EGTA, 0.5mM TCEP, 0.01% Brij-35, 0.05% BSA) and added to a 96-well plate at a final concentration of 20nM. Then, a gradient dilution of the compound of the present invention to be tested was added (10 concentration points were set for each compound). HPK1 kinase was pre-incubated with the compound of the present invention for 30min, and then 20μL of substrate solution (final concentration of 0.5mg / mL SLP76-SH2 domain and 10μM ATP) was added to each well to start the enzymatic reaction. Incubate at room temperature for 1h, and then determine the inhibition rate of the compound of the present invention on HPK1 kinase activity at each concentration according to the instructions of Luminescent Kinase Assay Kit (Beyotime Biotechnology Company). The inhibitory activity IC of the compound of the present invention on HPK1 kinase was calculated using GraphPad fitting. 50 The experimental results are shown in Table 1. Compounds A and B are used as positive controls. The enzyme inhibitory activity of the compounds of the present invention on HPK1 is equivalent to or better than that of the positive control compounds A and B.
[0653]
[0654]
[0655]
[0656] Example 140 Test of the HPK1 protein degradation activity of the compounds of the present invention
[0657] (1) Cell collection: Jurkat cells were cultured for 12 h, and some compounds of the present invention were co-incubated with the cells for 24 h.
[0658] (2) Protein extraction: discard the original culture medium, wash the cells three times with pre-cooled PBS, add an appropriate amount of lysis buffer, mix well, place on ice for 30 min, centrifuge at 12000 rpm at 4°C for 5 min, transfer the supernatant after centrifugation into a new centrifuge tube, and prepare for quantification.
[0659] (3) Protein quantification: Protein was quantified using the BCA method. Solution A and solution B were mixed at a ratio of 50:1 to obtain the BCA working solution. 100 μL of BCA working solution, 9 μL of triple distilled water, and 1 μL of protein sample were added to a 96-well plate, mixed, and incubated at 37°C for 30 min. The absorbance was measured using a full-wavelength microplate reader, and the protein concentration was calculated based on the standard curve. The quantified protein was mixed with 5× loading buffer at a ratio of 4:1, denatured in boiling water for 8 min, cooled on ice, and stored at -20°C for later use.
[0660] (4) Prepare SDS-PAGE gel, with the voltage of the concentrating gel at 90 V and the voltage of the separating gel at 120 V. Transfer the membrane at 100 V for 1 h at 4°C. After transfer, immediately place the protein membrane in a pre-prepared 5% BSA solution, shake it slowly on a shaker, and block it at room temperature for 1 h.
[0661] (5) Refer to the instructions of HPK1 Antibody (4472SCST), GLK (D1L4G) Rabbit mAb (92427SCST), Rabbit mAb (92711TCST), and β-actin Mouse Monoclonal antibody (BE0021 easybio), dilute the primary antibody in an appropriate ratio, incubate at 4°C with slow shaking overnight, and then wash three times with PBST, 10 min each time.
[0662] (6) Select Goat Anti-Rabbit IgG (H&L)-HRP Conjugated (BE0101easybio) or Goat Anti-Mouse IgG (H&L)-HRP Conjugated (BE0102easybio) according to the primary antibody, refer to the instructions of the secondary antibody, dilute the secondary antibody according to the appropriate ratio, incubate at room temperature with slow shaking for 1 hour, and wash three times with PBST, 10 minutes each time.
[0663] (7) Add ECL luminescent liquid, observe the results by developing instrument, quantify the Western results by using Image J software, and calculate the degradation rate (HPK1 and GLK) by comparing with the control group without adding the compound. The experimental results are shown in Table 2. The compounds of the present invention have excellent degradation activity for HPK1, but have no obvious degradation activity for GLK, indicating that the compounds of the present invention have high selectivity and low toxicity.
[0664] Table 2 Degradation activity of the compounds of the present invention on HPK1 and GLK proteins
[0665]
[0666]
[0667] Example 141 Detection of T cell cytokine release
[0668] HPK1 kinase inhibits the release of T cell effector cytokines, so the ELISA method was used to detect whether the compounds of the present invention can enhance the ability of T cell cytokine release. Human PBMC cells were thawed and suspended in RPMI1640 (Gibco) culture medium containing 10% bovine placental serum, and the cells were seeded in 96-well plates (1×10 5 / well). The gradient dilution of the compound of the present invention was added to a 96-well plate and incubated in a 37°C, 5% CO2 incubator for 1 hour. 100 μL of anti-CD3 / CD28 antibody (final concentration 1 μg / mL) was added to activate PBMCs cells, and then incubated in a 37°C, 5% CO2 incubator for 48 hours. The supernatant was diluted with 8 times PBS, 100 μL of the diluted supernatant was taken, and the release amount of cytokine IL-2 at each concentration of the compound of the present invention was detected using a human IL-2 ELISA kit. The EC of the compound of the present invention was calculated using GraphPad fitting. 50 The experimental results are shown in Table 3. The compounds of the present invention can significantly enhance the release of IL-2 by PBMC cells, and are significantly better than the HPK1 small molecule inhibitor (Compound B). This shows that the compounds of the present invention can restore or enhance the ability of T cells to release factors by degrading HPK1 protein, thereby restoring or enhancing the anti-tumor immune response.
[0669] Table 3 Test results of the activity of the compounds of the present invention in stimulating PBMC to release IL-2
[0670] serial number <![CDATA[EC 50 (nM)]]> serial number <![CDATA[EC 50 (nM)]]> S1 150 S49 82 S3 162 S53 79 S5 149 S60 82 S10 79 S61 87 S11 71 S62 80 S12 68 S63 79 S13 77 S71 59 S14 80 S72 60 S15 78 S74 63 S16 86 S81 72 S17 73 S85 69 S18 70 S103 70 S47 86 S106 65 S48 73 B 255
[0671] Example 142 PBMC and tumor cell co-culture experiment
[0672] PBMC cells were stimulated with CD3 / CD28 mixed antibodies for 24 hours. Then, MDA-MB-231 cells (triple-negative breast cancer) and CT-26 (mouse colon cancer) were co-cultured with PBMC cells activated by CD3 / CD28 antibodies at an effector-target ratio of 1:10 for 6 hours, and the cytotoxic activity of PBMC cells against tumor cells in the co-culture system was detected by LDH release assay. The destruction of the cell membrane structure caused by cell apoptosis or necrosis will cause the release of enzymes in the cytoplasm into the culture medium, including lactate dehydrogenase (LDH), which has relatively stable enzyme activity. By detecting the activity of LDH released into the culture medium from cells with ruptured plasma membranes, quantitative analysis of PBMC's killing of tumors can be achieved. The experimental results are shown in the following figure. Figure 1 and Figure 2 As shown, compared with the DMSO control group, the target compounds S10 and S47 can significantly promote the release of LDH, which indicates that S10 and S47 significantly increased or restored the killing and lysis of tumor cells by PBMC.
Claims
1. A compound of formula I, or its enantiomers, diastereomers, racemates, cis-trans isomers, deuterated derivatives, metabolites, prodrugs, solvates, hydrates, pharmaceutically acceptable salts or cocrystals, characterized in that: Its structural formula is shown below: ELB (I) In Formula I: E is R is -CH-, -C(CH3)- or -N-; Y is deuterium, halogen, cyano, C 1-4 Alkyl, deuterated (C 1-4 Alkyl), halogenated (C 1-4 Alkyl), deuterated (C 1-4 Alkoxy) or halogen (C 1-4 Alkoxy); M is deuterium, halogen, C 1-4 Alkyl, deuterated (C 1-4 Alkyl) or halogenated (C 1-4 alkyl); a is 0, 1, 2, 3 or 4; b is 0, 1, 2, or 3; Q is a single bond, -NH-, -CH2- or -O-; W is -CH2-, -C(CH3)2 or L is L1 is connected to E, L4 is connected to B; L1 is a single bond, -O-, -NR a -, -C≡C-, 4-10 membered monocyclic heterocycloalkylene, 6-20 membered spirocyclic heterocycloalkylene, 6-18 membered cyclic heterocycloalkylene or 7-10 membered bridged heterocycloalkylene; L2 is a single bond, -(CH2)r2-, -(CH2)r2NH-, (CH2)r3NH(C=O)-, -(CH2)r3(C=O)NH-, 4-10 membered monocyclic heterocycloalkylene, 6-20 membered spirocyclic heterocycloalkylene, 6-18 membered cycloheterocycloalkylene or 7-10 membered bridged heterocycloalkylene; L3 is a single bond, -(CH2)r4NH-, a 4-10 membered monocyclic heterocycloalkylene, a 6-20 membered spirocyclic heterocycloalkylene, a 6-18 membered cycloheterocycloalkylene or a 7-10 membered bridged heterocycloalkylene; L4 is a single bond or -(CH2)r5NR b -; R a is hydrogen or C 1-4 alkyl; R b is hydrogen or C 1-4 alkyl; r2 is 0, 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11 or 12; r3 is 1, 2, 3, 4, 5, 6, 7 or 8; r4 is 0, 1, 2, 3, 4, 5, 6, 7, 8, 9 or 10; r5 is 0, 1, 2, 3, 4, 5 or 6; B is X is or "a 5- to 6-membered heteroarylene group having a heteroatom selected from one or more of N, O and S, and having 1 to 3 heteroatoms; Z is C 4-10 Alkylene, C 4-10 Alkenylene or C 4-10 Alkyne, the C 4-10 Alkylene, C 4-10 Alkenylene, C 4-10 One or two methylene groups -CH2- in the alkynylene group are optionally and independently replaced by O, -NH- or -N(C 1-4 alkyl).
2. The compound of formula I according to claim 1, or its enantiomer, diastereomer, racemate, cis-trans isomer, deuterated substance, metabolite, prodrug, solvate, hydrate, pharmaceutically acceptable salt or cocrystal, characterized in that: R is -CH- or -N-; and / or, Y is deuterium, fluorine, chlorine, cyano, methyl, trifluoromethyl, methoxy or trifluoromethoxy; and / or, M is deuterium, methyl, fluorine or trifluoromethyl; and / or, a is 0, 1, 2 or 3; and / or, b is 0 or 1; and / or, Q is a single bond or -NH-; and / or, W is -CH2- or and / or, X is Pyrazolylene, 1,3,4-oxadiazolylene or 1,2,4-oxadiazolylene; And / or, Z is -OCH2CH2CH2CH2-, -OCH2CH2CH2CH2CH2-, -OCH2CH2OCH2-, -OCH2CH2OCH2CH2-, -OCH2CH2OCH2CH2-, -OCH2CH2N(CH3)CH2- or -CH2OCH2CH=CHCH2OCH2CH2-.
3. The compound of formula I according to claim 1, or its enantiomer, diastereomer, racemate, cis-trans isomer, deuterated substance, metabolite, prodrug, solvate, hydrate, pharmaceutically acceptable salt or cocrystal, characterized in that: and / or, X is The left side is connected to L and the right side is connected to connected; and / or, E is 4. The compound of formula I according to claim 1, or its enantiomer, diastereomer, racemate, cis-trans isomer, deuterated substance, metabolite, prodrug, solvate, hydrate, pharmaceutically acceptable salt or cocrystal, characterized in that: L1 is a single bond, -O-, -NH-, -N(CH3)-, -C≡C-, L2 is a single bond, -(CH2)r2-, -(CH2)r2NH-, -(CH2)r3NH(C=O)-, -(CH2)r3(C=O)NH-, L3 is a single bond, -(CH2)r4NH-, L4 is a single bond, -(CH2)r5NH- or -(CH2)r5NCH3-; n1 is 1, 2, 3 or 4; n2 is 1, 2, 3 or 4; n3 is 1, 2 or 3; n4 is 1, 2 or 3; n5 is 1, 2 or 3; n6 is 1, 2 or 3; n7 is 0, 1, 2 or 3; n8 is 0, 1, 2, or 3; n9 is 0, 1, 2 or 3; n10 is 0, 1, 2 or 3; Q 1 is CH or N; Q 2 is CH or N; Q 3 is CH or N; R 1 is hydrogen, halogen, -(C=O) or C 1-3 alkyl; c is 0, 1, 2, 3, or 4; r2 is 0, 1, 2, 3, 4, 5, 6, 7, 8, 9, 10 or 11; r3 is 1, 2, 3, 4, 5 or 6; r4 is 0, 1, 2, 3, 4, 5, 6, 7 or 8; r5 is 0, 1, 2, 3 or 4.
5. The compound of formula I according to claim 1, or its enantiomer, diastereomer, racemate, cis-trans isomer, deuterated substance, metabolite, prodrug, solvate, hydrate, pharmaceutically acceptable salt or cocrystal, characterized in that: L1 is -O-, -NH-, -C≡C-, and / or, L2 is a single bond, -(CH2)r2-, -(CH2)r2NH-, -(CH2)r3NH(C=O)-, -(CH2)r3(C=O)NH-, and / or, L3 is a single bond, -(CH2)r4NH-; and / or, L4 is a single bond or -(CH2)r5NH-; and / or, n1 is 1, 2 or 3; and / or, n2 is 1, 2 or 3; and / or, n3 is 1 or 2; and / or, n4 is 1 or 2; and / or, n5 is 1 or 2; and / or, n6 is 1 or 2; and / or, n7 is 1 or 2; and / or, n8 is 1 or 2; and / or, n9 is 0, 1 or 2; and / or, n10 is 0, 1 or 2; and / or, Q 2 For CH, Q 3 is N; Or, Q 2 N, Q 3 for CH; and / or, R 1 is hydrogen; and / or, c is 0, 1 or 2; and / or, r2 is 0, 1, 2, 3, 4, 5, 6, 7, 8, 9 or 10; and / or, r3 is 1, 2, 3 or 4; and / or, r4 is 0, 1, 2, 3, 4, 5 or 6; And / or, r5 is 0, 1, 2 or 3.
6. The compound of formula I according to claim 1, or its enantiomer, diastereomer, racemate, cis-trans isomer, deuterated substance, metabolite, prodrug, solvate, hydrate, pharmaceutically acceptable salt or cocrystal, characterized in that: L is -O-(CH2)r2NH-single bond-single bond-, -O-(CH2)r3NH(C=O)-(CH2)r4NH-single bond-, -O-(CH2)r3(C=O)NH-(CH2)r4NH-single bond-, -NH-(CH2)r2NH-single bond-single bond-, -NH-(CH2)r3NH(C=O)-(CH2)r4NH-single bond-, -NH-(CH2)r3(C=O)NH-(CH2)r4NH-single bond-, -NH-(CH2)r2-single bond-single bond, -C≡C-(CH2)r2NH-single bond-single bond-, -C≡C-(CH2)r2-single bond-single bond-, The left side is connected to E, and the right side is connected to B; n1 is 1, 2 or 3; n2 is 1, 2 or 3; n3 is 1 or 2; n4 is 1 or 2; n5 is 1 or 2; n6 is 1 or 2; n7 is 1 or 2; n8 is 1 or 2; n9 is 0, 1 or 2; n10 is 0, 1 or 2; Q 1 is CH or N; Q 2 is CH or N; Q 3 is CH or N; R 1 is hydrogen; c is 0, 1, or 2; r2 is 0, 1, 2, 3, 4, 5, 6, 7, 8, 9 or 10; r3 is 1, 2, 3 or 4; r4 is 0, 1, 2, 3, 4, 5 or 6; r5 is 0, 1, 2 or 3.
7. The compound of formula I according to any one of claims 1 to 6, or its enantiomer, diastereomer, racemate, cis-trans isomer, deuterated substance, metabolite, prodrug, solvate, hydrate, pharmaceutically acceptable salt or cocrystal, characterized in that: L1 is -O-, -NH-, -C≡C-, The left side is connected to E, and the right side is connected to L2; and / or, L2 is a single bond, -(CH2)r2-, -(CH2)r2NH-, -(CH2)r3NH(C=O)-, -(CH2)r3(C=O)NH-, r2 is 0, 1, 2, 3, 4, 5, 6, 7, 8 or 9; r3 is 1, 2 or 3; The left side is connected to L1, and the right side is connected to L3; and / or, L3 is a single bond, -(CH2)r4NH-, The left side is connected to L2, and the right side is connected to L4; r4 is 0, 1, 2 or 3; and / or, L4 is a single bond or -(CH2)r5NH-; r5 is 0, 1 or 2.
8. The compound of formula I according to any one of claims 1 to 6, or its enantiomer, diastereomer, racemate, cis-trans isomer, deuterated substance, metabolite, prodrug, solvate, hydrate, pharmaceutically acceptable salt or cocrystal, characterized in that: L is The left side is connected to E, and the right side is connected to B; r21 is 1, 2, 3, 4, 5, 6, 7 or 8; r22 is 0, 1, 2 or 3; r31 is 1, 2 or 3; r41 is 1, 2 or 3; r42 is 0, 1, 2, or 3; r52 is 0 or 1.
9. The compound of formula I according to claim 1, or its enantiomer, diastereomer, racemate, cis-trans isomer, deuterated substance, metabolite, prodrug, solvate, hydrate, pharmaceutically acceptable salt or cocrystal, characterized in that: The compound represented by formula I is selected from the following compounds of any structure:
10. A pharmaceutical composition comprising a therapeutically effective amount of a compound of formula I as described in any one of claims 1 to 9 or its enantiomer, diastereomer, racemate, cis-trans isomer, deuterated substance, metabolite, prodrug, solvate, hydrate, pharmaceutically acceptable salt or cocrystal, and a pharmaceutically acceptable carrier or excipient.
11. Use of a compound of formula I as described in claims 1 to 9 or its enantiomer, diastereomer, racemate, cis-trans isomer, deuterated product, metabolite, prodrug, solvate, hydrate, pharmaceutically acceptable salt or cocrystal, or the pharmaceutical composition as described in claim 10 in the preparation of a hematopoietic progenitor cell kinase 1 degrader.
12. Use of a compound of formula I as described in claims 1 to 9 or its enantiomer, diastereomer, racemate, cis-trans isomer, deuterated product, metabolite, prodrug, solvate, hydrate, pharmaceutically acceptable salt or cocrystal, or the pharmaceutical composition as described in claim 10 in the preparation of a medicament for treating and / or preventing cancer.
Citation Information
Patent Citations
Benzopyrimidine and benzotriazine hematopoietic progenitor cell kinase 1 degradation agent and application thereof
CN115873018A
Compound of hematopoietic progenitor cell kinase 1 inhibitor and preparation method and application thereof
CN116143779A
